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The influence of plasticization and other formulation factors on the properties of 
hot-melt extruded dosage forms for the controlled release of water-soluble active 
compounds was investigated. 
Citric acid monohydrate was demonstrated to function as a solid-state plasticizer 
in hot-melt extruded Eudragit® RS PO tablets and in cast films when concentrations 
below the compatibility limit were employed. Melting of the organic acid and 
solubilization in the polymer during extrusion were necessary to observe the plasticizing 
effect. The release rate of diltiazem hydrochloride, used as a high-melting, water-soluble 
model drug, from melt extruded Eudragit® RS PO matrix tablets increased and became 
independent of the original drug particle size in the presence of citric acid monohydrate. 
Thermal analysis of physical mixtures demonstrated that citric acid promoted drug 
melting during extrusion by interaction and melting point depression. Diltiazem 
hydrochloride remained amorphous in the final dosage form, and leaching of citric acid 
monohydrate enhanced drug diffusion by increasing the matrix porosity. 
 viii
Delayed-release matrix pellets with particle sizes below one mm were prepared 
by hot-melt extrusion, and the influence of the matrix forming polymer and the type and 
level of plasticizer on the processibility and release properties was investigated. Pellets 
complied with the USP requirement for delayed release articles to release less than 10% 
drug at pH 1.2 after 2 hours when plasticized Eudragit® S100 was used as the release-
controlling material. High levels of efficient plasticizers had to be employed to decrease 
the polymeric melt viscosity, increase the process yield and enable extrusion at moderate 
temperatures to avoid instabilities during processing and storage. The aqueous solubility 
of the plasticizer further impacted the drug release rate in acid. 
A novel application of hot-melt extrusion for the preparation of monolithic 
matrices comprising enteric coated particles was studied. The influence of the mechanical 
strength of the multiparticulates, pellet loading and nature of the hydrophilic carrier 
material on the preservation of the delayed-release properties after extrusion was 
investigated. Soft particles coated with brittle films remained intact when low-melting 
carriers that did not solubilize the enteric film during extrusion were used, and the 
dissolution profile was stable over one year. 
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Chapter 1: Introduction 
1.1 CONTROLLED RELEASE DOSAGE FORMS FOR ORAL DRUG DELIVERY 
1.1.1 Advantages of controlled release systems 
Controlled or modified release systems are characterized by their ability to either 
control the rate or the area of drug release. With respect to oral drug delivery, the release 
can either be sustained during the transit of the dosage form in the gastro-intestinal tract 
(extended, sustained or prolonged drug release), or delayed to regions subsequent to the 
stomach including the small intestine or the colon (delayed release). Dosage forms with 
controlled release properties provide numerous advantages over conventional, immediate 
release systems [1]. From a biopharmaceutical standpoint, controlled release systems 
generate more consistent drug plasma concentrations over a prolonged period of time. 
Toxic peaks in drug concentration as occurring in the initial phase after administration of 
immediate release products or inefficient plasma levels at later time points can be 
avoided. The plasma concentration fluctuates less and remains within the therapeutic 
window over a prolonged time interval. As a result, not only drug efficacy and safety, but 
also patient compliance will be enhanced since dosing can be simplified to a once or 
twice a day regimen. Delayed release applications are indicated when the drug is instable 
in the acidic environment of the stomach, causes local side effects to the stomach 
mucosa, or if particular regions in the intestine or in the colon need to be targeted to 
improve drug absorption and bioavailability. Another field of application for delayed 
delivery systems focuses on active ingredients with chronotherapeutic effects. In this 
case, the lag-time between drug administration and release allows the coordination of the 
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release with the body's circadian rhythms to maximize effectiveness and minimize side 
effects. 
 
1.1.2 Classifications and release mechanisms 
Numerous approaches have been pursued to control the drug release in a temporal 
or spatial manner. The drug may be embedded in a release-controlling matrix (matrix 
systems) or inside a core which is surrounded by a release-controlling shell or membrane 
(reservoir system). Natural or synthetic polymers are mainly used as drug carriers or 
coating materials to provide the dosage form with the desired release properties. The drug 
is liberated from these systems by diffusion, matrix or coat dissolution, osmosis or by a 
combination of these mechanisms. Alternative delivery approaches include gastro-
retentive systems, bioadhesive and particulate dosage forms. 
Controlled delivery dosage forms can further be classified as single-unit 
(monolithic) or multiple-unit systems. Multiple-unit dosage forms with modified release 
properties yield advantages over monolithic systems in terms of beneficial 
pharmacokinetic properties and formulation flexibility [2]. Particles small enough to pass 
through the stomach pylorus spread more rapidly and homogeneously in the intestine 
independently of gastric emptying and feeding state. The drug absorption can be 
maximized while plasma level fluctuations and intra- and inter-subject variations are 
reduced. In contrast to monolithic dosage forms including film-coated tablets, high local 
concentrations and dose dumping are avoided. The blending of pellets containing 
different drugs or providing different drug release rates allows the simultaneous delivery 
of incompatible drugs and the creation of tailored release profiles.  
Downstream processing of multiple-unit systems into monolithic, multi-
particulate dosage forms is necessary to improve patient compliance and dosing accuracy. 
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The most common techniques are the filling of multi-particulates into capsules or the 
compression into tablets. Capsules are more cost-intensive than tablets and may be less 
secure due to their higher susceptibility to tampering. Capsule shells are further 
hygroscopic and provide little protection to light, oxygen and moisture. The compression 
of pellets into multi-particulate tablets has gained popularity, but remains technologically 
challenging [3]. Compaction forces during tableting can fracture the film of functionally 
coated pellets and result in the loss of their modified release properties. The requirement 
of large amounts of cushioning agents to absorb compaction forces and physically 
separate the pellets during compression limits the amount of pellets that can be loaded 
into the tablet.  
 
1.2 HOT-MELT EXTRUSION FOR PHARMACEUTICAL APPLICATIONS 
1.2.1 Advantages and applications of hot-melt extrusion 
Hot-melt extrusion is a well established process that is widely used in the plastic, 
rubber and food industry. More recently, the process has been adapted for the preparation 
of pharmaceutical matrix systems providing immediate or controlled drug release. During 
hot-melt extrusion, a blend consisting of a drug, a thermoplastic carrier and further 
optional excipients is transported through a heated barrel by one or two rotating screws. 
The drug is homogeneously dispersed in the softened carrier and then extruded under 
high pressure through a product-shaping die to yield a matrix-type dosage form.  
The interest in hot-melt extrusion for pharmaceutical applications has increased 
recently as evident from a growing number of patents, scientific publications and 
marketed drug products [4-6]. Hot-melt extrusion allows the manufacture of dosage 
forms in a continuous and efficient manner, provides potential for scale-up and 
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experiences high industrial acceptance. The process is highly versatile as numerous 
different dosage forms including tablets, granules, pellets, transdermal and transmucosal 
films, powders and implants can be obtained by utilizing appropriate dies and 
downstream processing equipment. The technology has been successfully applied for the 
preparation of solid dispersions to improve the solubility, dissolution rate and 
bioavailability of poorly soluble compounds [7]. Alternatively, matrix systems providing 
controlled release for high loadings of soluble drugs may be manufactured by melt 
extrusion. The initial porosity of melt extruded matrices is low due to the high degree of 
carrier coalescence during thermal compounding as compared to wet-massed [8] or 
directly compressed matrices [9], minimizing percolation effects and hence drug 
diffusion. Subsequent processing steps including film coating and the use of organic or 
aqueous solvents can be avoided, making the process amenable for hydrolysable drugs 
and reducing time and efforts associated with coating procedures and solvent removal. 
The rotating screw inside the extrusion barrel exerts shearing, kneading and mixing 
forces on the processed material, promoting a deaggregation, particle size reduction and 
homogenous dispersion of the drug within the thermoplastic carrier. 
 
1.2.2 Composition of formulations and general requirements for hot-melt 
extrusion 
A formulation for a hot-melt extruded dosage form typically comprises the drug 
embedded in a thermoplastic carrier. Optionally, further functional excipients may be 
utilized including processing aids (plasticizers, glidants or thermal lubricants), stability 
enhancers (antioxidants, pigments) or release-modifying agents (pore-formers, gelling 
polymers, superdisintegrants, retardants or electrolytes for pH modification, solubilizing 
agents or surfactants). The carrier can be a thermoplastic polymer or other meltable 
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substances including waxes, lipids, organic acids, urea and inorganic salts. Polymeric 
carriers may be completely amorphous or semi-crystalline, and have been traditionally 
used for other pharmaceutical applications including film-coating, granulation, direct 
compression, or in liquid dosage forms. All formulation components need to meet the 
following requirements in order to be acceptable for hot-melt extruded pharmaceutical 
systems:  
1. Be of a pharmaceutical grade and generally regarded as safe for the 
intended dose and route of administration. 
2. Stability under processing conditions. 
3. Stability during shelf-life. 
 
1.2.3 Characterization of hot-melt extruded dosage forms 
Hot-melt extruded delivery systems should be carefully characterized regarding 
chemical stability, solid state properties including degree of crystallinity and interactions 
between formulation components, drug release properties and content uniformity. The 
characterization work includes the evaluation of the status quo subsequent to manufacture 
as well as the monitoring of these properties as a function of storage time and storage 
conditions.  
Thermogravimetry (TG) or chromatographic methods represent popular analytical 
techniques to assess the chemical stability of the components in hot-melt extruded dosage 
forms. Instabilities of low-molecular weight components including the drug or processing 
aids may be detected using stability-indicating high-pressure liquid chromatography 
(HPLC) assays [10-12]. Polymer degradation in form of depolymerization or chain 
scission has been studied by gel permeation chromatography (GPC) [11, 13] or HPLC 
assaying of free monomers [14]. Thermally induced reactions in the polymeric side 
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chains often involve functional groups and can be monitored by Fourier transform 
infrared spectroscopy (FT-IR) coupled with differential scanning calorimetry (DSC) [15, 
16] or TG [17], mass spectroscopy (MS) coupled with TG [18], solid-state nuclear 
magnetic resonance spectrometry (NMR) [19] or by titration.  
Processing under elevated pressure and temperature may induce changes to the 
solid-state of the drug or the processing aids. Extrusion at temperatures below the drug’s 
melting point in carriers that show low compatibility with the drug will primarily result in 
a dispersion of the crystalline drug at reduced particle size and in its original polymorphic 
modification. These systems are favorable for controlled release delivery systems due to 
their advantageous storage stability. However, elevated temperature and polymer-drug 
interactions may favor polymorphic conversions or induce complete or partial melting or 
solubilization of the drug in the polymer matrix. The drug may be dispersed on a 
molecular level to form a true solid solution with the polymer, or be present as a separate 
phase to form an amorphous mixture with the carrier. This approach has been pursued for 
the bioavailability enhancement of poorly soluble drugs attributed to the higher solubility 
and dissolution rate of amorphous compounds. On the downside, these systems are 
susceptible to physical instabilities in the form of drug recrystallization or polymorphic 
conversion to the most stable modification after cooling and during storage. In any case, 
the solid state of the drug and the excipients should be characterized, the degree of 
crystallinity quantified and monitored during shelf-life. Popular analytical techniques that 
are used for the assessment of drug and excipient solid state properties include DSC or 
modulated DSC (MDSC), powder X-ray diffraction analysis (PXRD), solid-state NMR, 
FT-IR and Raman spectroscopy [20].   
The same analytical tools may be employed to investigate solid-state interactions 
between the drug and functional excipients. These interactions may be of a chemical 
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nature due to reactions between functional groups as it has been reported for 5-
aminosalicylic acid and citric acid during hot-melt extrusion [21]. Attractive 
intermolecular forces between blend components including hydrogen bonding, 
electrostatic and hydrophobic forces are typical physical interactions that may occur in 
the solid state. These interactions may decrease the melting point and viscosity of the 
blend, promote drug solubilization and amorphization during the extrusion process and 
oppose complete drug release from the matrix due to drug adsorption phenomena. 
When selecting an analytical method, several criteria need to be taken into 
consideration: How is the sample prepared, and does the preparation technique introduce 
solid-state changes into the system? Methods involving as little sample manipulation as 
possible should be preferred such as diffraction or diffuse reflectance techniques. Milling 
of the extrudates or the exposure to high pressure can potentially reduce drug crystallinity 
or induce polymorphic conversions. Heating procedures as used for DSC experiments 
may manipulate the solid state of the drug due to solubilization during testing. The 
characteristic limit of detection of the analytical method plays an important role if the 
drug loading in the matrix is low or small changes in crystallinity need to be detected. 
Although all of the listed techniques have the potential to be used for quantitative solid-
state analysis when calibrated carefully, some methods may provide signals that are more 
sensitive to the degree of crystallinity within the sample than others such as FT-IR. 
Signal independence from particle size represents an important advantage of NMR 
spectroscopy. When the nature of interactions needs to be identified, some methods 
including FT-IR or MS provide more useful information than others.  
Imaging techniques including scanning electron microscopy (SEM), transmission 
electron microscopy (TEM), energy dispersive spectroscopy (EDS) or atomic force 
microscopy (AFM) have proven useful to study the microstructure of hot-melt extruded 
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delivery systems. SEM has been demonstrated to be a highly sensitive method for the 
detection of drug recrystallized on the surface of supersaturated, hot-melt extruded tablets 
at concentrations below the limit of detection of PXRD or DSC [22]. EDS or AFM can 
be employed to investigate the drug particle size and degree of dispersion within the 
extruded matrix. Alternatively, peak broadening in PXRD patterns has been used to 
calculate the average particle size of drug nanocrystals in solid dispersions [23]. The 
porosity of hot-melt extrudates has been studied quantitatively by helium pycnometry and 
mercury intrusion porosimetry [9] or qualitatively by SEM. In addition, hot-melt 
extruded systems are generally characterized with respect to content uniformity and drug 
release profile. Fitting of the release data to mathematical models provides a tool to 
identify underlying drug release mechanisms.  
 
1.2.4 Hot-melt extrusion process technology  
Hot-melt extrusion represents a complex process combining co-melting with 
particle size reduction, homogenization and compression at elevated pressure. The 
formulation is ususally pre-blended and then fed into the extruder, or blend components 
can be metered separately using different feeders. Extruders may be flood-fed, implying 
that the feedstock is delivered into the screw channel by gravity, and that the rate of 
transport is controlled by the rotation speed of the screw(s). This method is commonly 
employed for free-flowing powder blends and when using single screw extruders. Starve-
feeding involves the delivery of material by a rate controlling feeder, making the 
throughput independent of the extruder screw rotation speed. Most commonly used 
devices are screw feeders which meter the blend either volumetrically or gravimetrically 
to achieve the target mass flow. Alternative feeding devices include vibration-assisted 
feeders, belt feeders, hoppers with agitators or roll feeders [24].  
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The heart of the extruder consists of a single- or twin-screw system rotating inside 
a heated barrel. The screw design strongly impacts the performance of the extruder, the 
properties of the extruded material and the throughput rate. Characteristic screw 
parameters represent the screw diameter, the screw length and the ratio thereof (L/D). 
The screw may be one piece or modular to allow application-oriented tailoring of the 
extrusion process. Typical screw elements include a feeding and conveyance zone in the 
initial section exhibiting a large channel volume, followed by melting, mixing and 
metering elements towards the die end. Twin-screw extruders may be operated using a 
co- or counter-rotating screw design. The co-rotating principle provides better mixing, 
can be operated at higher screw speeds and exhibits self-wiping properties [25]. Two 
different mixing processes occur during the extrusion process, dispersive and distributive 
mixing. Dispersive mixing results in a reduction in drug particle size due to the shear 
stress exerted by the rotating screw. Since shear stress is the product of shear rate and 
melt viscosity, dispersive mixing is highest within the initial segments of the extruder 
when the polymer melt exhibits the highest viscosity [26]. On the other hand, distributive 
mixing is essential to produce a homogeneous product of high content uniformity, and 
can be achieved by screw designs promoting splitting and recombination of the softened 
material. The barrel may also be in one piece or modular, is electrically heated and 
usually comprises several heating zones to generate temperature profiles. Venting 
modules may be incorporated into the barrel design to remove volatiles including 
moisture and residual monomers during extrusion. 
In addition to the extruder design, typical process control parameters include the 
feeding rate, screw rotation speed, and the temperature profile. Readout parameters that 
assist process monitoring are melt pressure and temperature, torque or motor load and 
energy consumption. The material exits the barrel through a product-shaping die whose 
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geometry is dictated by the application. The die poses a resistance to the material that 
needs to be overcome by the pressure which is generated by the moving melt. Depending 
on the dosage form requirements, dies with circular, annular and slit-shape orifices are 
available. 
 
1.2.5 Formulation stability during processing 
In spite of the tremendous research activity within the field of pharmaceutical hot-
melt extrusion during the past 20 years, the number of melt extruded products on the 
market remains slim until today. Most aspects contributing to this circumstance are 
directly or indirectly related to concerns of chemical or physical instabilities of single 
components or the drug product. Instabilities may occur during processing and become 
immediately apparent subsequent to the melt extrusion process, or manifest themselves 
during shelf-life. The extent of degradation is primarily dependent on the formulation, 
extrusion equipment and process design. The stability of the formulation components 
during the hot-melt extrusion process may be affected adversely by one or a combination 
of the following factors: 
1. Elevated temperature. 
2. Extensive mechanical shear rate or stress. 
3. High pressure. 
The extent of thermally induced degradation reactions is a function of the 
extrusion temperature, duration of heat exposure and heat susceptibility of the extruded 
material. The processing temperature is mainly dictated by the melt viscosity-temperature 
behavior and the glass transition temperature or melting point of the polymeric carrier. 
Selecting polymers with low melt viscosities and transition temperatures represents a 
viable approach to reduce the extrusion temperature and hence thermal degradation of the 
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drug and/ or the functional excipients. The use of processing aids including plasticizers 
and thermal lubricants enlarge the temperature window for hot-melt extrusion by 
decreasing the glass transition temperature of the polymer and the viscosity of the blend. 
Oxidation reactions may be reduced by either using anti-oxidants or by processing under 
vacuum or in an inert-gas atmosphere.  
The duration of heat exposure is determined by the residence time of the material 
inside the extruder. Short residence times of a few minutes are pivotal to limit 
degradation and may be realized by an appropriate extruder design and the use of well-
plasticized blends. Increasing the screw speed can reduce the residence time, but 
extensive shearing of the polymer by the rotating screws may provoke mechanical 
degradation. Crowley and coworkers reported that the degradation of polyethylene oxide 
during extrusion at low screw speeds could be diminished by reducing the temperature, 
suggesting a thermal degradation mechanism. Increasing the screw speed initially 
decreased polymer degradation due to shorter residence times, before mechanical fracture 
occurred at very high screw speeds. Low-molecular weight polyethylene oxide 
functioned as a plasticizer and enhanced the chemical stability of the parent polymer 
during extrusion [13]. 
 
1.3 IMPLICATIONS OF PLASTICIZATION OF HOT-MELT EXTRUDED DELIVERY 
SYSTEMS 
1.3.1 Definition and effects of plasticizers in polymeric systems 
Traditional plasticizers are compounds that are added to formulations to modify 
the properties of the polymer. When used in hot-melt extruded blends, the plasticizer will 
decrease the polymer’s glass transition temperature and melt viscosity. The blend can be 
processed applying lower temperatures and reduced mechanical work. The significance 
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of efficient plasticization increases when polymers with high glass transition 
temperatures are used, or if any blend component is susceptible to thermally induced 
degradation. Low melt viscosities are pivotal to maximize the output and yield of the 
extrusion process, and to minimize the residence time of the material inside the heated 
barrel. When added to coating formulations, plasticizers improve the film coalescence at 
reduced temperatures during the coating process and make the film more flexible.  
Plasticizers can be classified regarding their state being liquid or solid, their 
hydrophobicity, molecular weight, chemical structure or whether they are externally 
added to the blend or grafted into the polymer during polymerization. Solid-state 
plasticizers yield numerous advantages over liquid plasticizers in terms of handling and 
processing. Powdered plasticizers can be easily dry-blended with the drug and the 
polymer without forming tacky pastes with poor flow properties. The produced blends 
are of high homogeneity, and feeding into the extruder is facilitated due to superior 
powder flow. Solid plasticizers are generally less volatile, so that evaporate loss during 
extrusion is minimized. 
 
1.3.2 Mechanisms of plasticizer action 
The most important theories on mechanisms of plasticizer action were developed 
in the 40’s and 50’s including the lubricity theory, gel theory and free volume theory 
[27]. 
According to the lubricity theory, the plasticizer positions itself between the 
polymer chains so that attractive forces between the macromolecules are lowered and the 
gliding of the planes is facilitated during plastic flow. The gel theory describes a polymer 
as a three-dimensional network structure that is stabilized by temporary points of 
attachment between the polymeric chains similarly to a physically cross-linked gel. 
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Plasticizers reduce the number of contacts by solvation of the chains, resulting in a less 
rigid network of higher elasticity.  
The free volume theory was established by Fox and Flory and is based on 
thermodynamic principles. It defines the volume of a polymer as the sum of the occupied 
and the free volume. The free volume is created by the movement of polymeric chain 
ends, side chains and the main chain, and is impacted by the polymer molecular weight, 
structure and the temperature. The mobility of the polymer chains and hence the free 
volume increase greatly above the glass transition temperature or in the presence of 
plasticizers. Mathematical models to predict the glass transition temperature of a polymer 
blend including the Fox equation or Gordon-Taylor equation are based on the free 
volume theory. 
 
1.3.3 Polymer-plasticizer compatibility 
Polymer-plasticizer compatibility is defined as the ability of the plasticizer to 
form a homogeneous phase with the polymer without exudation of liquid-state 
plasticizers or crystallization of solid-state plasticizers. Thermodynamic concepts have 
been developed to explain or predict the compatibility between a polymer and a 
plasticizer. The compatibility during hot-melt extrusion is generally enhanced since 
plasticizer-polymer miscibility is thermodynamically favored. The entropy gain by 
mixing at elevated temperatures contributes to the negative free energy of the process. 
However, the plasticizer needs to remain solubilized in the polymer on the molecular 
level during storage at room temperature, which is only the case for highly compatible 
polymer-plasticizer combinations. 
Early on, it was observed that like dissolves like, concluding that plasticizer and 
polymer should exhibit similar polarities to maximize compatibility. Interaction 
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parameters including the Flory-Huggins interaction parameter χ were introduced to 
predict the compatibility of a polymer with solvents, but can also be applied for other low 
molecular weight compounds including plasticizers or drugs. Interaction parameters are 
based on enthalpic and entropic principles, and obtained from the calculation of the free 
energy of mixing. Polymer-plasticizer combinations exhibiting interaction parameters 
below 0.5 are likely to produce miscible, one-phase systems when extruded, but may not 
necessarily remain stable one-phase systems during storage [28]. 
Cohesive density energy or solubility parameters have been developed to predict 
the long-term stability of solid solutions during storage. These concepts consider only 
enthalpic aspects, since the entropy gain due to mixing is expected to be similar for most 
systems. Intermolecular forces between the polymer and low-molecular weight 
compounds are treated as a sum of dispersive, polar and hydrogen-bonding interactions. 
Solubility parameters can either be determined experimentally from evaporation 
enthalpies, equilibrium swelling or surface tensions, or be calculated from the chemical 
structure of the components. Highly compatible plasticizer-polymer systems should 
exhibit very similar solubility parameters with a difference of less than 2 [28]. 
 
1.3.4 Plasticizer effects on polymers and plasticization efficiency 
Plasticizers are added to hot-melt extrusion formulations for several reasons: 
1. Hot-melt extrusion of polymers with high glass transition temperatures may 
become feasible by the addition of a plasticizer. A decrease in glass transition 
temperature below the onset temperature of thermal degradation reactions will 
open a temperature window within which thermal processing will be possible. 
2. A plasticizer-induced decrease in melt viscosity of the polymeric carrier during 
extrusion will enhance the process output rate, increase the yield, minimize the 
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residence time of the material inside the extruder and hence reduce heat exposure. 
Low melt viscosities are further pivotal for the extrusion of multiparticulates due 
to the small orifice diameters of the applied dies. 
3. Plasticizers minimize the shear stress acting on the material during hot-melt 
extrusion by reducing the melt viscosity of the formulation. This is important for 
high-molecular weight components including polymeric excipients or biological 
compounds which may be sensitive to shearing. 
4. The finishing and visual appearance of the extruded dosage form will be enhanced 
by adding a plasticizer. 
Since plasticizers modify the physico-chemical properties of the polymer, a 
quantification of the plasticizer effects on the polymer provides a tool to evaluate their 
plasticization efficiency. Based on the nature of hot-melt extrusion as a thermal and 
mechanical process, an analysis of plasticization efficiency should encompass the 
polymer properties most relevant for the extrusion process: glass transition temperature 
and melt viscosity.  
Amorphous polymers undergo a transition from the brittle, glassy to a rubbery, 
deformable state characterized by a sharp increase in chain mobility and free volume at 
their glass transition temperature or Tg. The measurement of a polymer’s Tg in the 
presence of increasing levels of plasticizers requires monitoring of characteristic polymer 
properties that change at the Tg while heating the specimen. A popular and versatile tool 
represents differential or modulated differential scanning calorimetry (DSC or MDSC) 
which detects the characteristic change in heat capacity occurring at the Tg. A plot of the 
plasticizer concentration versus the Tg may yield a straight relationship within the 
compatibility limit of the system, with the slope of the line being characteristic of the 
plasticization efficiency. When exceeding the compatibility limit, the plasticizer will 
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form a separate phase, and the Tg of the polymer will remain constant. The Tg of the 
plasticized polymer will be intermediate to the Tg of the polymer and the plasticizer, and 
may be predicted using mathematical models as discussed by Marcilla and Beltran [27]. 
These models are based on the free volume theory and examples include the Gordon-
Taylor equation, Fox equation and expressions proposed by Kelly and Bueche or by 
Couchman. Alternatively to changes in heat capacity, the Tg can be determined as 
changes in the thermal expansion coefficient using thermo-mechanical analysis (TMA), 
changes in viscoelastic properties employing differential mechanical analysis (DMA), 
altered dielectric properties or changes in magnetic properties applying magnetic 
resonance spectrometry [29].  
Rheology studies characterize the deformation and flow behavior of polymers and 
can also be employed to characterize the efficiency of plasticizers. Plasticizers have been 
shown to decrease the melt viscosity as well as the process torque in a concentration 
dependent manner [30, 31]. Most polymeric melts show non-Newtonian flow with 
pseudoplastic and viscoelastic elements attributed to the chain entanglement of the 
macromolecules [32]. Besides the presence of plasticizers, the melt viscosity of extrusion 
blends is influenced by many other factors including the molecular structure and 
molecular weight of the polymeric carrier, the content of non-melting solids in the blend, 
the processing temperature and the shear rate. In most experimental set-ups, the viscosity 
or the torque is monitored either as a function of increasing temperature, screw speed or 
time while keeping the other parameters constant. Different analytical instruments may 
be employed to study the effect of plasticizers on the polymer melt viscosity including 
capillary viscometers, rotational viscometers (also referred to as cone-plate/ parallel-plate 
or cylinder-cup type rheometers) or Brabender torque rheometers. Most rotational 
viscometers may be operated at oscillatory frequencies to minimize sample disturbance 
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during testing. This allows the monitoring of viscoelastic properties including elastic and 
viscous modulus and complex viscosity during the temperature scan, which were 
demonstrated to decrease with increasing plasticizer concentrations [33]. Torque 
rheometers or hot-melt extruders may be used to investigate torque/ temperature or 
torque/ rotation speed relationships. The obtained data may be converted into viscosity 
units when calibrated versus a traditional viscometer [34].  
Besides Tg determinations and rheology studies, the effects of plasticizers on the 
mechanical properties of the polymer can be employed to evaluate plasticization 
efficiencies. The most frequently used mechanical parameter is the tensile strength, 
which generally decreases with increasing plasticizer concentrations in a linear manner 
[35]. More efficient plasticizers and increasing plasticizer concentrations further increase 
the elongation or strain and decrease the hardness and elastic modulus of polymeric 
specimens. 
 
1.3.5 Potential pitfalls encountered with plasticized systems 
It is important to be aware of the problems and challenges one may encounter 
when employing plasticizers in pharmaceutical dosage forms. Unwanted effects of 
plasticizers in hot-melt extruded delivery systems include: 
1. An increased extrudate flexibility or tackiness may compromise downstream-
processing including milling or strand cutting. 
2. High plasticizer levels may be physiologically incompatible and/ or be toxic. 
3. Plasticizers increase the free volume of the polymer, which can be studied using 
positron annihilation lifetime spectroscopy (PALS) [36]. As a consequence, 
physical instabilities may be promoted in the presence of plasticizers. The 
increased mobility of the polymeric chains will promote aging processes of the 
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polymer itself including continuing matrix coalescence or crystallization during 
storage, both processes resulting in slower drug release rates. Second, the 
molecular mobility of drug molecules that are dispersed in the amorphous state 
will be increased. If the amorphous system is thermodynamically instable, solid-
state changes including phase separation and drug recrystallization will occur at 
accelerated rates and reduce the shelf-life of the product. 
4. Plasticizers may compromise the ability of the matrix to control the drug release 
since water-soluble plasticizers can leach from the system and increase the matrix 
porosity. 
5. When using a plasticizer in pharmaceutical formulations, one must be aware that 
the plasticizer itself exhibits a certain molecular mobility within the polymer 
matrix and may migrate into contacting materials during storage. This material in 
contact with the plasticized dosage form may be a gas, for example when volatile 
plasticizers evaporate, a liquid as during dissolution studies or a second polymer. 
Common primary packaging materials contain polymers and plasticizers, and 
plasticizer migration can occur in both directions.  
These examples demonstrate that a careful consideration of the benefits and 
drawbacks of plasticization and an extensive characterization of the multi-component 
system are pivotal in the development of formulations for hot-melt extrusion. 
 
1.4 MODIFIED RELEASE MATRIX SYSTEMS PREPARED BY HOT-MELT EXTRUSION 
1.4.1 Factors influencing the drug release from matrix systems 
The drug release rate and mechanisms from matrix-type delivery systems are 
influenced by a multitude of factors including matrix porosity, permeability, swelling 
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behavior and solubility of the polymer, loading of soluble compounds in the formulation, 
drug solubility, drug solid-state and particle size, plasticizer type and level and dosage 
form geometry and surface area. The drug release from insoluble carrier materials 
including polymers and lipids is mainly governed by diffusion, which can be understood 
as a three-step process: water ingression into the matrix, drug dissolution and drug 
diffusion through the matrix into the dissolution medium. Each of the steps can be rate-
controlling, depending on the properties of the matrix. If the polymer swells or dissolves 
in the dissolution medium, further release mechanisms come into play. The matrix 
permeability to the penetrating water or diffusing drug is a function of the initial porosity, 
the number and size of pores formed by leaching of soluble components, and also by the 
thickness and viscosity of polymeric gel layers on the surface. For a complete drug 
release, the polymer needs to either dissolve, or the loading of soluble formulation 
components needs to be above a characteristic threshold value to eliminate finite drug 
clusters in the interior and allow a percolation of the entire matrix. The initial porosity of 
hot-melt extruded matrices is generally low and can be minimized using elevated 
processing temperatures or including plasticizers to enhance polymer coalescence. In 
addition to drug diffusion through water-filled pores, diffusion though the polymer 
network has also been discussed as release mechanism for poorly water-soluble drugs 
[37]. In this case, the diffusion rate will also depend on the degree of polymer 
crystallinity, since diffusion is only possible in amorphous regions as the permeability of 
crystalline regions is very low due to dense chain packing. The solid state and the particle 
size of the drug further impact the dissolution rate of the drug inside the matrix. Most 
matrix-type systems undergo burst release during the initial period of dissolution testing 
which is attributed to the release of unprotected drug at the surface. Burst release effects 
 
 20
are more pronounced for dosage forms exhibiting large surface-area-to-volume ratios 
including multiparticulates, and at elevated drug loadings. 
 
1.4.2 Applications and downstream processing of hot-melt extruded dosage forms 
The pioneering work in the adaption of hot-melt extrusion for pharmaceutical 
applications was conducted by Speiser and Huettenrauch in the 60’s and 70’s. Over the 
past 20 years, tremendous research efforts have been directed towards the bioavailability 
enhancement of poorly soluble drugs using solid dispersion technology. Hot-melt 
extrusion has been demonstrated to be an efficient and highly accepted technology for the 
preparation of amorphous solid solutions or fine crystalline suspensions exhibiting 
enhanced solubility and dissolution rates [7]. The formulation of soluble compounds for 
extended or delayed delivery provides a further important application field for hot-melt 
extrusion. 
The utilization of differently shaped dies and appropriate downstream processing 
makes hot-melt extrusion a highly versatile technology for the manufacture of a vast 
number of different dosage forms. Films can be produced by extruding the material 
through slit-shaped dies onto cooled rolls which stretch the film to the targeted thickness. 
Extruded strands may be cut into tablets or pelletized into short cylinders, which can then 
be spheronized to obtain spherical particles. Cutting may be performed after cooling of 
the strand on conveyer belts (strand pelletizers), or directly upon extruder exit in the soft 
state (die-face pelletizers). In addition to cutting operations, monolithic matrices may be 
obtained by injection molding into tablet-shaped cavities [38, 39] or by calendaring in the 
soft state between two counter-rotating calendar rolls [40]. Grinding of hot-melt 
extrudates yields powders which may be filled into capsules, directly compressed into 
tablets or used for dry powder coating applications [41].  
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1.4.3 Monolithic, hot-melt extruded dosage forms providing modified drug release 
1.4.3.1 Water-soluble, swellable polymers as carriers 
Hydrophilic swellable polymers are popular materials for directly compressed 
matrix tablets due to their ability to provide zero-order release profiles [42]. However, 
most of these polymers including hydroxypropyl methylcellulose and other 
polysaccharides exhibit very high glass transition temperatures, making their hot-melt 
extrusion challenging. A review of the scientific literature showed that polyethylene 
oxide (PEO) in varying molecular weights is the most widely used matrix material for 
hot-melt extruded, hydrophilic systems for sustained drug delivery attributed to its low 
melting range and good thermal processibility. Zhang and McGinity demonstrated that 
the release of chlorpheniramine maleate from PEO 1000K and 7000K melt extruded 
matrices was controlled by the erosion kinetics of the polymer and by drug diffusion 
though the swollen gel layer [43]. The drug release from melt extruded tablets was 
further found to be more sustained than from directly compressed tablets of the same 
composition due to the reduced porosity of the hot-melt extruded matrix [9]. 
Plasticization of PEO with supercritical carbon dioxide increased the polymer 
crystallinity, but also the drug release rate due to the increased porosity of the produced 
extrudate [44]. Elevated amounts of hydrophilic or amphiphilic additives including PEG 
3350 [43] and vitamin E TPGS [13] accelerated the drug release from PEO matrices, 
while hydrophobic polycaprolactone [45] or viscous agar [46] prolonged the release. The 
drug release was neither influenced by the extrusion screw speed nor by the extrusion 
temperature within the investigated ranges [45]. Mixtures of PEO and chitosan or 
xanthan gum could be successfully extruded and provided pH-dependent dissolution 
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profiles, while the combination of both polymers in PEO sustained the release and made 
it pH-independent attributed to intermolecular hydrogel formation [47]. 
 
1.4.3.2 Insoluble polymers as carriers 
Drug release from insoluble polymeric matrices is primarily governed by 
diffusion processes, which are a function of the porosity of the system. Applying the 
percolation theory, the major pathway of drug release from an insoluble matrix is by 
diffusion through water-filled pores, and to a lesser extent, by diffusion through the 
polymer [48]. Only drug particles that are in contact with the dissolution medium (infinite 
clusters) will dissolve and be released by diffusion. The critical drug load or total soluble 
fraction that is necessary to form a continuous network of pores during the dissolution 
process is referred to as percolation threshold [49]. Below the percolation threshold, only 
drug at the surface in contact with the medium will be released, while significant amounts 
of drug remain trapped as finite clusters inside the insoluble polymer matrix. Attributed 
to the high degree of matrix coalescence during hot-melt extrusion, the initial porosity of 
hot-melt extruded dosage forms prior to dissolution of soluble components is very low 
when compared to compressed tablets [9]. The contribution of initially present pores to 
drug diffusion is hence minor, and drug release rates are dependent on diffusion through 
channels created by leaching of soluble formulation components including the drug, 
hydrophilic plasticizers or polymers during the dissolution process. This circumstance 
makes hot-melt extrusion a valuable technology for the preparation of sustained release 
matrices containing high loadings of water-soluble drugs. Common strategies to tailor the 
release profile or achieve a complete drug release over the dissolution period include the 
addition of soluble low-molecular weight excipients or polymers, increasing the drug 
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load or modifying the dosage form geometry and hence surface area that is available for 
diffusion processes. 
Sprockel incorporated 50 or 70% theophylline into polymeric disks by hot-melt 
extrusion using polyethylene, polycaprolactone, polyvinyl acetate or cellulose acetate 
butyrate as the release-controlling carrier. Higher drug amounts could not be loaded since 
the processibility of higher percentages of non-melting drug in the formulation was 
compromised. The nature of the polymer influenced the diffusion rates from the disk 
surfaces at constant drug loadings. Increasing the soluble fraction in the matrix by using 
higher drug levels or soluble additives increased the drug diffusion rates attributed to a 
higher number of infinite clusters. The drug release was also found to be influenced by 
the solubility and true density of the drug since the occupied drug volume is higher for 
low-density drugs at equal mass percentages in the formulation [50]. The drug release 
from polyvinyl acetate based tablets prepared by either cutting of the extruded strands or 
by compression of the milled extrudates was mainly governed by diffusion and could also 
be accelerated by higher drug loadings or water-soluble polymers as additives in the 
formulation [51]. 
Crowley and coworkers prepared ethylcellulose-based matrix tablets containing 
30% guaifenesin by either direct compression or hot-melt extrusion to investigate the 
influence of the processing method on the drug release. Further studied parameters 
included ethylcellulose particle size, the compaction force used for tablet compression 
and the processing temperature for melt-extruded systems. The drug release rate could be 
correlated to the porosity of the prepared tablets and was diffusion-controlled for hot-melt 
extruded products. Processing by hot-melt extrusion, a higher extrusion temperature and 
small particle size ethylcellulose decreased the porosity and increased the tortuosity of 
the matrices, resulting in slower drug diffusion and release rates [9]. 
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Further popular polymers for the melt extrusion of sustained release dosage forms 
include Eudragit® RS PO and Eudragit® RL PO attributed to their low glass transition 
temperatures and melt viscosities. Zhu and coworkers demonstrated that the effect of the 
TEC level in melt extruded tablets was different from the film coated systems. While 
higher plasticizer levels promoted the film coalescence and decreased the drug release 
from the coated dosage form, the drug release increased at higher TEC levels for hot-melt 
extruded tablets due to pore formation in the matrix after TEC dissolution [52]. An 
increase in drug amount also increased the diffusion controlled release rate of a soluble 
model drug, while the release of poorly soluble indomethacin remained unchanged at a 
higher drug level [37]. The indomethacin release from a Eudragit® RL based matrix 
could be enhanced by adding polymers that were soluble and/ or decreased the adsorption 
of the drug to the quaternary ammonium groups of the polymer during dissolution [53]. 
Fukuda and coworkers incorporated sodium bicarbonate into Eudragit® RS PO matrices 
to prepare porous, buoyant tablets since carbon dioxide was generated during the 
extrusion process. Hot-melt extruded formulations of low density were demonstrated to 
float for 24 hours und provided a sustained drug release for one of the two investigated 
model drugs. The release rate could be tailored by increasing the drug load, adding acid-
soluble Eudragit® EPO or by modifying the matrix geometry [54]. 
More recently, Kollidon® SR, a copolymer of polyvinyl acetate and 
polyvinylpyrrolidone (8:2) with a low glass transition temperature, has been explored as 
sustained release carrier for melt extruded tablets. The diffusion controlled drug release 
increased at higher drug loadings and when water-soluble hydroxypropyl cellulose was 
added [55]. Tablets compressed from milled extrudates exhibited a lower tensile strength 
but a better control of the drug release by diffusion processes compared to directly 
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compressed compacts. The release rate could be tailored by adding soluble Kollidon® 
VA (polyvinylpyrrolidone-co-vinyl acetate) at a 10 or 20% level to the composition [56]. 
 
1.4.3.3 Lipids and waxes as carriers 
Lipid or wax carriers are popular matrix materials for sustained release 
formulations due to their low costs, high physiological compatibility and low melting 
ranges. The most common preparation methods for lipids require their complete melting 
to exploit their binding properties as in melt granulation and spray-congealing. Liu and 
coworkers prepared wax granules containing 15% drug and 30% glyceryl palmitostearate 
(Precirol® ATO 5) by either hot-melt extrusion or melt granulation at temperatures above 
the melting point, and compared the properties of the granules and of compressed tablets. 
Both methods produced sustained release granules, and the tablets prepared from these 
granules released the drug at a slower rate than directly compressed compacts of the same 
composition. Hot-melt extruded granules provided a more uniform drug content over 
different particle size fractions and produced harder tablets [57].  
A frequently encountered problem with thermally processed wax carriers is their 
physical instability during storage, resulting in unstable drug release profiles. Lipids are 
complex polymorphic compounds, and storage ususally leads to re-crystallization of 
amorphous regions and conversions of metastable modifications. It has been shown that 
the polymorphic composition of recrystallized lipids after hot-melt extrusion is dependent 
on the extrusion temperature [58] and on the presence of partial glycerides in the 
formulation [59]. Solid lipid extrusion in a twin-screw extruder allows processing of 
lipids below their melting point to minimize physical instabilities and produce extrudates 
of low porosity. Reitz and Kleinebudde demonstrated that the melt extrusion of glyceryl 
trimyristate (Dynasan® 114) at low temperature produced matrices of very low porosity 
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(1.5%), exhibiting a stable and sustained theophylline release at high drug loadings (50 
and 75%). The processing temperature was optimized so that the lipid only softened 
instead of melted, and the solid lipid fraction was high at 80-90% during thermal 
processing. The solid state of the lipid remained unchanged after extrusion below the 
melting point and during accelerated storage [60]. Using solid lipid extrusion, stable 
extrudates with tailored drug release profiles could be obtained by extruding mixtures of 
tripalmitin (Dynasan® 116) and polyethylene glycol [61]. 
 
1.4.3.4 Enteric polymers as carriers 
Hot-melt extrusion of enteric polymers produces matrix systems with delayed 
release properties. Andrews and coworkers demonstrated that melt extruded tablets 
containing 15% 5-aminosalicylic acid and Eudragit® L100-55 released less than 5% drug 
over 2 hours in acid [62], while hot-melt extruded Acryl-EZE® tablets containing 20% 
theophylline yielded 10% drug release [63]. Yang and coworkers prepared enteric 
Eudragit® L100 tablets releasing less than 3% drug by either cutting of the extruded 
strands into tablets or by direct compression of comminuted extrudates [64]. Melt 
extruded Eudragit® S100 tablets for the colonic delivery of 5-aminosalicylic acid also 
showed excellent gastric protection [21]. When compared to directly compressed matrix 
tablets which failed to efficiently delay the drug release in acidic media, hot-melt 




1.4.4 Multiparticulate, hot-melt extruded dosage forms providing modified drug 
release 
1.4.4.1 Methods of pellet preparation and general properties of hot-melt extruded 
pellets 
Traditional methods of pellet preparation require multiple steps and the use of 
water or organic solvents. Popular techniques including wet-mass extrusion/ 
spheronization, granulation or balling utilize binder solutions or dispersions in 
combination with kneading and compaction forces to generate spherical or semi-spherical 
particles. Alternatively, pellets may be prepared by layering of core seeds or by spray 
drying. Modified release properties are mainly achieved by the subsequent application of 
a functional coat in case of reservoir-type pellets, or may be provided by the dissolution 
properties of the matrix material itself (matrix pellets). Although film-coating is well 
established and widely used, this procedure is labor intensive and costly since it requires 
the careful optimization of multiple steps including coating, drying and curing. The 
preparation of matrix pellets instead reduces the number of production steps and may 
overcome challenges associated with film-coating. Wet-mass extruded matrix pellets may 
provide sustained release profiles for poorly soluble compounds whose release is 
controlled by the erosion kinetics of the matrix material [65]. Thermal methods such as 
melt granulation or spray congealing may be used to sustain the release of soluble drugs 
in lipophilic matrices based on triglycerides, waxes or fatty acids [66, 67]. 
Alternatively, hot-melt extrusion can be used for the preparation of modified 
release pellets containing a highly soluble drug dispersed in a release-controlling 
polymer. The diameter and cross sectional geometry of the extruded pellets are mainly 
controlled by the design and orifice size of the product-shaping die. The produced pellets 
show a narrow particle size distribution and tight particle size fractions may be obtained 
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at high yields compared to traditional wet-mass extrusion methods [8]. The release of 
water-soluble drugs from hot-melt extruded pellets is mainly controlled by the 
permeability and dissolution behavior of the carrier and by the amount of soluble 
components in the formulation. As opposed to pellets prepared by traditional wet-
massing techniques, the initial porosity of melt extruded matrix pellets is low, minimizing 
drug diffusion through water-filled pores [9]. Pellets with high drug loads may be 
successfully prepared under preservation of the controlled release properties. As 
demonstrated for a formulation containing 30% theophylline, pellets providing sustained 
drug release could be prepared by hot-melt extrusion, while wet-massed pellets failed to 
prolong the drug release [8]. Electron microscopic images of pellet cross-sections showed 
that melt extruded matrices were highly coalesced and void of pores, while wet-massed 
pellets remained porous agglomerates of distinct particles.  
 
1.4.4.2 Hot-melt extruded pellets with sustained release properties 
Follonier and coworkers investigated four polymers (ethylcellulose, cellulose 
acetate butyrate poly(ethylene-co-vinyl acetate) and Eudragit® RS PM) as thermoplastic 
carriers for the melt extrusion of sustained release diltiazem hydrochloride matrix pellets 
containing drug amounts of 30-70% [14, 68]. The rate and extent of drug release was 
dependent on the carrier polymer, the pellet particle size and the drug load. All 
formulations yielded sustained release profiles with biphasic dissolution characteristics: 
an initial burst release due to dissolution of drug at the pellet surface, followed by a slow, 
diffusion-controlled phase. Hydrophilic polymers and swelling superdisintegrants were 
added to the formulation to suppress the initial burst by gel formation and promote a 
complete drug release by increasing the matrix porosity in the second phase. Miyagawa 
and coworkers demonstrated that a twin-screw extruder may be used for the preparation 
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of cylindrical sustained release pellets based on carnauba wax [69]. The generation of 
high pressures in the melting zone enabled processing at temperatures below the wax 
melting point. Soluble and swellable polymers increased the drug release rates in a 
concentration dependent manner by promoting crack and pore formation in the matrix. 
Granules based on glyceryl palmitostearate could be successfully prepared with a single-
screw extruder when the ratio between melting wax and non-meltable filler was 
optimized [57]. Brabender et al. developed mini-matrices containing ethylcellulose as the 
thermoplastic carrier for the sustained release of ibuprofen [11]. Although high drug 
loads of 60% were used, the release from the ethylcellulose matrices was very slow with 
only 20% drug released in 24 hours. Hydrophilic polymers were added to increase the 
drug release rate. In contrast to hydroxypropyl methylcellulose compacts, higher 
viscosity grades increased the dissolution rate to a larger extent attributed to their higher 
swelling capability which promoted water penetration into the matrix. When xanthan 
gum was used instead of hydroxypropyl methylcellulose, the initial burst release was 
eliminated and drug release profiles approaching zero-order kinetics could be produced. 
 
1.4.4.3 Hot-melt extruded pellets with delayed release properties 
According to the current USP, the drug release from delayed release articles is 
limited to no more than 10% in acidic medium pH 1.2 over 2 hours. As previously 
pointed out for sustained release pellets, drug at the particle surface is exposed to the 
release medium and undergoes burst release during the initial acidic stage of the 
dissolution test. High drug loads and small pellet particle size increase the fraction of 
drug that is devoid of the control by the enteric polymer, resulting in failure of the USP 
requirement for the maximum release in acid. As previously demonstrated for hot-melt 
extruded matrix systems based on Eudragit® L100-55, pellets extruded through a 1.2 mm 
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die and containing 20% theophylline released more than 25% drug in 2 hours at pH 1.2, 
compared to 10% drug release from melt-extruded tablets with a diameter of 6 mm [63]. 
As disclosed in patent application WO 2008/101743, the permeability of enteric polymers 
may be reduced by utilizing blends with an insoluble polymer [70]. It could be 
demonstrated that matrix pellets containing 50% drug exhibited enhanced gastric 
resistance when anionic Eudragit® FS 30D in the spray-dried form was extruded in a 
physical mixture with insoluble Eudragit® RS PO [71]. Additional challenges arise from 
the thermal properties of most enteric polymers. The temperature window between glass 
transition and thermal degradation is oftentimes small, so that the use of plasticizers 
becomes indispensable. Efficient plasticization is further required to lower the melt 
viscosity and reduce the elastic recovery or die swelling of the polymer as the preparation 
of small pellets involves an extrusion of the softened material through die orifices with 
diameters of 1 mm or less. Plasticizers exhibiting aqueous solubility may leach from the 
pellet or promote water penetration into the matrix, resulting in increased drug release 
rates by diffusion through the porous network during the acidic stage. 
 
1.4.4.4 Advantageous downstream processing of hot-melt extruded pellets 
Hot-melt extruded matrix pellets potentially exhibit a higher robustness than 
coated particles towards downstream processing procedures which is attributed to their 
high mechanical strength, low friability and the circumstance that the release 
performance is independent of the intactness of a functional coat. Since wet-massed 
pellets are porous agglomerates of distinct particles, they mainly fail by adhesive or 
cohesive fracture, or by crack propagation of flaws when subjected to compression forces 
[72]. On the other hand, hot-melt extruded dosage forms are highly coalesced matrices 
exhibiting low porosity and being held together by intermolecular forces and physical 
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entanglement between polymeric chains. These strong cohesive forces and the lack of 
pores are responsible for the high mechanical strength of melt extruded pellets. As 
demonstrated by Young and coworkers, multi-particulate tablets of acceptable hardness 
and low friability could be prepared by direct compression of 50% hot-melt extruded 
pellets with tableting excipients [73]. Furthermore, the release properties of the 
unprocessed pellets could be reproduced after tableting independent of the compaction 
force, pellet-to-filler ratio and tableting excipient when a rapid disintegration of the 
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Chapter 2: Research Outline 
2.1 OVERALL OBJECTIVE 
The overall objective was to investigate the influence of formulation factors and 
processing parameters on the properties of hot-melt extruded, controlled release dosage 
forms for the oral delivery of water-soluble active compounds. The impact of polymer 
plasticization on the processibility, solid-state properties and release characteristics of the 
active compound was studied. The applicability of hot-melt extrusion technology for the 
preparation of a variety of solid dosage forms including tablets, pellets and 
multiparticulate matrices was investigated. 
 
2.2 SUPPORTING OBJECTIVES 
2.2.1 Investigation of Citric Acid as a Solid-State Plasticizer for the Hot-Melt 
Extrusion of Eudragit® RS PO Matrix Tablets 
Plasticization of pharmaceutical polymers by solid compounds has been 
previously reported. Efficient plasticization requires the melting of the plasticizer and its 
miscibility with the polymer during extrusion. The utilization of solid-state plasticizers 
yields advantages over traditional liquid plasticizers in terms of material handling and 
processing, product content uniformity and stability. The capability of citric acid to 
interact with polymers by hydrogen bonding and its high physiological acceptance make 
it an ideal candidate for the plasticization of pharmaceutical formulations for hot-melt 
extrusion applications. The compatibility of citric acid monohydrate with Eudragit® RS 
PO, a methacrylic polymer providing sustained drug release, was studied by modulated 
differential scanning calorimetry (MDSC) and powder X-ray diffraction analysis 
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(PXRD). The plasticization efficiency was examined by mechanical testing of plasticized 
films and by monitoring the extrusion process parameters. 
 
2.2.2 Study of the Effects of Citric Acid Monohydrate on the Solid-State and Drug 
Release Properties of Diltiazem Hydrochloride in Melt Extruded Eudragit® 
RS PO Matrix Tablets 
The utilization of plasticizers in matrix systems potentially impacts their drug 
release performance by alteration of the matrix microstructure, polymer properties and 
solid-state characteristics of the drug itself. The miscibility between diltiazem 
hydrochloride with the polymer and with citric acid monohydrate during thermal 
processing was investigated by MDSC and PXRD. The influence of the citric acid 
monohydrate level and the diltiazem hydrochloride particle size on the drug dissolution 
rate was investigated at constant drug-to-polymer ratios. It was observed that the drug 
release rate increased and became independent of the drug particle size as a function of 
the citric acid monohydrate level. The mechanisms of dissolution rate enhancement in the 
presence of citric acid monohydrate were studied in comparison to alternative pore 
forming excipients at constant polymer levels. The matrix porosity and morphology were 
examined by scanning electron microscopy (SEM), and the degree of drug crystallinity 
was analyzed using PXRD. 
 
2.2.3 Investigation of the Influence of Formulation Factors on the Properties of 
Enteric Hot-Melt Extruded Matrix Pellets 
This study was driven by the objective to prepare multiparticulates by hot-melt 
extrusion that have diameters below one mm and provide delayed drug release. 
Traditional multiparticulates of the reservoir-type require an additional coating step to 
impart controlled release properties to the dosage form. The hypothesis was that enteric, 
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matrix-type multiparticulates can be prepared by hot-melt extrusion. Attributed to the low 
porosity of melt extruded systems, the drug release is controlled solely by the matrix, so 
that subsequent coating with release-controlling polymers is not necessary. Five anionic 
polymers that had been traditionally employed for enteric coating applications were 
investigated as matrix materials regarding their processibility by melt extrusion and their 
gastric resistance. Based on the results of this study, Eudragit® S100 was selected, and 
the effect of drug loading on the processibility and release properties of the matrix pellets 
was studied. The influence of five plasticizers differing in aqueous solubility, 
plasticization efficiency and molecular weight was examined with respect to the thermal 
properties of the polymer, solid-state of the drug, pellet microstructure and delayed 
release characteristics.  
 
2.2.4 Investigation of the Influence of Plasticizer Type and Level on the Properties 
of Eudragit® S100 Matrix Pellets Prepared by Hot-Melt Extrusion 
Based on the results obtained in the previous chapter, three efficient plasticizers 
for the hot-melt extrusion of Eudragit® S100 were selected for further studies. The 
viscosity-temperature behavior of polymeric melts was investigated at a constant shear 
rate as a function of the plasticizer type and level. In addition to the thermal behavior, the 
drug release properties and mechanical strength of the plasticized pellets were studied 
using dissolution experiments and diametral compression analysis. 
 
2.2.5 Study of Formulation and Processing Factors that Impact the Applicability 
of Hot-Melt Extrusion for the Embedment of Enteric Coated Particles into 
Multiparticulate Monolithic Matrices 
Although multiple-unit systems exhibit beneficial biopharmaceutical properties, 
monolithic dosage forms are preferred with regard to the final product to ensure patient 
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compliance and dosing accuracy. The most common post-processing technologies 
include the filling into hard-gelatin capsules and the compression into multiparticulate 
tablets. Tableting of functionally coated particles is challenging since the integrity of the 
film may be compromised during the compaction process. Differences in size, shape, 
density and flowability between coated particles and powdered tableting excipients 
further promote blend segregation, resulting in tablets with poor content uniformity. The 
objective was to investigate hot-melt extrusion as an alternative technology for the 
preparation of multiparticulate monolithic matrices without compromising the delayed-
release properties of the enteric particles. Attributed to the absence of unidirectional 
compaction forces and vibrational movements during tableting, improved content 
uniformity and gastric protection of the final dosage form were expected. Particles of 
different mechanical strength (theophylline granules, pellets and layered microcrystalline 
cellulose spheres) were enteric coated with Eudragit® L30D-55 and characterized by 
diametral compression analysis and dissolution testing. Six hydrophilic, semi-crystalline 
polymers were studied as potential carriers for the enteric particles. The miscibility 
between the carrier polymer and the enteric polymer was investigated by differential 
scanning calorimetry to predict a potential solubilization and damage of the particle 
coating during the extrusion process. The influence of the carrier polymer, particle load 
and the particle strength on the preservation of the enteric properties during hot-melt 
extrusion was studied. The delayed-release characteristics of soft particles that were 
extruded in a poloxamer 407 matrix were examined after one year of storage and 
compared to a directly compressed formulation.  
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Chapter 3: Investigation of Citric Acid as a Solid-State Plasticizer for 
the Hot-Melt Extrusion of Eudragit® RS PO Matrix Tablets1 
 
Abstract: 
The use of solid-state plasticizers for the hot-melt extrusion of pharmaceutical 
dosage forms has been shown to be beneficial compared to liquid plasticizers. The 
purpose of this study was to determine the suitability of citric acid (CA) as a solid 
plasticizer for the preparation of Eudragit® RS PO extended release matrix systems by a 
melt extrusion technique. The influence of increasing levels of CA monohydrate (CA 
MH) or anhydrous CA in the powder blend on the extrusion process parameters (screw 
speed and motor load) was determined as a function of temperature. The solubility of CA 
MH in extruded tablets was studied by means of modulated differential scanning 
calorimetry (MDSC) and powder X-ray diffraction (PXRD). Films were cast from 
organic solutions to demonstrate the plasticizing effect of CA MH as a change in 
physico-mechanical properties (tensile strength, elastic modulus and elongation). The CA 
release from extruded tablets was studied over 12 hours. The monohydrate form was 
found to distinctly facilitate the extrusion of Eudragit® RS PO, whereas the addition of 
anhydrous CA to the polymer powder was less effective. This divergent behavior in 
plasticization of Eudragit® RS PO was attributed to the higher solubility of the 
monohydrate in the acrylic polymer. The plasticizing effect of the CA MH reached a 
plateau at 25% during hot-melt extrusion which coincided with the solubility limit of the 
organic acid in the polymer as shown by MDSC and PXRD results. The citric acid 
                                                 
1 Significant portions of this chapter were taken from: Schilling, S.U., Shah, N.H., Malick, A.W., Infeld, 
M.H., Martin H. Infeld, and McGinity, J.W. Citric acid as a solid-state plasticizer for Eudragit® RS PO. 
Journal of Pharmacy and Pharmacology, 2007, 59, p: 1493-1500. 
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monohydrate increased the flexibility of Eudragit® RS PO films as demonstrated by a 
decrease in tensile strength and elastic modulus, and an increase in elongation as a 
function of CA MH concentration. The dissolution of CA from the matrix tablets 
followed an extended-release profile, with CA MH exhibiting a faster dissolution rate 
than the anhydrous form. In conclusion, CA MH was found to be an effective plasticizer 
for Eudragit® RS PO that facilitates the production of controlled release matrix systems 




Hot-melt extrusion is a simple method to produce solid dispersions/ solutions of 
poorly water-soluble drugs to increase their release rate [1], and an alternative method to 
tablet compression or film coating to manufacture controlled-release dosage forms of 
highly soluble drugs [2, 3]. The large variety in die shapes allows the manufacture of 
various dosage forms such as tablets, pellets or films [4]. The extrudate can also be 
ground to a powder and compressed into tablets or used for dry powder coating [5]. 
Benefits of melt extrusion include efficient and continuous processing, the elimination of 
solvents and the absence of compressibility requirements for the excipients in the powder 
blend. 
The inclusion of a plasticizer into the formulation is generally necessary since 
most pharmaceutical polymers exhibit high glass transition temperatures (Tg). Plasticized 
polymers soften at a lower temperature and yield a lower melt viscosity, and thus, can be 
melt processed at lower temperatures. Most pharmaceutical plasticizers employed today 
are in the liquid state, for example organic esters (citrates and phthalates) and polyols 
(glycerol, PEG’s with low molecular weight). Several solid compounds such as lidocaine 
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hydrochloride [6], methylparaben [7], ibuprofen [8, 9], chlorpheniramine maleate [10], 
tartaric acid [11] and indomethacin [12] have been reported previously to exert 
plasticizing effects on polymers of pharmaceutical interest. Solid-state plasticization is 
thought to occur through distribution of the plasticizer in the molten polymer after being 
melted or dissolved during extrusion, and occupation of active binding sites following the 
same mechanisms as with liquid plasticizers. Therefore, the solid compound must be 
sufficiently soluble in the polymer, and an interaction between both materials is 
necessary to achieve plasticization [9]. 
The application of solid-state plasticizers is advantageous compared to liquid 
plasticizers. The mixing process prior to extrusion is more efficient, and the higher 
homogeneity of the obtained powder formulation yields an enhanced uniformity of the 
final product. Improved flow properties assure a stable and continuous powder flow 
through the extruder. Further important advantages are the higher thermal stability of 
most solid-state plasticizers and the decreased weight loss due to evaporation during the 
melt extrusion process. A lower tendency of plasticizer leaching or migration upon 
storage has also been discussed [13]. 
Citric acid (CA) is a widely used excipient in pharmaceutical formulations as an 
acidifying agent to decrease the microenvironmental pH in enteric coated dosage forms 
[14-16]. Researchers have further used CA as a hydrophilic carrier for poorly soluble 
drugs in solid dispersions produced by co-melting techniques to increase the dissolution 
rate and bioavailability [17, 18]. The CA molecule has a high capacity for hydrogen-bond 
formation and thus possesses a potential to interact with and plasticize certain 
pharmaceutical polymers. Bruce et al. reported a plasticizing effect of CA on Eudragit® 
L 30D-55 [16] and Eudragit® S100 [19] when incorporated into either enteric film 
coatings or matrix tablets, respectively. Wan et al. [20, 21] found CA to be beneficial for 
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wall formation in spray dried HPMC microcapsules. Chitosan films cast from aqueous 
CA solutions were reported to exhibit a high flexibility, demonstrating CA to be a good 
plasticizer for this polymer [22, 23].  
The application of Eudragit® RS PO as carrier polymer in hot-melt extruded 
matrix systems has been previously reported [24]. The objective of the present study was 
to investigate the ability of citric acid to function as a solid-state plasticizer for the melt 
extrusion of Eudragit® RS PO. The properties of extruded tablets and cast films 
containing different levels of CA were determined. The solubility of the organic acid in 
the polymer was studied by modulated differential scanning calorimetry (MDSC) and 
powder X-ray diffraction (PXRD). The mechanical properties of cast films were 
investigated, and the CA release from extruded tablets was observed over 12 hours. Since 
the anhydrous form of CA exhibits different properties when compared to the 
monohydrate, both materials were processed separately with the acrylic polymer, and the 
properties of the resulting tablets were determined. 
 
3.2 MATERIALS 
CA MH (powder, U.S.P.) and anhydrous CA (powder, U.S.P.) were purchased 
from Spectrum Chemicals (Gardena, CA). The monohydrate was ground with a mortar 
and a pestle and passed through a 60 mesh sieve (250 μm) prior to use. Eudragit® RS PO 
was donated by Degussa Röhm America (Piscataway, NJ), while Cab-O-Sil® M-5P was 





3.3.1 Manufacture of hot-melt extruded tablets 
The anhydrous citric acid (25% based on the total weight) or citric acid 
monohydrate (0 to 30% based on the total weight) was geometrically diluted with the 
polymer and blended. Cab-O-Sil® M-5P (0.5%) was included into the formulations to 
promote a constant powder flow during the extrusion process. The blends were manually 
fed through a hopper into an extruder (Randcastle single-screw extruder, model RCP 
0750 Microtruder, Cedar Grave, NJ) and processed at temperatures between 90 and 
140°C, depending on the processability of the formulation. The screw speed was set to a 
maximum of 20 rpm, while the motor load was limited to 0.700 drive amperes, and the 
pressure did not exceed 200 PSI (1.379 MPa). The molten polymer strand exited through 
a circular 6 mm die and was manually cut into 250 mg tablets. 
 
3.3.2 Preparation of films 
Eudragit® RS PO and CA MH (0 to 30%) were dissolved in 50 ml acetone so that 
15% (w/v) solutions were obtained. The films were cast onto leveled 15 × 15 cm square 
teflon-coated plates and allowed to dry at room temperature for 24 hours, followed by an 
additional 24 hours in a 40°C oven to facilitate solvent removal. After the drying process, 
uniform rectangular specimens (15 mm × 70 mm × 300 µm) were cut and stored at 
25±1°C and 50±5% relative humidity for at least 48 hours prior to analysis. Film 
thickness was measured at 6 different locations along the entire length of the film with a 
manual micrometer (Mituoyo, model ID C1012EBS, Aurora, IL). Only films with an 




3.3.3 Influence of CA concentration on extrusion process parameters 
To determine the influence of CA on the processability of Eudragit® RS PO 
during hot-melt extrusion, the process parameters screw speed and motor load (current) 
were monitored as a function of CA content and the preset temperature in the die zone. 
The quotient of the maximal applicable screw speed divided by the measured load at a 
given temperature was calculated for each CA level. 
 
3.3.4 Thermal analysis 
The solubility of CA in the extrudates and the influence of CA on the glass 
transition temperature of Eudragit® RS PO were studied by modulated differential 
scanning calorimetry (MDSC) with a TA Instrument model 2920 (New Castle, DE). 
Extrudates containing 0 to 30% CA MH were ground to a fine powder, and 8 to 12 mg 
samples were accurately weighed into aluminum pans and sealed. The samples were 
heated from -30 to 170°C at a rate of 10°C/min with the modulation set to ±1°C every 60 
seconds and a nitrogen flow of 40 ml/min. The maximal amount of CA MH that could be 
incorporated into the extrudate without exhibiting any melting peak for the organic acid 
during the first heating run was reported as the solubility limit.  
 
3.3.5 X-ray diffraction analysis 
The degree of CA crystallinity in ground extrudates was evaluated by powder X-
ray diffraction (PXRD) using a Philips Electronic Instrument type 42273 (Mount Vernon, 
NY). Samples were analyzed in the 2-theta range from 5 - 50° with a step size of 0.05° 
every 4 seconds. They were exposed to a Cu-K alpha radiation under 40 kV and 40 mA. 
The crystallinity of extrudates containing increasing monohydrate levels or anhydrous 
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CA was compared to the physical mixtures, and the influence of the extrusion 
temperature on the crystallinity of CA MH was investigated. 
 
3.3.6 Physico-mechanical properties of films 
The mechanical properties of the cast films were investigated using an Instron 
Model 4201 equipped with Bluehill 2.5 material testing software (Instron, Norwood, 
MA). The procedure was based on the ASTM D 882 guideline for mechanical testing of 
thin films [25]. The rectangular strips were fixed between two hydraulic grips with an 
initial grip separation of 50 mm and stretched at a rate of 25 mm/min. The effect of the 
CA MH level on the tensile strength, elastic modulus and elongation of the films was 
studied. The tensile strength was calculated by dividing the maximal load by the initial 
cross-sectional area of the film, while the elastic modulus was determined as the slope of 
the initial linear part of the load-strain curve. The elongation was reported as the absolute 
increase in length of the film at the moment of break. All values were the average of at 
least 6 determinations. 
 
3.3.7 Content of volatile components in films 
The content of volatile components in films equilibrated at 25±1°C and 50±5% 
RH for 48 hours was determined to exclude large amounts of moisture or residual solvent 
as plasticizing agents. The technique was based on the USP loss on drying method and 
was carried out in a moisture analyzer AND MF-50 (A&D Engineering, Inc., Milpitas, 
CA). Approximately 1 g of film material was accurately weighed and spread as a single 
layer in a circular aluminum dish that was dried beforehand until weight constancy was 
reached. The sample was kept at a constant temperature of 110°C until the weight loss 
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per minute did not exceed 0.02%/ min. The content of volatiles was reported as the 
average percent weight loss from 3 tested specimens. 
 
3.3.8 Citric acid release study 
Release studies from melt extruded tablets containing 25% CA MH or anhydrous 
CA and processed at a die temperature of 120°C were carried out according to the USP 
27 procedure for extended release dosage forms in a USP apparatus 2 (paddle method, 
Varian, Cary, NC). Phosphate buffer pH 6.0 (900 ml, 37°C) was used as the dissolution 
medium, and the paddle speed was set to 100 rpm. For each determination, 6 samples 
consisting of 2 tablets (500 mg) were analyzed over 12 hours. The actual CA content was 
determined after complete destruction of the tablets with a Polytron homogenizer 
(Kinematica Inc., Newark, NJ). The percent CA released from the tablets was calculated 
from the actual CA content of each sample as a function of dissolution time. 
 
3.3.9 Citric acid assay 
A Waters HPLC System (Milford, MA) equipped with a C18-reversed phase 
column (Capcell PAK, 3 × 100 mm, Shiseido Co., Tokyo, Japan) and a UV-detector set 
to 212 nm (996-PDA detector, Waters Inc., Milford, MA) was utilized to determine the 
CA content in the dissolution samples. The method was based on the findings of Ding et 
al. [26]. The column temperature was held constant at 30°C during analysis, and the 
injection volume was 20 µl. Phosphate buffer (10 mM), which was adjusted to pH 2.4 
with concentrated phosphoric acid, and methanol were used as the mobile phase (95:5) at 
a constant flow rate of 0.5 ml/min. The low pH of the mobile phase was necessary to 
prevent ionization of the trivalent organic acid during analysis. The relationship between 
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CA content and UV signal was found to be linear with a correlation coefficient of 
0.99997 over the range between 2 and 200 µg/ml (corresponding to 1.44 – 144.00% of 
CA MH in tested samples). The reproducibility for multiple injections (n = 3) exhibited 
less than 2.0% relative standard deviation for each tested concentration. 
 
3.3.10 Statistical analysis 
Minitab Release 14 Statistical Software (Minitab Inc., State College, PA) was 
employed to carry out statistical analysis on the extrusion, physico-mechanical and 
dissolution data. All tests were based on the 95% confidence interval or on the closest 
provided value (Mann-Whitney), respectively. The effect of the CA MH concentration 
and the formulation type (anhydrous CA or CA MH) on the extrusion process parameters 
was analyzed by Kruskal-Wallis Test and pairwise Mann-Whitney median comparisons 
(nonparametric analysis, n = 3). The value for the screw speed/ motor load quotient 
obtained for an extrusion at 120°C die temperature was selected as the response 
parameter since all formulations could be processed at this temperature. The influence of 
the CA MH concentration on the film properties (elastic modulus, tensile strength and 
elongation) was evaluated using one-way ANOVA followed by post hoc Tukey’s test (n 
= 6). A univariate two-factor ANOVA design with repeated measures on one factor 
(time) and Tukey’s test were applied to determine the effect of the formulation type on 
the CA released at each sampling time point (n = 6). Also, the f2 similarity factor [27] 
was calculated from the means of % released at each time point to compare the entire 




3.4 RESULTS AND DISCUSSION 
3.4.1 Influence of CA on extrusion parameters 
Formulations containing Eudragit® RS PO with 0 to 30% CA MH or 25% 
anhydrous CA, based on the total formulation weight, were extruded at temperatures 
between 90 and 140°C, with a screw speed of 20 rpm or less, so that the motor load was 
maintained below 0.700 drive amperes. Improved processability of a powder blend by 
plasticization of the polymer yields a higher screw speed and a lower motor load for a 
predefined extrusion temperature. Plasticizers act by interposing themselves between 
polymer chains and disrupting cohesive interactions, thus resulting in a more malleable 
polymer with a lower melt viscosity. Since the resistance of the polymeric melt towards 
the rotating movement of the screw decreases, the load required of the motor is 
diminished. Consequently, the blend can be processed at higher screw rotation speeds 
without exceeding the safety motor load or screw pressure limits. To consider the 
influence of both parameters, the quotient of the highest applicable screw speed divided 
by the necessary motor load was investigated as a function of the CA content. This 
quotient can be interpreted as an index of processibility of the formulation at the preset 
die temperature, and improved processibility due to plasticization became noticeable as 
high quotients at lower temperatures. 
Fig. 3.1 shows the screw speed/ load ratios for formulations with increasing CA 
MH levels at different extrusion temperatures (end zone). A relatively high temperature 
of 140°C was necessary to extrude the pure polymer at a screw speed of 20 rpm, while 
blends containing CA MH could be processed at lower temperatures (130-110°C). 
Statistical analysis using a Kruskal-Wallis test demonstrated a significant influence of the 
CA MH concentration on the response parameter at 120°C die temperature (P=0.003). A 
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pair-wise median comparison by Mann-Whitney test showed that the screw speed/ motor 
load quotient significantly increased when the CA MH concentration was changed from 0 
over 10, 15 and 20 to 25% (significant difference in all medians). The improved 
processability of blends comprising higher CA MH level at increased screw speeds under 
a reduced motor load indicated a decrease in melt viscosity and made an extrusion at 
lower temperatures possible. The absence of a statistically significant difference between 
the 25 and 30% CA formulation suggested that the plasticizing effect of CA MH 
plateaued at these concentrations. This ceiling effect coincided with the solubility limit of 
CA MH in Eudragit® RS PO as determined by MDSC (Fig. 3.2), supporting the 
hypothesis that only dissolved CA functioned as a plasticizer. These results demonstrated 
that the CA MH acted as a plasticizer and/ or as a thermal lubricant on Eudragit® RS PO 
when the polymer was melt extruded. 
The results in Fig. 3.1 further illustrate that CA MH facilitated the extrusion 
process more efficiently than the anhydrous form, since significantly higher screw speed/ 
motor load values were obtained for the 20 and 25% CA MH formulation when 
compared to the blend with 25% anhydrous CA at three temperature levels (110-130°C). 
This phenomenon can be explained by the lower melting point of the monohydrate and its 
higher tendency to interact with the polymer due to lower cohesive forces when 
compared to the anhydrous form; CA MH has a melting point of 135°C, while anhydrous 
CA melts at 155°C (determined by DSC, data not shown). It can be assumed that the 
melting point of the monohydrate was further depressed through interactions with the 
Eudragit® RS PO, so that at least a softening during extrusion, and consequently, an 
enhanced distribution of the organic acid in the polymer melt was facilitated. 
Recrystallization of CA MH after cooling of the extrudate to room temperature did not 
occur in tablets containing up to 20% CA, since the interactions between Eudragit® RS 
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PO and CA MH enabled the CA MH to dissolve in the extrudates. The anhydrous form, 
having a higher melting point and more stable lattice structure, did not melt or dissolve 
completely in the polymer during processing. These differences in solubility were 
supported by PXRD data. As only molecularly dispersed CA can function as a plasticizer, 
the monohydrate with its higher solubility in Eudragit® RS PO was more effective in 
reducing the polymer’s melt viscosity and hence improving its processability for melt 
extrusion than the anhydrous form. 
 
3.4.2 Solubility of CA in Eudragit® RS PO 
Solubility of the solid plasticizer in a polymer is crucial since only molecularly 
distributed plasticizer is able to interact with the polymer chains and hence reduce 
cohesion forces. The CA molecule possesses a high capacity for hydrogen bonding, 
which was reported to be responsible for the stability of the amorphous state and prevents 
its recrystallization in solid dispersions [18]. Hydrogen-bond formation between the CA 
molecules and the Eudragit® RS PO chains should account for a sufficient solubility and 
a plasticizing effect of the organic acid in the polymer melt. 
The solubility of CA in Eudragit® RS PO hot-melt extrudates was studied by 
MDSC and PXRD. Thermal analysis of extrudates containing 0 to 30% CA MH was 
carried out over a temperature range of -30 to 170°C. The MDSC method yielded 
sufficient sensitivity to detect a melt endotherm for 10% crystalline CA in a physical 
mixture with Eudragit® RS PO (Fig. 3.2). All thermograms exhibited a single glass 
transition for the acrylic polymer between 35 and 55°C. Extrudates with high CA levels 
(25 or 30%) displayed an additional endothermic event at either 144 or 152°C, 
respectively. This peak was attributed to the melting of anhydrous CA when the solubility 
of CA in the polymer was exceeded and excess CA re-crystallized from the solid solution 
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in the anhydrous form. Concentrations of up to 20% CA MH in extruded polymer 
resulted in one-phase amorphous systems with a single Tg and no melting endotherm. In 
these cases, the organic acid melted or dissolved in the polymer during the extrusion 
process and remained dispersed at a molecular level in the solidified polymer after 
cooling. The corresponding extrudates were transparent strands, supporting the existence 
of a molecular dispersion, while extrudates comprising 25% CA MH or higher levels 
were opaque. 
The solubility of CA in Eudragit® RS PO was further investigated by PXRD. 
Extrudates processed at 110°C and containing 10, 20, 25 or 30% CA MH or 25% 
anhydrous CA were compared. Fig. 3.3 shows that extrudates with 10 and 20% CA MH 
were completely amorphous, while the 25% CA MH sample exhibited peaks of low 
intensity, suggesting a low degree of crystallinity for this formulation. The diffraction 
patterns of extrudates containing 25% anhydrous CA or 30% CA MH exhibited more 
distinct peaks and hence an increased degree of crystallinity. The results demonstrated 
that the solubility of the monohydrate form was exceeded at concentrations of 25% or 
higher. The excess of the CA MH solubility in the extrudates led to re-crystallization of 
CA in the anhydrous form. These findings were in agreement with the results from the 
MDSC experiments. The solubility of the anhydrous CA in the acrylic polymer was 
lower than that of the monohydrate; however, the peak intensity of anhydrous CA in the 
extrudate was reduced when compared to the physical mixture, which suggested that 
there was a partial dissolution of anhydrous CA in the polymer during extrusion. The 
lower solubility of the anhydrous form was attributed to the higher stability of the lattice 
due to stronger intermolecular forces, resulting in a higher melting point and a lower 
tendency to interact with the polymer. The monohydrate form softened or melted during 
the extrusion process which facilitated its molecular distribution between the polymeric 
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chains, while the anhydrous lattice remained intact to a higher degree. These findings 
support the previously reported differences in extrusion process parameters. 
The extrusion temperature was found to influence the degree of CA crystallinity 
in the extrudates (Fig. 3.4). Extrudates containing 25% CA MH and processed at 100, 
110 and 120°C die temperature were selected for further PXRD studies, since the CA 
solubility in the polymer was exceeded at this CA concentration. An increase in the 
processing temperature led to a decrease in CA crystallinity. The degree of crystallinity in 
samples extruded at 110°C was lower than for the 100°C samples, while extrudates 
processed at 120°C were amorphous. These findings demonstrated that a sufficiently high 
extrusion temperature either led to an increased miscibility between the components, or 
that the formation of a stable amorphous two-phase system was facilitated. Since similar 
tendencies were observed for samples with other CA levels, it can be concluded that the 
higher the content of CA MH in the formulation, the higher the required extrusion 
temperature for the formation of a non-crystalline extrudate. 
 
3.4.3 Plasticizing effect of CA on Eudragit® RS PO 
The mechanism of CA-induced facilitation of the Eudragit® RS PO extrusion 
process was expected to be due to plasticization. Since the interactions between the 
polymeric chains were reduced by the incorporation of a plasticizer, a shift in the 
polymer’s glass transition to lower temperatures should be detectable as a function of an 
increasing CA concentration. The data obtained by MDSC (Fig. 3.2), however, showed 
only a very slight decrease in the Tg with increasing CA MH levels in the extrudates and 
hence did not convincingly demonstrate a plasticizing effect. This observation might be 
attributed to the fact that unplasticized Eudragit® RS PO possesses a low Tg around 
60°C, and that the change in heat capacity was not distinct. 
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Plasticizers also decrease the stiffness and increase the flexibility of polymeric 
films. To demonstrate the plasticizing properties of CA MH on Eudragit® RS PO, films 
were produced applying a casting-solvent evaporation technique. Films containing 0 to 
30% CA MH based on the total weight were cast from acetone solutions, and their 
physico-mechanical properties were investigated. The tensile strength and the elastic 
modulus characterize the stiffness of a film and are directly proportional to the force that 
is required for film-stretching, whereas the maximal elongation correlates with the film 
flexibility. The presence of a plasticizer in a film formulation generally results in a 
decreasing tensile strengths and moduli and increasing elongations. Films cast from 
solutions containing 20% CA or less were smooth and transparent, confirming the 
solubility of the organic acid in Eudragit® RS PO up to this concentration. Higher levels 
of CA such as 25 or 30%, however, led to films with macroscopically visible crystals on 
the film surface and exhibited dramatically altered mechanical properties. These films 
were very brittle and readily broke when being attached to the grips of the Instron, and 
thus they were not analyzed. The data in Fig. 3.5 demonstrates a reduction in the tensile 
strength from 4.46 to 2.30 MPa when the CA MH concentration was increased from 0 to 
20%. According to the results of ANOVA and Tukey’s test, the tensile strength values for 
the 0%, 10% and 20% level were significantly different. The decrease in the elastic 
modulus from 492 to 48 MPa with increasing CA concentrations was found to be 
significant for the 0, 5, 10 and 15% level, but not for the 20% level. The elongation 
increased only insignificantly at low CA concentrations (0.76 ± 0.21 mm to 1.65 ± 0.20 
mm for 0% and 10%, respectively), while the 15 and 20% level exhibited significantly 
higher elongation values (7.59 ± 1.01 cm and 10.89 ± 1.07 cm). These findings for the 
physico-mechanical properties of the polymeric films support the hypothesis that CA 
functioned as a plasticizer for Eudragit® RS PO. 
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Adsorbed water and residual acetone are able to exert plasticizing effects in cast 
films. The high hygroscopicity of CA is well known [28]. To exclude adsorbed moisture 
and residual solvent as possible reasons for the observed changes in film properties at 
higher CA levels, the content of volatile components of the films was determined. The 
volatile content was low in all films (3.28 ± 0.08%-3.85 ± 0.18%, n = 3) and not 
dependent on the CA concentration, so that their influence on the mechanical properties 
was deemed negligible and the observed changes were attributed to the differences in the 
CA level. 
 
3.4.4 CA release from extruded tablets 
The dissolution profile of citric acid from the polymer matrix was investigated to 
evaluate the capability of the system to retard the release of water-soluble API’s. 
Leaching of hydrophilic plasticizers such as TEC from insoluble matrix systems during 
the dissolution process was demonstrated to impact the drug release rate and mechanism 
[10]. Hot-melt extruded matrices are characterized by a low porosity and a high tortuosity 
when compared to direct compressed or granulated dosage forms. The addition of 
hydrophilic compounds such as citric acid to the formulation will lead to an increased 
channel formation in the insoluble matrix when the system is exposed to the dissolution 
medium, allowing incorporated drugs to diffuse through the water-filled pores at a faster 
rate. 
Dissolution studies with Eudragit® RS PO matrix tablets containing 25% CA MH 
or anhydrous CA were carried out over 12 hours in a pH 6.0 phosphate buffer (apparatus 
2, paddle method). Since the maximal extrusion temperature (130°C) was below the 
decomposition temperature of CA, which has been reported to be thermally stable up to 
160°C [29], and the transition time through the extruder did not exceed four minutes, 
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thermal decomposition of CA was unlikely. The actual CA content of each tablet after 
complete destruction with a Polytron homogenizer was found to be between 98.0% and 
101.0% by HPLC analysis, confirming the thermal stability and content uniformity of CA 
in the polymeric carrier after the extrusion process. 
Although Eudragit® RS PO is insoluble at all pH values and consequently 
controls the release of highly water-soluble components, a rapid release profile of the CA 
from the extrudates was expected due to the high water solubility of the organic acid, 
allowing a quick diffusion through channels formed in the polymer matrix. The pore 
formation in HPMC matrix systems through rapid CA leaching has been previously 
reported [30]. However, dissolution testing revealed an extended release profile for CA 
with 42.05±0.76% and 36.55±1.45% released after 6 hours and 57.99±1.35% and 
53.66±1.98% released after 12 hours for CA MH and anhydrous CA, respectively (Fig. 
3.6). The small surface area of the studied monolithic dosage form and the high affinity 
between the polymer and the organic acid, which is essential for plasticization, are two 
possible explanations for the slow CA release. Furthermore, the incorporated level of CA 
(25%) might have been below the minimal concentration which is necessary for 
continuous channel formation to allow percolation throughout the polymer matrix. 
For the release of the monohydrate and the anhydrous CA, an f2 value above 50 
(f2 = 66.90) demonstrated the similarity of the dissolution profiles. The comparison of 
both profiles by repeated measures ANOVA and Tukey’s test showed a significantly 
lower release for the anhydrous form at each sampling time point. The differences in 
release rates can be explained by the different degree of crystallinity of the CA in the 
samples with anhydrous CA being more crystalline in melt extruded Eudragit® RS PO. 
Since crystalline phases are more stable systems and possess a lower surface energy, they 
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usually have a lower dissolution tendency than amorphous phases, resulting in a 
decreased dissolution rate when compared to non-crystalline systems. 
 
3.5 CONCLUSION 
The present study demonstrated that citric acid functioned as an effective solid-
state plasticizer in Eudragit® RS PO films and hot-melt extrudates. The extrusion process 
was found to be facilitated by increasing the concentration of citric acid, and plateaued at 
25% based on the total formulation weight. Citric acid monohydrate (CA MH) was more 
effective in improving the processability than the anhydrous form, with the higher 
plasticization efficiency of the monohydrate being attributed to its higher solubility in the 
acrylic polymer. The solubility of CA MH in Eudragit® RS PO was limited and 
dependent on the extrusion temperature. Concentrations of up to 20% CA MH were 
found to be soluble in extrudates as well as in cast films, while extrudates with 25% CA 
MH required an extrusion temperature of at least 120°C to remain amorphous. A 
reduction in the glass transition temperature of Eudragit® RS PO extrudates by CA MH 
was not convincingly shown by MDSC data; however, the tensile strength and elastic 
modulus of polymeric films decreased as a function of CA level, while the elongation 
increased, indicating plasticization of the polymer. Dissolution studies demonstrated a 
slow and controlled release of CA from extruded tablets with the monohydrate form 
being released faster than the anhydrous form. In conclusion, citric acid monohydrate was 
shown to be sufficiently soluble in Eudragit® RS PO and was successfully used for the 
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Figure 3.1: Influence of citric acid monohydrate (CA MH) concentration and anhydrous 
citric acid on the extrusion parameters (screw speed divided by motor load) 
for the melt extrusion of Eudragit® RS PO as a function of die temperature. 
( ) pure Eudragit® RS PO; Eudragit® RS PO with ( ) 10% CA MH; ( ) 
15% CA MH; ( ) 20% CA MH; (□) 25% CA MH; ( ) 30% CA MH; ( ) 
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Figure 3.2: MDSC thermograms (1st runs) of hot-melt extrudates containing 0 – 30% 
citric acid monohydrate (CA MH). (a) physical mixture of 10% anhydrous 
CA in Eudragit® RS PO; Extrudate with (b) 0% CA MH; (c) 10% CA MH; 
(d) 15% CA MH; (e) 20% CA MH; (f) 25% CA MH*; (g) 30% CA MH*. 
* An excess of CA MH solubility in the extrudates led to re-crystallization 
in the anhydrous form. 
 





















Figure 3.3: Influence of citric acid (CA) concentration and type (anhydrous form or 
monohydrate = MH) on the crystallinity of hot-melt extrudates obtained at 
110°C. PXRD patterns of (a) anhydrous CA powder; (b) physical mixture of 
Eudragit® RS PO and 25% anhydrous CA; (c) Eudragit® RS PO powder; 
(d) extrudate with 10% CA MH; (e) extrudate with 20% CA MH; (f) 
extrudate with 25% CA MH*; (g) extrudate with 30% CA MH*; (h) 
extrudate with 25% anhydrous CA. 
* An excess of CA MH solubility in the extrudates led to re-crystallization 
in the anhydrous form. 
 

















Figure 3.4: Influence of extrusion temperature on the crystallinity of hot-melt extrudates 
containing 25% citric acid monohydrate. PXRD patterns of (a) anhydrous 
citric acid powder; (b) extrudate obtained at 100°C*; (c) extrudate obtained 
at 110°C*; (d) extrudate obtained at 120°C; (e) Eudragit® RS PO powder. 
* An excess of CA MH solubility in the extrudates led to re-crystallization 
in the anhydrous form. 
 














Figure 3.5: Influence of citric acid monohydrate (CA MH) concentration on the tensile 
strength and elastic modulus of films containing 0 – 20% CA MH (n = 6, 
error bars represent the standard deviation). Films were stored at 25±1°C/ 
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Figure 3.6: Release of citric acid monohydrate and anhydrous citric acid from 
Eudragit® RS PO tablets extruded at 120°C. ( ) formulation with 25% 
citric acid monohydrate; ( ) formulation with 25% anhydrous citric acid. 
Dissolution: USP paddle method, 900 ml phosphate buffer pH 6.0 as 
























Chapter 4: Study of the Effects of Citric Acid Monohydrate on the 
Solid-State and Drug Release Properties of Diltiazem Hydrochloride in 




Incomplete drug release and particle size dependent dissolution performance can 
compromise the quality of controlled release matrix systems. The objective of the current 
study was to investigate the ability of citric acid monohydrate (CA MH) to enhance the 
release of diltiazem hydrochloride from melt extruded Eudragit® RS PO tablets and to 
eliminate drug particle size effects. Preformulation studies demonstrated the thermal 
stability of all components, drug insolubility in the polymer but miscibility with the CA 
MH. Tablets with either constant polymer levels or constant drug to polymer ratios and 
containing different drug particle size fractions and increasing amounts of CA MH were 
manufactured by melt extrusion and characterized by dissolution testing, powder X-ray 
diffraction and scanning electron microscopy. The addition of CA MH to the formulation 
promoted the thermal processibility and matrix integrity by plasticization of the polymer. 
The drug release from systems with constant drug-to-polymer ratio was significantly 
increased when CA MH was added as a result of enhanced pore formation. Particle size 
effects were eliminated when large amounts of CA MH were used due to the loss of drug 
crystallinity. Matrix tablets with CA MH furthermore showed a faster and more complete 
drug release compared to systems with drug only or alternative pore formers (sucrose, 
NaCl, or PEG 3350). The enhanced drug release was attributed to the amorphous 
                                                 
2 Significant portions of this chapter were taken from: Schilling, S.U., Bruce, C.D., Shah, N.H., Malick, 
A.W., Infeld, M.H., and McGinity, J.W. Citric acid monohydrate as a release-modifying agent in melt 
extruded matrix tablets. International Journal of Pharmaceutics, 2008, 361, p: 158-168. 
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character of the soluble components, improved drug dispersion in the plasticized polymer 
along with increased polymer permeability. In summary, CA MH promoted the 
miscibility between the drug and Eudragit® RS PO during hot-melt extrusion, resulting 




Hot-melt extrusion has been employed to manufacture matrix delivery systems 
exhibiting sustained or immediate drug release. Formulations to be processed by melt 
extrusion most commonly comprise the active drug together with one or several 
functional excipients [1]. Due to the poor thermoplastic properties of most drugs, the 
addition of a deformable carrier polymer or wax is required. The selection of the carrier 
material as well as the drug-to-carrier ratio greatly impacts the release properties of the 
dosage form [2]. Processing aids including plasticizers, glidants or thermal lubricants can 
be added to promote processibility and allow a reduction in extrusion temperature, 
making the process feasible for dosage forms containing drugs with compromised 
thermal stability. 
A third group of excipients for melt extrusion can be characterized as drug release 
modifying agents. The mechanisms of release modification are varied and frequently 
linked to an alteration in the matrix properties, which can lead to an increase in the drug 
release rate by promoting either drug diffusion and/ or carrier erosion. A popular 
approach to increase the release of a poorly soluble active pharmaceutical ingredient 
(API) is the incorporation of hydrophilic polymers such as PVP and PVP-VA [3], PEO 
[4], HPMC [5] or Eudragit® EPO [6] into the matrix. Enhanced drug release from these 
systems can be attributed to a reduced drug particle size, increased API solubility in the 
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amorphous state and/ or the maintenance of drug supersaturation in the dissolution 
medium. Cyclodextrins [7] and surfactants [8, 9] have been successfully used to enhance 
the drug solubility in the dissolution medium and to improve powder wettability. 
Polymeric or low-molecular weight additives with high aqueous solubility can enhance 
drug dissolution due to leaching into the dissolution medium and formation of a porous 
network [2]. Water-soluble excipients of low molecular weight that are miscible with the 
polymer can simultaneously function as plasticizer and pore former. Zhu and coworkers 
reported increased drug release rates when high TEC levels were incorporated into 
diltiazem hydrochloride matrix tablets due to leaching of the plasticizer during 
dissolution [10].  
Citric acid has been widely used as an acidifying agent in solid oral dosage forms 
[11, 12]. Solid dispersions of poorly soluble APIs in citric acid produced by co-melting 
techniques exhibited increased dissolution rates [13-15]. Furthermore, the plasticizing 
effects of citric acid monohydrate (CA MH) on certain acrylic polymers including 
Eudragit® L 30D-55 [16], Eudragit® S100 [17] and Eudragit® RS PO [18] have been 
previously demonstrated. 
The objective of this study was to investigate the influence of CA MH on the 
release rate of a model API from a hot-melt extruded, extended release matrix system. 
Diltiazem hydrochloride (DIL HCl), a calcium channel blocker commonly used in the 
long-term treatment of hypertension, was selected as the model drug. The hydrochloride 
salt form is thermally stable below its melting point at 215°C and does not melt or 
dissolve when extruded in an Eudragit® RS PO matrix [10]. Drug release from extruded 
composites was investigated as a function of the drug particle size and the citric acid 
concentration, and compared to formulations containing alternative pore formers. 
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Characterization of the solid systems regarding true density, crystallinity and morphology 
was performed to explain the altered dissolution properties.  
 
4.2 MATERIALS 
Diltiazem hydrochloride (DIL HCl), citric acid monohydrate (powder, U.S.P.), 
anhydrous citric acid, sucrose and sodium chloride (NaCl) were purchased from 
Spectrum Chemicals (Gardena, CA). Polyethylene glycol 3350 (Carbowax Sentry™) was 
obtained from the Dow Chemical Company (Midland, MI). Citric acid monohydrate, 
sucrose and sodium chloride were ground in a mortar and pestle to obtain particles 
smaller than 250 µm. To investigate the influence of DIL HCl particle size on the 
dissolution rate, the obtained material was sieved into 3 different particle size fractions, 
and fine DIL particles (< 75 µm) and coarse DIL particles (150-250 µm) were used for 
the extrusion of the formulations 8-15 (Table 1). Eudragit® RS PO was kindly donated 
by Evonik Degussa (Piscataway, NJ). 
 
4.3 METHODS 
4.3.1 Thermogravimetric analysis (TGA) 
The thermal stability of DIL HCl, CA MH, anhydrous citric acid, and Eudragit® 
RS PO was evaluated by thermogravimetric analysis (TGA). A powder sample of 
approximately 10 mg was accurately weighed into an aluminum pan and placed into the 
furnace of a Perkin-Elmer thermogravimetrical analyzer (7-series, Norwalk, CT). The 
percentage weight loss of the samples was monitored from 50 to 500°C employing a 
heating rate of 10°C/min. A compound was considered thermally stable when the percent 
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weight loss was smaller than 1% during heating to the highest employed extrusion 
temperature (150°C). 
 
4.3.2 Drug-polymer binding study 
A stock solution of DIL HCL in phosphate buffer pH 6.0 (0.1mg/ml) was 
prepared, and aliquots of 50 ml were filled into Erlenmeyer beakers. Increasing 
increments of Eudragit® RS PO (0, 10, 20, 40, 60 mg) were added to the beakers, and the 
suspensions were incubated at 37°C in an Innova 4300 Incubator Shaker (New 
Brunswick Scientific Co., Edison, NJ) at 200 rpm. After 24 hours, 1 ml of the suspension 
was removed from each beaker, centrifuged, filtered and analyzed for DIL HCl content 
using a UV spectrophotometer (μQuant 96-Well Plate Reader, Bio-Tek Instruments Inc., 
Winooski, VT) at 237 nm. Analysis was performed in triplicate. 
 
4.3.3 Differential scanning calorimetry (DSC) 
Physical mixtures composed of different drug to anhydrous citric acid ratios (7:1, 
3:1, 1:1, 1:3, 1:7) were prepared to evaluate the miscibility between DIL HCl and the 
organic acid.  An accurately weighed amount of powder (8-12 mg) was placed in 
aluminum pans, which were crimp sealed and heated from 0 – 250°C using a TA 
Instrument model 2920 (New Castle, DE).  The heating rate was set to 10°C/min, and all 
thermograms show the heat flow versus temperature as monitored during the first run. 
 
4.3.4 Processibility 
Powder blends comprising a constant level of Eudragit® RS PO (60%, 
formulations 1-4) were extruded at different temperature settings to study the 
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processibility as a function of the DIL HCl to CA MH ratio. The preset temperature 
values were increased from zone 1-3 by 10°C, while the die temperature was equal to the 
temperature in zone 3. Temperature profiles between 60/70/80/80°C and 
130/140/150/150°C were investigated. The processibility of a formulation by hot-melt 
extrusion can be characterized by process parameters such as screw speed, torque or 
motor load and melt pressure. The application of elevated screw speeds is advantages due 
to shorter residence times of the drug inside the barrel and hence a reduced exposure to 
high temperatures and in terms of process output rates and efficiency. The motor load 
was kept constant at 0.650±0.010 drive amperes, and the dependence of the applicable 
screw speed on the DIL HCl to CA MH ratio was investigated. Furthermore, the 
influence of the formulation on the motor load was determined at a constant screw speed 
of 20 rpm as a function of temperature. Low motor loads implicate a reduced work input 
of the engine due to the lower resistance of the moving screw against softened material 
with reduced melt viscosity. 
 
4.3.5 Helium pycnometry 
The true density of extruded tablets was evaluated by means of helium 
pycnometry using an AccuPyc 1330 Pycnometer, (Micromeritics Instrument Corporation, 
Norcross, GA). For each formulation, six specimens were analyzed by placing a 250 mg 
tablet into the chamber (cell volume of 12 cm3) and purging with helium for 4 times at 20 





4.3.6 Manufacture of melt-extruded tablets 
Fifteen formulations (Table 4.1) were processed using a vertical single screw 
extruder (Randcastle, model RCP 0750 Microtruder, Cedar Grove, NJ). Powder blends 
(150-200g) comprising either a constant percentage of Eudragit® RS PO (60%, 
formulations 1-7) or a constant API to polymer ratio (1:4) and employing either fine or 
coarse DIL HCl particles with increasing levels of CA MH (formulations 8-15) were 
premixed  and manually fed into the extruder. The organic acid plasticized the polymer, 
which influenced the choice of extruder temperature settings. For all formulations, the 
temperature did not exceed 150°C in any of the 4 heating zones and the transition time 
through the barrel was less than 4 minutes. The screw speed was set to a maximum of 20 
rpm, while the motor load was limited to 0.700 drive amperes, and the pressure did not 
exceed 200 PSI. The molten polymer strand exited through a circular die (6 mm 
diameter) and was manually cut into tablets. 
 
4.3.7 Dissolution Experiments 
Diltiazem HCl dissolution testing from extruded matrix tablets was carried out in 
900 ml of 50 mM phosphate buffer pH 6.0 using a USP paddle apparatus (Varian, Cary, 
NC) over 12 hours. The paddle speed was set to 50 rpm, and the bath temperature was 
kept constant at 37.0±0.5°C. All experiments were run with 6 replicates. The percent DIL 
HCl released from the tablets at each time point was calculated as the percentage of the 
actual DIL HCl content of each tablet, which was determined in a sample of the final 
media after complete destruction of the tablet with a Polytron homogenizer (Kinematica 




4.3.8 Diltiazem HCl assay 
The DIL HCL concentration in the dissolution medium at each sampled time 
point was analyzed by means of HPLC (Waters Inc., Milford, MA). An aliquot of 10 µl 
was injected onto a C18-reversed phase column (Capcell PAK, 3 × 100 mm, Shiseido Co., 
Tokyo, Japan) and analyzed at a flow rate of 0.5 ml/min using  a mixture of  50 mmol 
phosphate buffer pH 6.0/ acetonitrile/ methanol  at a 5:4:1 ratio and adjusted to pH 4.2 
with phosphoric acid as mobile phase. The drug content was measured at 237 nm with a 
UV detector (996-PDA detector, Waters Inc., Milford, MA), and peaks were integrated 
using Empower Version 5.0 software (Waters Inc.). The analytical method yielded 
linearity (R2 < 0.999) for 0.5 - 60 µg/ml DIL HCl (corresponding to 0.9-108.0% of DIL 
HCl in tested samples) and was reproducible (RSD < 2.4% at each tested concentration, n 
= 6). 
 
4.3.9 Powder X-ray diffraction (PXRD) 
The degree of drug crystallinity in physical mixtures and extruded formulations 
was investigated by PXRD.  Extrudates were ground with a mortar and pestle, and the 
powder was passed through a 60 mesh sieve (250 µm) prior to analysis. Physical 
mixtures were prepared in accordance with the extrudates by co-grinding of the 
components with a mortar and pestle. The samples were spread in a thin powder bed and 
subjected to X-ray in the 2-Theta range employing a Philips Electronic Instrument (Type 
42273) with Cu K alpha radiation operating at 45 kV and 40 mA. The samples were 





4.3.10 Scanning electron microscopy (SEM) 
The morphology of extruded tablets comprising 60% Eudragit® RS PO, DIL HCl 
and a soluble excipient was studied before and after 12 hours of dissolution in phosphate 
buffer pH 6.0 with a Zeiss Supra 40VP SEM (Carl Zeiss AG, Germany) equipped with a 
Gemini column in field emission mode. Cut tablets were placed onto mounts with carbon 
tape and coated with Pt/Pd (80:20) under argon atmosphere at 2.5 kV and 20mA to a 
thickness of 15 nm in a Cressington Sputter Coater 208 HR equipped with a Thickness 
Controller MTM 20 (Cressington Scientific Instruments Ltd., Watford, UK). The samples 
were exposed to an electron beam of 5 kV and an emission current of 300 μA, and 
pictures were taken employing Smart SEM V05.02.03 software. 
 
4.3.11 Statistical analysis 
Minitab Release 14 Statistical Software (Minitab Inc., State College, PA) was 
used to carry out statistical analysis (one-way ANOVA and post hoc Tukey’s test). All 
tests were based on the 95% confidence level. Furthermore, the f2 similarity factor was 
calculated for the dissolution profiles using the means of % released at each time point 
[19]. 
 
4.4 RESULTS AND DISCUSSION 
4.4.1 Thermal stability 
The TGA experiments (Fig. 4.1) confirmed the thermal stability of Eudragit® RS 
PO and DIL HCl at the temperatures employed for the extrusion process as reported 
previously by Zhu et al. [10]. The weight loss for the polymer was less than 0.33% up to 
150°C. The drug was stable with a loss in weight of 0.05% up to 150°C, and 0.55% 
 
 79
below its melting point at 215°C, respectively. The weight loss observed for CA MH 
below the extrusion temperatures was attributed to the loss of water bound in the lattice 
structure. Prior to its melting at 158°C, the percentage decrease in weight for CA MH 
was approximately 6%, a value below the percentage of lattice water in the MH (8.5% 
based on the chemical structure). The anhydrous form of citric acid exhibited a weight 
loss of less than 0.07% below its melting point, demonstrating the thermal stability at the 
extrusion temperatures. 
 
4.4.2 Binding of DIL HCl to Eudragit® RS PO 
Drug adsorption to the polymeric carrier may account for incomplete drug release 
from matrix dosage forms. Khalil and coworkers reported the complex formation 
between ammoniomethacrylates and salts of acidic drugs in phosphate buffer solutions, 
which was mainly attributed to electrostatic interaction [20]. In addition, nonelectrostatic 
binding due to hydrogen bonding or van der Waals forces may lead to adsorption of basic 
or neutral APIs, as has been shown for indomethacin and Eudragit® RL PO [8]. Due to 
the lower content of quaternary ammonium groups compared to Eudragit® RL PO, drug 
binding was expected to be less pronounced for Eudragit® RS PO. An overnight 
adsorption study with increasing increments of Eudragit® RS PO suspended in DIL HCl 
phosphate buffer pH 6.0 solutions showed only a small reduction in the concentration of 
free drug in solution (less than 3% at all investigated ratios) which was not statistically 
significant (Fig. 4.2). These results were consistent with the findings reported previously 




4.4.3 Solid-state miscibility between the formulation components 
Binary physical mixtures were prepared to characterize the interactions between 
DIL HCl, CA MH and Eudragit® RS PO. The binary system of CA MH and Eudragit® 
RS PO has been previously investigated by our group [18]. The organic acid was 
miscible with the polymer at concentrations up to 20% and functioned as a solid-state 
plasticizer during the melt extrusion process. Due to the strong interactions between the 
functional groups of both components, the cohesive forces between the polymeric chains 
were reduced and the melt viscosity decreased, promoting the processibility of the 
polymer at lower extrusion temperatures.  
Zhu and coworkers studied physical mixtures and extruded systems of DIL HCl 
and Eudragit® RS PO [10]. The drug did not exert plasticizing effects on the acrylic 
polymer and maintained a high degree of crystallinity during the extrusion process. We 
conducted extrusion experiments of binary drug-polymer blends comprising three 
different drug loadings (5, 10 and 20%) to determine the solubility of DIL HCl in the 
acrylic polymer and evaluate the limit of detection (LOD) for the PXRD method. Fig. 4.3 
displays the diffraction patterns that were obtained for the extrudates in comparison to the 
corresponding physical mixtures. The physical mixtures were prepared by co-grinding 
the drug with the polymer applying the same procedure as for the extrudates 
comminution to avoid differences in crystallinity due to amorphization during grinding. 
The peaks of crystalline DIL HCl that were found in the extrudates were of similar 
intensity as in the physical blends at all three drug levels. A DIL HCl concentration as 
low as 5% was still detectable as a separate crystalline phase in the extruded systems, 
demonstrating that DIL HCl was virtually insoluble in Eudragit® RS PO. 
The affinity between DIL HCl and citric acid was evaluated by thermal analysis 
(DSC, Fig. 4.4) and by a comparison of the solubility parameters. The pure materials and 
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physical mixtures containing varying ratios of both components were heated to 250°C. 
The pure drug as well as citric acid exhibited a high degree of crystallinity as can be seen 
by the sharp melting peaks at 215 and 158°C, respectively. Decomposition of the organic 
acid started immediately after the melting event since the signal did not return to the 
baseline level, but continued its downward shift. This thermal instability of citric acid at 
temperatures above its melting point was consistent with the TGA findings and was 
detectable in all the physical blends as a broad peak around 190°C exhibiting 
concentration dependent intensity. The thermogram obtained at a high DIL HCl to citric 
acid ratio (7:1, curve a) shows that drug melting occurred below this temperature. A 
broad endothermic event between 100 and 150°C exhibiting low enthalpy values was 
found for the 7:1, 3:1 and 1:1 mixtures of drug and citric acid. This peak represented the 
simultaneous melting of DIL HCl and citric acid, indicating their presence as a single 
inseparable phase at this temperature. The observed loss in melting enthalpy can be 
interpreted as non-ideal mixing behavior due to an intensive interaction and a high degree 
of miscibility between the two components. The addition of citric acid to the extrusion 
formulation depressed the melting point of DIL HCl below the extrusion temperature 
(110-120°C versus 215°C). Increasing the amount of citric acid to ratios of 1:4 or 1:7 led 
to the appearance of an additional citric acid melting peak at 143 and 151°C, respectively, 
indicating that a separate citric acid rich phase was present at high concentrations. 
Comparison of the solubility parameters that were calculated for DIL HCl and 
citric acid according to Hansen (21.80 versus 25.52 MPa1/2) or Hoy (20.85 versus 24.52 
J1/2/ cm3/2) supported the high miscibility that was experimentally found for the two 
components. A difference of less than 7 between the solubility parameters of 2 




4.4.4 Influence of the DIL HCl to CA MH ratio on the processibility 
Powder blends with a constant polymer level of 60% (formulations 1 – 4) were 
investigated for their suitability for hot-melt extrusion. The influence of the DIL HCl to 
CA MH ratio (1:0, 3:1, 1:1, 1:3) was studied over a temperature range between 80 and 
150°C (zone 3 and die). The highest applicable screw speed under borderline motor load 
(0.640 – 0.660 drive amperage) was selected as the primary response parameter. When 
the target screw speed of 20 rpm was feasible, the motor load was monitored as a 
secondary response (values reported in parentheses in Fig. 4.5). Since hot-melt extrusion 
exerts a combination of melting and mechanical processes [23], the processibility of a 
formulation depends on its thermal as well as mechanical properties and the combination 
thereof. The thermoplastic behavior of the carrier polymer represents the dominating 
factor, but can be modulated by the incorporated API or additional excipients. 
Fig. 4.5 shows that pure Eudragit® RS PO could be extruded at 20 rpm when the 
extrusion temperature was 140°C or higher. The viscosity of the softened polymer was a 
function of the temperature and decreased when the temperature was increased. 
Consequently, at higher temperatures, the resistance of the material inside the extruder 
barrel to the screw rotation decreased and the required motor load diminished. A 
substitution of 40% polymer by DIL HCl resulted in a blend with decreased 
thermoplastic deformability, necessitating an increase in the processing temperature. The 
temperature was limited to 150°C, although the target extrusion speed was not reached 
under the tested conditions. Eudragit® RS PO is susceptible to thermal degradation of the 
side chains at temperatures above 140°C [24], and the occurrence of die swell 
compromised the quality of the extrudate at higher temperatures. These results 
demonstrated that DIL HCl is poorly thermoplastic and neither melted at extrusion 
temperatures nor plasticized the polymer.  
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Blends containing 10-30% CA MH in Eudragit® RS PO, however, could be 
processed at lower temperatures (130-100°C, zone 3 and die). This improvement in 
processibility was attributed to the plasticizing effect of CA MH on the acrylic polymer 
and was investigated in a previous study [18]. The inclusion of 20% CA MH (with 20% 
DIL HCl) improved the processibility to a higher extent when compared to blends 
containing 10% of the organic acid (with 30% DIL HCl) as extrusion at 20 rpm became 
feasible at only 100°C. Increasing the CA MH level to 30% based on the total 
formulation weight did not result in further improvements. A comparison of the motor 
load values obtained for the extrusion at 20 rpm showed that there was no significant 
difference between the 20% and 30% CA MH formulation at any of the three investigated 
temperature levels (100, 110, and 120°C). This observation was due to the limited 
solubility of CA MH in Eudragit® RS PO, impeding further plasticization of the polymer 
at the higher CA MH concentration.  
The plasticizing effect of CA MH on the acrylic polymer was supported by the 
results of helium pycnometry (Fig. 4.6). The increase in true density with increasing CA 
MH amounts was statistically significant up to 20% CA MH based on the total 
formulation weight, and demonstrated the formation of a denser matrix of higher integrity 
due to plasticization of the polymer.  
 
4.4.5 Influence of CA MH level and drug particle size on the dissolution of DIL 
HCl from extruded matrix tablets containing constant drug-to-polymer 
ratios 
The drug release rate from extruded matrices can be influenced by the raw 
material particle size of the API [25] or functional excipients [26]. Particle size 
independence of the drug dissolution profile is considered beneficial in terms of 
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robustness of the delivery system. Powder blends containing one of two different particle 
size fractions of DIL HCl (fine or coarse) and increasing increments of CA MH were 
extruded while maintaining a constant API-to-polymer ratio (1:4, formulations 8 – 15). 
Tablets containing 100 mg drug were cut manually and subjected to 12 hours dissolution 
in phosphate buffer pH 6.0 (Fig. 4.7).  
Drug particle size can impact the release rate in several ways. Smaller particles 
possess a larger surface area that is exposed to the release medium, and commonly 
exhibit faster dissolution rates (Noyes-Whitney relationship). Applying the percolation 
theory [27], the major pathway of API release from an insoluble matrix is by diffusion 
through water filled pores, and to a lesser extent, by diffusion through the polymer. Only 
drug particles that are in contact with the dissolution medium, so called infinite clusters, 
will dissolve and be released by diffusion. The critical drug load or total soluble fraction 
(TSF) that is necessary to form a continuous network of pores during the dissolution 
process is referred to as percolation threshold [28]. Below the percolation threshold, only 
drug located at the surface in contact with the medium will be released, while significant 
amounts of API remain trapped as finite clusters inside the insoluble matrix. This 
behavior was observed for tablets without CA MH (DIL75/RS-0 and DIL200/RS-0) with 
an incomplete drug release of 21.87% (DIL75/RS-0) and 29.82% (DIL200/RS-0) after 12 
hours. Both formulations further exhibited an initial burst effect that was attributed to the 
fast dissolution of API that was located at the surface of the tablet. 
The number of pores and the degree of pore network coherence are a function of 
TSF and, if the water-soluble material is insoluble in the matrix polymer, pore formation 
is dependent on the particle sizes of the soluble materials in the formulation [2]. The 
addition of CA MH to the formulation while maintaining a constant ratio of DIL HCl and 
Eudragit® RS PO represented an increase in TSF. The matrix fraction accessible by the 
 
 85
dissolution medium became larger, while the number of isolated API clusters diminished. 
Increasing the amount of CA MH to a DIL HCl / CA MH ratio of 2:1, 1:1 and 2:3 
resulted in faster drug release with 60.30, 69.95 and 75.69% being released after 12 hours 
from formulations containing fine API (DIL75/RS-10, DIL75/RS-20 and DIL75/RS-30). 
The same tendencies were found for the large particle size formulations (65.54, 72.37 and 
77.10% for DIL200/RS-10, DIL200/RS-20 and DIL200/RS-30, respectively). 
The influence of the DIL HCl particle size in the extrusion blend on the 
dissolution properties was further analyzed. Caraballo and coworkers reported a linear 
increase in percolation threshold with increasing drug particle size, implying that drugs of 
larger particle sizes required higher drug loadings to percolate an inert matrix [29]. For 
smaller particles, the formation of a coherent network of pores is statistically more 
probable due to the higher particle number at constant weight fraction when compared to 
coarse particles. For this reason and due to an increase in surface area, a faster DIL HCl 
release was expected for the fine particle size formulations. However, the results in Fig. 
4.7 indicated that formulations with larger API particles yielded a higher release rate at 
all tested CA MH levels. This observation implied that the dissolution of drug particles 
prior to diffusion was not the rate-limiting step for the release of DIL HCl from 
Eudragit® RS PO matrices. Furthermore, higher pore network coherence and increased 
accessible volume fractions as expected for smaller particle formulations did not yield 
improved drug dissolution. It must be concluded that other matrix properties impacted the 
drug dissolution to a larger extent than the previously discussed factors. One possible 
explanation is the theoretical increase in tortuosity and thus diffusion path length in 
networks created by leaching of small particle size compounds when compared to larger 
particles. A second aspect might be the formation of a more homogeneous and denser 
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matrix when powders of small particle size were extruded, resulting in decreased drug 
release rates.  
Interestingly, at high CA MH concentrations, the drug release became 
independent of the API particle size that was used for the extrusion. The release of DIL 
HCl from tablets of the formulation DIL75/RS-30 was very similar to the dissolution 
from DIL200/RS-30 (f2 = 79). Tablets including less CA MH yielded lower similarity 
factors (f2 = 61 or 59, respectively). These discrepancies in dissolution behavior were 
attributed to the elimination of DIL HCl crystallinity and the enhanced dispersion of the 
drug when large amounts CA MH were present. 
 
4.4.6 Influence of CA MH level and DIL HCl particle size on the crystallinity of 
extruded matrix tablets containing constant drug-to-polymer ratios 
Powder X-ray diffraction is a convenient method to investigate the physical state 
of solid dosage forms in terms of crystallinity. The previous experiments demonstrated 
that the LOD of this method for crystalline DIL HCl in Eudragit® RS PO extrudates was 
below 5%. The PXRD pattern of the formulations 8 – 15 are shown in Fig. 4.8. 
Extrudates without CA MH (DIL75/RS-0 and DIL200/RS-0) yielded a high degree of 
DIL HCl crystallinity with several characteristic peaks being present (2-Theta = 10.7, 
15.4, 18.2, 19.5, 20.7, 27.7). These findings were due to the high melting point and 
insolubility of the drug in the polymer. The addition of increasing amounts of CA MH led 
to a decrease in DIL HCl crystallinity as seen for formulations DIL75/RS-10, 
DIL200/RS-10, and DIL200/RS-20. Formulations containing drug and CA MH at a ratio 
of 2:3 (DIL75/RS-30 and DIL200/RS-30) were completely amorphous, and so was 
DIL75/RS-20. The loss of drug crystallinity was attributed to the strong interaction with 
CA MH as previously demonstrated by DSC. The depression of the DIL HCl melting 
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point below the extrusion temperature and the decrease in melting enthalpy by interaction 
with CA MH promoted in-situ melting of the drug during processing. The high shear 
forces that were exerted by the rotating screw facilitated the dispersion of the melted API 
in the softened polymer matrix. The high degree of dispersibility and the amorphous 
character of DIL HCl were maintained in the final product due to rapid cooling after 
extrusion. The high degree of dispersion and the amorphous state of the drug accounted 
for the high dissolution rates that were observed for tablets containing CA MH. 
A comparison of the extrudates prepared with either fine or coarse drug particles 
demonstrated a lower drug crystallinity in tablets prepared with fine DIL HCl. 
Formulation DIL75/RS-20 was completely amorphous, while DIL200/RS-20 exhibited 
small peaks at 10.7, 15.4 and 27.7 (2-Theta). Due to the short residence time of the 
powder material in the heated barrel, complete drug melting was more likely to occur if 
small particle sizes were used, whereas the melting of larger DIL HCl particles was 
incomplete. Surprisingly, the higher degree of crystallinity in extrudates manufactured 
with coarse API was correlated with faster drug dissolution. The employment of small 
particle size material for melt extrusion promoted the formation of a denser matrix with 
higher true density and tortuosity, but decreased porosity. Helium pycnometry showed 
the higher true density of matrices extruded with fine DIL HCl compared to their coarse 
DIL HCl equivalents, but the difference was only statistically significant for the 
formulations comprising DIL HCl and CA MH at a ratio of 2:1 (data not shown). 
Crowley and coworkers observed a decrease in drug release rate due to reduced porosity 
and increased tortuosity when small ethyl cellulose particles were used as the carrier 
material for hot-melt extrusion [26]. It can be concluded that differences in true density 
and porosity of extruded tablets with DIL HCl of different particle size compensated for 
the effects attributed to API crystallinity and surface area. 
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4.4.7 Dissolution of DIL HCl from extruded matrix tablets containing constant 
polymer levels 
Tablets containing either varying DIL HCl to CA MH ratios (formulations 1 – 4) 
or an alternative soluble excipient (sucrose, NaCl or PEG 3350, formulations 5 – 7) were 
prepared, and their drug release properties were analyzed. Dissolution experiments were 
carried out in phosphate buffer pH 6.0 with 250 mg tablets over 12 hours. The polymer 
level was maintained constant for all formulations (60% of the total powder weight), as 
was the total soluble fraction (TSF = 40%), consisting of DIL HCl and either CA MH or 
a different soluble excipient. The release profiles in Fig. 4.9 demonstrated that a partial 
replacement of DIL HCl by CA MH resulted in an accelerated drug release rate. 
Formulation RS60-40/0 (TSF consisting of drug only) released 54.54% DIL HCl during 
the 12-hour experiment, whereas tablets containing CA MH yielded 76.50% (RS60-
10/30), 83.09% (RS60-20/20) and 83.38% (RS60-30/10) after 12 hours. The difference in 
the amount of API released between the three tablet formulations containing drug and CA 
MH in varying ratios was small with f2 similarity factors of 77 (RS60-20/20 versus 
RS60-30/10), 70 (RS60-30/10 versus RS60-10/30) and 60 (RS60-20/20 versus RS60-
10/30), respectively. According to Shah and coworkers [19], release profiles with a f2 
similarity factor higher than 50 can be regarded as similar since the average variation at 
each sampling time point is less than 10% (less than 5% for f2 ≥ 65). 
Reviewing the scientific literature, the effect of citric acid on the drug release rate 
from sustained release matrix systems is mainly attributed to two properties: For weakly 
basic drugs with pH dependent solubility, the enhanced drug release has been attributed 
to the acidic character of citric acid. In buffered dissolution media, the acidity of citric 
acid is sufficient to maintain a low pH in the microenvironment of the API. Hence, a 
higher ratio of the API will be present in the more soluble ionized form, resulting in a 
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faster drug release. This phenomenon has been reported for the release of vinpocetine 
[30], trimethoprim [12] and dipyridamole [11] from HPMC matrices. An alternative 
mechanism explaining the higher drug dissolution from citric acid-containing systems is 
based on the high aqueous solubility of this compound (Table 4.2). Due to rapid 
dissolution of citric acid from the matrix, the porosity will increase, and drug diffusion 
through the water-filled porous network will be facilitated. This mechanism was reported 
to dominate the release of pelanserin hydrochloride from HPMC tablets [31]. Both 
mechanisms impose different requirements for the residence time of citric acid within the 
polymeric matrix. For the first effect, a delayed citric acid release is beneficial to prolong 
the acidic pH in the API environment, whereas the activity as a pore former requires a 
rather rapid citric acid release from the system. Drug solubility represents an additional 
factor that needs to be considered when evaluating the impact of both mechanisms. Only 
poorly soluble drugs will benefit from a solubility increase attributed to pH modification, 
while the effect will be negligible for compounds with high aqueous solubility over the 
entire physiologic pH range. 
An increase in DIL HCl release induced by microenvironmental acidification due 
to CA addition can be excluded for three reasons: First, although the solubility of DIL 
HCl decreases with increasing pH values, it is still sufficiently soluble to maintain sink 
conditions during dissolution studies at pH 6.0. Second, Fig. 4.9 provides evidence that 
the release of DIL HCl was not influenced by the pH of the dissolution medium. 
Formulation RS60-40/0 exhibited highly similar dissolution curves in two different 
media, phosphate buffer pH 6.0 and simulated gastric fluid pH 1.2 (without pepsin, USP 
29) with a f2 similarity factor of 90, corresponding to 1.43% average variation. Third, the 
release of CA MH from RS60-20/20 tablets was relatively rapid (Fig. 4.10), with 56.92% 
being released after 3 hours in phosphate buffer pH 6.0 (HPLC assay described in [18]). 
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These results suggest that the retention time of CA MH inside the matrix was too short to 
provide an acidic microenvironmental pH during dissolution. 
To further investigate the capability of CA MH to act as a pore forming agent and 
to evaluate the contribution of this effect to the increased DIL HCl release rate, three 
additional formulations (no. 5-7) containing 20% drug and alternative pore formers at a 
20% level were extruded. The TSF was held constant at 40% to eliminate modifications 
in drug release due to differences in Eudragit® RS PO level. All studied excipients 
showed high aqueous solubility, but differences in melting properties and plasticization 
effect on the polymer (Table 4.2). Sucrose was selected due to its high solubility and its 
similarities to citric acid concerning chemical structure and melting point. Sodium 
chloride is a salt with a very high melting point, making in-situ melting impossible. A 
medium molecular weight polyethylene glycol (PEG 3350) was chosen due to its 
plasticizing effect on Eudragit® RS PO similar to CA MH. 
Fig. 4.11 demonstrates that formulations containing the alternative pore formers 
sucrose, PEG 3350 or NaCl yielded a slower drug release than RS60-40/0 tablets. Their 
ability to improve drug diffusion by pore formation did not exceed the pore forming 
capacity of the API itself at the same TSF. In contrast, tablets comprising CA MH (RS60-
20/20) exhibited a significantly faster drug release than the formulation with drug only or 
additional alternative pore formers. The high aqueous solubility and rapid dissolution of 
CA MH during dissolution suggests a contribution of pore formation to the increased 
release rate. However, this property alone did not entirely account for the fast DIL HCL 
release that was observed for CA MH containing extrudates, since alternative pore 




4.4.8 Morphology of extruded matrix tablets containing constant polymer levels 
From the results of the dissolution experiments with alternative pore formers, it 
was assumed that the faster DIL HCl release from tablets with drug being partially 
replaced by CA MH could not only be explained by increased matrix porosities. 
Therefore, the influence of CA MH on the matrix morphology and on the solid state of 
the drug was investigated. 
The morphology of cut tablets before and after 12 hours dissolution in phosphate 
buffer pH 6.0 was visualized with scanning electron microscopy (Fig. 4.12). The ratio of 
polymer to soluble fraction was 60:40 for the investigated formulations (nos. 1, 3 and 6). 
The SEM pictures of the tablets containing either 40% drug (RS60-40/0) or 20% drug 
with 20% NaCl (RS60-20/20N) yielded strong morphological similarities. Before 
dissolution, the surfaces were uneven and exhibited numerous large pores with diameters 
of 10-40 µm, both properties attributed to a lack of plasticization of the brittle polymer by 
the included additives. Following dissolution testing, the matrices were highly porous 
with rough surface structures due to the dissolution of drug and NaCl particles exposed to 
the release medium and the percolation of these soluble components through the inert 
matrix. Tablets containing CA MH as the soluble additive (RS60-20/20) yielded 
relatively even surfaces of high integrity and without pores before the dissolution 
experiment. This can be explained by the ability of the organic acid to plasticize the 
acrylic polymer during the extrusion process, promoting the formation of an intact matrix 
of higher apparent density. The exposure of the tablets to the dissolution medium over 12 
hours resulted in the generation of cracks and few large pores, while the bulk of the 
surface remained relatively intact as opposed to the other two formulations. Large 
magnifications of 30,000x or higher indicated the existence of pores that were smaller 
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than 300 nm and were due to the leaching of soluble, fine dispersed compounds from the 
dosage form. 
It can be concluded that the drug release from CA MH containing extrudates 
occurred through different mechanisms than from matrices with high drug loading or 
pore forming excipients. The DIL HCl release from formulations with 40% drug or 
alternative pore formers occurred primarily by diffusion through a network of pores in 
the micrometer range, which was generated by the leaching of soluble components. The 
pore formation was restricted to the exterior layers of the matrix, since the dissolution 
period was insufficient to allow water penetration though the whole tablet. This aspect 
was responsible for the incomplete drug release after 12 hours (27.88 – 54.54% 
depending on the additive) as demonstrated for these composites. Based on the findings 
from the binding study, DIL HCl adsorption to the polymer matrix during dissolution 
could be excluded as the explanation for the incomplete release. 
Tablets with CA MH as a release modifying excipient exhibited a faster and more 
complete release of DIL HCl (83.09% after 12 hours). Two different mechanisms could 
account for this observation. The high miscibility between CA MH and DIL HCl and the 
decreased polymer melt viscosity due to plasticization promoted the melting and fine 
dispersion of the soluble compounds within the polymer during extrusion. Leaching of 
the highly dispersed API and CA MH from the matrix during dissolution testing may 
create an extensive and coherent pore network. The volume fraction of matrix material 
that is accessible for the dissolution medium was increased, resulting in a faster and more 
complete drug release. This process was less efficient for tablets containing alternative 
pore formers since their lack of miscibility with the API and the polymer impeded the 
melting and fine dispersion of the soluble material.  
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A second approach considers the modification of the polymer permeability by CA 
MH. The molecular dispersion of the organic acid between the polymeric chains resulted 
in an alteration of the polymer’s properties in terms of processibility and aqueous 
permeability. Due to its hygroscopic nature [32] and high aqueous solubility, CA MH 
promoted the water penetration into the matrix by increasing the permeability of the 
polymer. Furthermore, when exposed to dissolution medium, chloride ions at the 
quaternary ammonium groups of Eudragit® RS PO can be exchanged by citrate counter 
ions. Wagner and coworkers [33] demonstrated that anions of mono- and diprotic acids 
present in the dissolution medium displayed a permeability enhancing effect after ion 
exchange. This was attributed to the larger hydration shell of these anions when 
compared to chloride, promoting water uptake and polymer swelling. The magnitude of 
permeability enhancement was dependent on the extent of ion exchange, anion valence 
and concentration, and on the properties of the hydration shell. Citric acid dissociates in 
water as a function of the pH into mono-, di- and trivalent ions that are capable of 
electrostatic interaction with the quaternary ammonium groups, resulting in an enhanced 
hydration and water permeability of the polymer. 
 
4.4.9 Drug crystallinity in extruded matrix tablets containing constant polymer 
levels 
Powder X-ray diffraction analysis was carried out with extrudate powders 
(formulations 3, 5 – 7) to assess the physical states of DIL HCl and of the soluble 
excipients in the Eudragit® RS PO matrices. The PXRD patterns obtained for the 
extruded materials were compared to the physical mixtures and the pure crystalline 
materials (Fig. 4.13). Patterns of crystalline DIL HCl exhibited numerous peaks in the 2-
Theta range, and six characteristic peaks (10.7, 15.4, 18.2, 19.5, 20.7, 27.7) were selected 
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for the evaluation of the extrudate properties. The majority of these DIL HCl peaks could 
be identified in the extrudates comprising either sucrose (10.7, 15.4, 18.2, 27.7), NaCl 
(10.7, 15.4, 18.2, 19.5, 20.7, 27.7) or PEG 3350 (10.7, 15.4, 20.7, 27.7), while extruded 
material containing CA MH as the release modifying excipient was completely 
amorphous. Neither the drug nor CA MH itself was in the crystalline state, whereas the 
crystallinity of the other three excipients was evident from the presence of their 
characteristic peaks. The crystalline nature of sucrose and NaCl in the extrudates was 
expected since both compounds did not melt at extrusion temperatures, whereas PEG 
3350 recrystallized after in-situ melting. The amorphous character of DIL HCl was a 
result of an enhanced miscibility with the polymer. Strong interactions between DIL HCl 
and CA MH promoted drug melting during extrusion and the stabilization of the 
amorphous state. Plasticization of the polymer by CA MH further encouraged the mixing 
process and improved the dispersion of DIL HCl and CA MH inside the Eudragit® RS 
PO matrix due to the reduced melt viscosity during extrusion. 
 
4.5 CONCLUSION 
The present study demonstrated the suitability of citric acid monohydrate (CA 
MH) to promote the release of a soluble model drug from hot-melt extruded Eudragit® 
RS PO matrices. Extrudates with drug only were crystalline due to the insolubility of DIL 
HCl in Eudragit® RS PO and yielded a slow and incomplete drug release attributed to the 
low porosity of the matrix. CA MH promoted the thermal processibility and matrix 
integrity by plasticization of the polymer. The addition of CA MH to formulations with 
constant drug-to-polymer ratios significantly increased the rate and extent of drug release 
as a more coherent porous network was formed during dissolution. Drug particle size 
effects on the dissolution rate were eliminated when large amounts of CA were added due 
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to complete drug melting and loss of drug crystallinity as a result of strong DIL HCl – 
CA MH interactions during extrusion. At constant polymer levels, the partial replacement 
of drug by alternative pore forming agents exhibiting high water solubility (sucrose, 
NaCl, PEG 3350) led to decreased drug release rates compared to formulations with only 
API, while CA MH greatly enhanced drug dissolution. We concluded that the 
mechanisms of the CA MH induced modification in drug release are complex and exceed 
pure pore formation. A promotion of the API dispersion in the polymer melt during 
extrusion, alterations in the solid state of the drug from crystalline to amorphous as well 
as a modification of the polymeric matrix were discussed as possible mechanisms of 
action. 
In summary, the addition of CA MH as a release modifier and processing aid to 
an insoluble drug-polymer system enabled the extrusion of an amorphous matrix system 
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Table 4.1: Composition of tablets prepared by hot-melt extrusion. 










1 RS60-40/0 40 75 – 150 0 60 
2 RS60-30/10 30 75 – 150 10 60 
3 RS60-20/20 20 75 – 150 20 60 
4 RS60-10/30 10 75 – 150 30 60 
5 RS60-20/20S 20 75 – 150 20 Sucrose 60 











PXRD RS60-20/20P 20 75 – 150 20 PEG  60 
8 DIL75/RS-0 20 < 75 0 80 
9 DIL200/RS-0 20 150 – 250 0 80 
10 DIL75/RS-10 20 < 75 10 80 
11 DIL200/RS-10 20 150 – 250 10 80 
12 DIL75/RS-20 20 < 75 20 80 
13 DIL200/RS-20 20 150 – 250 20 80 














Table 4.2:  Physical properties of water-soluble excipients that were selected as release-
modifying additives for the hot-melt extrusion of diltiazem hydrochloride / 
Eudragit® RS PO matrices. 
Excipient Water Solubility  Melting Point In Situ Plasticization 
 (at 20°C) [%] [°C] Melting of the Polymer 
Citric Acid 
Monohydrate 59 135 yes yes 
Sucrose 200 160 no no 
Sodium 
Chloride 36 804 no no 






Figure 4.1:  Thermal gravimetric analysis of (a) citric acid monohydrate, (b) anhydrous 
citric acid, (c) diltiazem hydrochloride, and (d) Eudragit® RS PO. 















Figure 4.2: Binding of diltiazem hydrochloride to Eudragit® RS PO as a function of the 
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Figure 4.3: Powder X-ray diffraction patterns of physical mixtures (PMs) and hot-melt 
extrudates (HMEs) containing 5-20% diltiazem hydrochloride (DIL HCl) in 
Eudragit® RS PO. (a) HME with 20% DIL HCl, (b) PM with 20% DIL 
HCl, (c) HME with 10% DIL HCl, (d) PM with 10% DIL HCl, (e) HME 
with 5% DIL HCl, (f) PM with 5% DIL HCl. 















Figure 4.4: Differential scanning calorimetry profiles of diltiazem hydrochloride (DIL 
HCl) and anhydrous citric acid (CA) and physical mixtures thereof. (a) DIL 
HCl/ CA 7:1, (b) DIL HCl/ CA 3:1, (c) DIL HCl/ CA 1:1, (d) DIL HCl/ CA 
1:3, (e) DIL HCl/ CA 1:7, (f) pure DIL HCl, and (g) pure anhydrous CA. 

















Figure 4.5: Influence of the diltiazem hydrochloride (DIL HCl) to citric acid 
monohydrate (CA MH) ratio on the screw speed applied for the melt 
extrusion of Eudragit® RS PO (constant level of 60%) as a function of 
temperature.  
( ) Pure Eudragit® RS PO. Eudragit® RS PO with ( ) 40% DIL HCl, ( ) 
30% DIL HCl and 10% CA MH, ( ) 20% DIL HCl and 20% CA MH, ( ) 
10% DIL HCl and 30% CA MH. (n = 3, error bars represent the standard 
deviation) The values in parentheses represent the motor load (drive 
amperage multiplied by 100) measured during extrusion at the target screw 
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Figure 4.6: Influence of the diltiazem hydrochloride (DIL HCl) to citric acid 
monohydrate (CA MH) ratio on the true density of hot-melt extrudates 
























Figure 4.7: Influence of the diltiazem hydrochloride (DIL HCl) particle size in the 
extrusion blend and the addition of citric acid monohydrate (CA MH) on the 
drug release from extruded Eudragit® RS PO matrix tablets with constant 
DIL HCl to polymer ratio (1:4). ( ) Small DIL HCl particle size (< 75 µm), 
and ( ) large DIL HCl particle size (150-250 µm). (A) DIL HCl and no CA 
MH, (B) DIL HCl / CA MH 2:1, (C) DIL HCl / CA MH 1:1, and (D) DIL 
HCl / CA MH 2:3.  
Dissolution: USP paddle method, 900 ml phosphate buffer pH 6.0 as 
dissolution medium, 37°C, 50 rpm, n = 6. 

























































































Figure 4.8: Influence of citric acid monohydrate (CA MH) concentration and diltiazem 
hydrochloride (DIL HCl) particle size on the crystallinity of hot-melt 
extrudates. PXRD patterns of extrudates with constant DIL HCl to 
Eudragit® RS PO ratio (1:4) and (a) DIL HCl (< 75 µm) / CA MH 2:3, (b) 
DIL HCl (150-250 µm) / CA MH 2:3, (c) DIL HCl (< 75 µm) / CA MH 1:1, 
(d) DIL HCl (150-250 µm) / CA MH 1:1, (e) DIL HCl (< 75 µm) / CA MH 
2:1, (f) DIL HCl (150-250 µm) / CA MH 2:1, (g) DIL HCl (< 75 µm) and 
no CA MH, (h) DIL HCl (150-250 µm) and no CA MH. 

















Figure 4.9: Influence of the diltiazem hydrochloride (DIL HCl) to citric acid 
monohydrate (CA MH) ratio and the pH of the dissolution medium on the 
drug release from extruded Eudragit® RS PO matrix tablets containing 60% 
polymer. (+) 10% DIL HCl and 30% CA MH, release in phosphate buffer 
pH 6.0, ( ) 20% DIL HCl and 20% CA MH, release in phosphate buffer pH 
6.0, ( ) 30% DIL HCl and 10% CA MH, release in phosphate buffer pH 
6.0, ( ) 40% DIL HCl and no CA MH, release in phosphate buffer pH 6.0, 
( ) 40% DIL HCl and no CA MH, release in simulated gastric fluid pH 1.2. 
Dissolution: USP paddle method, 900 ml dissolution medium, 37°C, 50 

























Figure 4.10:  Release of citric acid monohydrate (CA MH) from extruded Eudragit® RS 
PO matrix tablets containing 60% polymer, 20% diltiazem hydrochloride 
and 20% CA MH.  
Dissolution: USP paddle method, 900 ml phosphate buffer pH 6.0 as 






















Figure 4.11:  Effect of pore forming excipients on the diltiazem hydrochloride (DIL HCl) 
release from extruded Eudragit® RS PO matrix tablets containing 60% 
polymer, 20% DIL HCl and 20% of ( ) citric acid monohydrate, ( ) 
sucrose, ( ) PEG 3350, and ( ) NaCl. (+) Extrudate with 40% DIL HCl 
and no pore forming excipient.  
Dissolution: USP paddle method, 900 ml phosphate buffer pH 6.0 as 

























Figure 4.12:  SEM of hot-melt extruded tablets composed of 60% Eudragit® RS PO, and 
(A) 40% diltiazem hydrochloride (DIL HCl), (B) 20% DIL HCl and 20% 
citric acid monohydrate, and (C) 20% DIL HCl and 20% NaCl. Pictures 
were taken before (X-1) and after (X-2) dissolution in phosphate buffer pH 






















Figure 4.13: Effect of pore forming excipients on crystallinity of diltiazem hydrochloride 
(DIL HCl) in extruded Eudragit® RS PO matrix tablets containing 60% 
polymer, 20% DIL HCl and 20% of either citric acid monohydrate (CA 
MH), sucrose, sodium chloride (NaCl) or PEG 3350. PXRD patterns of (a) 
hot-melt extrudates, (b) physical mixtures, (c) pore forming excipient, (d) 
DIL HCl. 
 















































Chapter 5: Investigation of the Influence of Formulation Factors on the 
Properties of Enteric Hot-Melt Extruded Matrix Pellets3 
 
Abstract: 
The objective of this study was to investigate the properties of enteric matrix 
pellets that were prepared by hot-melt extrusion in a one-step, continuous process. 
Five polymers (Eudragit® L100-55, L100 and S100, Aqoat® grades LF and HF) 
were investigated as matrix formers, and pellets prepared with Eudragit® S100 
demonstrated superior gastric protection and acceptable processibility. Extruded pellets 
containing Eudragit® S100 and up to 40% theophylline released less than 10% drug over 
2 hours in acid, however, the processibility and yields were compromised by the high 
amounts of the non-melting drug material in the formulation. Efficient plasticization of 
Eudragit® S100 was necessary to reduce the polymer’s glass transition temperature and 
melt viscosity. Five compounds including triethyl citrate, methylparaben, polyethylene 
glycol 8000, citric acid monohydrate and acetyltributyl citrate, were investigated in terms 
of plasticization efficiency and preservation of the delayed drug release properties. The 
aqueous solubility of the plasticizer and its plasticization efficiency impacted the drug 
release rate from the matrix pellets. The use of water-soluble plasticizers resulted in a 
loss of gastric protection, whereas low drug release rates in acid were found for pellets 
containing insoluble plasticizers or no plasticizer, independent of the extent of Eudragit® 
S100 plasticization. The release rate of theophylline in buffer pH 7.4 was faster for 
pellets that were prepared with efficient plasticizers. The microstructure and solid-state 
                                                 
3 Significant portions of this chapter were taken from: Schilling, S.U., Shah, N.H., Malick, A.W., and 
McGinity, J.W. Properties of melt extruded enteric matrix pellets. European Journal of Pharmaceutics and 
Biopharmaceutics, in press October 2009. 
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properties of plasticized pellets were further investigated by scanning electron 
microscopy and powder X-ray diffraction. Pellets prepared with efficient plasticizers 
(TEC, methylparaben, PEG 8000) exhibited matrices of low porosity, and the drug was 
homogeneously dispersed in its original polymorphic form. Pellets containing ATBC or 
citric acid monohydrate had to be extruded at elevated temperature and showed physical 
instabilities in the form of recrystallization at room temperature. Enteric matrix pellets 
with a diameter below one mm and containing 30% theophylline could be successfully 
prepared by hot-melt extrusion when Eudragit® S100 plasticized with either TEC or 




Multiparticulate oral dosage forms offer several advantages over monolithic 
systems. The pellets disperse rapidly and more uniformly along the gastro-intestinal tract, 
reducing food effects on drug absorption and avoiding high local drug concentrations. 
The bioavailability of certain drugs can be enhanced in terms of increased absorption and 
minimized inter- and intra-subject variability [1]. Enteric or sustained release pellets can 
either be of the matrix type where the drug is embedded in the release controlling matrix, 
or of the reservoir type. The drug containing core of reservoir-type pellets is traditionally 
produced by wet-mass extrusion/ spheronization or by layering of the drug onto 
nonpareils. A functional coating is then applied to the pellets in a subsequent step. Matrix 
systems may be produced by wet-mass extrusion and spheronization, melt granulation or 
hot-melt extrusion using release-controlling carriers. 
Hot melt extrusion has emerged as a recognized pharmaceutical manufacturing 
technology for the preparation of a variety of dosage forms including implants, tablets, 
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pellets and films [2]. The process has been successfully adapted for the preparation of 
sustained release matrix tablets [3-6] and pellets [7-9]. More recently, the preparation of 
enteric matrix systems by hot-melt extrusion has been reported. Andrews and coworkers 
demonstrated that melt extruded tablets containing 5-aminosalicylic acid and Eudragit® 
L100-55 released less than 5% drug over 2 hours in acid [10]. Yang and coworkers 
prepared enteric matrix tablets releasing less than 3% drug by cutting as well as direct 
compression of comminuted extrudates when using Eudragit® L100 as the matrix former 
[11]. Melt extruded Eudragit® S100 tablets for the colonic delivery of 5-aminosalicylic 
acid also showed excellent gastric protection [12]. The authors demonstrated that hot-
melt extruded matrices exhibited reduced drug diffusion rates in acid due to their low 
porosity when compared to directly compressed matrix tablets which failed to delay the 
drug release in acidic media. The drug release from melt extruded pellets based on 
Eudragit® 4135 F was demonstrated to be slow with around 20% drug released within 2 
hours at pH 1.2, while more than 85% theophylline were released from the corresponding 
wet-mass extruded systems [13]. In addition to prolonged drug release properties, melt 
extruded pellets are more robust when directly compressed into multiparticulate 
monolithic systems due to their high mechanical strength and the circumstance that the 
release performance is independent of the intactness of a functional coat. From a 
processing point of view, hot-melt extrusion is a continuous process abstaining from the 
use of solvents and involving fewer steps than traditional extrusion and coating 
procedures. 
However, the manufacture of enteric pellets exhibiting particle sizes below 1 mm 
and releasing less than 10% of their drug content over 2 hours in acid remains 
challenging. Pharmaceutically acceptable enteric polymers generally exhibit high melt 
viscosities and glass transition temperatures above 120°C. The limited thermal stability 
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of most polymers and drugs and the use of dies smaller than 1 mm in diameter make 
efficient plasticization of the polymeric carrier necessary to reduce the glass transition 
temperature and melt viscosity during extrusion. Soluble plasticizers, however, can 
function as pore formers and increase diffusion controlled drug release [14, 15] which is 
undesirable for delayed release dosage forms. Furthermore, the incorporation of high 
drug loads into microparticulate pellets is challenging as a large fraction of the drug is 
located near the particle surface and will be exposed to burst release during the acidic 
stage. Beads based on Eudragit® L100-55 that were extruded through a 1.2 mm die and 
contained 20% theophylline as the model drug released more than 25% drug in 2 hours at 
pH 1.2, compared to 10% drug released for tablets with a diameter of 6 mm [16]. In 
patent application WO 2008/101743, a water-insoluble carrier (Eudragit® RL, RS or NE) 
was used in combination with an anionic polymer to reduce the permeability of the 
enteric matrix pellets during the acidic stage [17].  
The objective of the present study was to investigate the properties of hot-melt 
extruded matrix pellets with a particle size below 1 mm and the ability to delay the 
release of theophylline as a water-soluble model drug. The thermal processibility and 
drug release characteristics of matrix pellets prepared with cellulosic polymers (Aqoat® 
LF and HF) and acrylic polymers (Eudragit® L100-55, S100 and L100) were studied. 
The effect of drug loading ranging from 10 to 40% on the processibility and release 
properties of pellets based on Eudragit® S100 was investigated. The compatibility and 
plasticization efficiency of five plasticizers including TEC, ATBC, PEG 8000, 
methylparaben and citric acid monohydrate with Eudragit® S100 were evaluated. Matrix 
pellets consisting of 30% theophylline and plasticized Eudragit® S100 were prepared by 
hot-melt extrusion, and the influence of the plasticizer on the release properties, solid-




Anhydrous theophylline was selected as the water-soluble model drug and was 
purchased from Spectrum Chemicals (Gardena, CA). Hydroxypropyl methylcellulose 
acetate succinate (HPMC AS, Aqoat®) was used in two grades (LF and HF) and kindly 
provided by Shin-Etsu (New York, NY). Methacrylic acid copolymers of three different 
grades (Eudragit® L100-55, L100, S100) were donated by Evonik, (Piscataway, NJ). The 
plasticizers used for the study included triethyl citrate (TEC) and acetyltributyl citrate 
(ATBC, both donated by Vertellus, Greensboro, NC), citric acid monohydrate (CA MH, 
Fisher Scientific, Fair Lawn, NJ), polyethylene glycol 8000 (PEG, Carbowax Sentry, 
powder NF, Dow Chemical Company, Midland, MI) and methylparaben (MP, Spectrum 
Chemicals, Gardena, CA). 
 
5.3 METHODS 
5.3.1 Preparation of melt extruded pellets 
Powder blends for extrusion (10g) were prepared by pre-mixing the polymer with 
the plasticizer and subsequent blending with the drug using a kitchen aid mixer (St. 
Joseph, MI). A mini extruder equipped with two co-rotating screws and a circular 500μm 
die (Haake Minilab, Rheomax CTW5, Thermo Electron, Germany) was used for the 
extrusion of drug loaded, polymeric strands, which were manually cut to obtain 
cylindrical pellets. Formulations and processing parameters are listed in Tables 5.1-5.3. 
The diameters of the extruded strands were measured with a manual micrometer 




5.3.2 Plasticization efficiency: thermal analysis of physical mixtures 
Eudragit® S100 and 30% plasticizer (based on the polymer weight) were blended 
with a mortar and pestle and analyzed by modulated differential scanning calorimetry 
(MDSC) to investigate plasticization efficiency. An accurately weighed amount of 
powder was sealed in an aluminum pan and heated using a TA Instrument model 2920 
(New Castle, DE). The material was equilibrated at 0°C for 5 minutes and then ramped to 
180°C at 10°C/min with a modulation of 0.5°C every 40 seconds. After quench cooling 
to 0°C at a rate of 20°C/min, a second run was performed. The glass transition 
temperature was measured in the second cycle as the midpoint of the step transition in the 
plot of reverse heat flow versus temperature. 
 
5.3.3 Dissolution studies and theophylline assay 
Dissolution testing was carried out in a USP paddle apparatus (Varian, Cary, NC) 
according to the method described for delayed release articles USP chapter <724>, 
method A. Pellets (100 mg, n = 3) were placed in 750 ml simulated gastric fluid pH 1.2 
(SGF, without pepsin). After 2 hours, the pH was increased to pH 6.8 (HPMC AS LF and 
Eudragit® L100) or to pH 7.4 (HPMC AS HF, Eudragit® S100) by adding 250 ml 0.2M 
tribasic phosphate buffer and adjusting with diluted sodium hydroxide solution to the 
desired pH. The medium temperature and paddle speed were maintained at 37.0±0.5°C 
and 50 rpm, respectively. The theophylline content in withdrawn samples was quantified 
using a HPLC system (Waters Inc., Milford, MA) equipped with a C18-reversed phase 
column (Capcell PAK 3 mm * 100 mm, Shiseido Co, Japan) and a UV detector (996-
PDA, Waters Inc. Milford, MA). The mobile phase consisted of 20 mM phosphate buffer 
pH 5 and acetonitrile (9:1), the injection volume was 10μl and the flow rate was constant 
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at 0.5 ml/ min. Theophylline was eluted after 3.5 min, and the peak areas captured at 
271.5 nm were integrated using Empower Version 5.0 software (Waters Inc.). Linear 
correlation was confirmed between 0.1 and 100.0μg/ ml (R2 = 0.99997), and multiple 
injections yielded good reproducibility with RSD values between 0.08% (100.0μg/ ml) 
and 1.77% (0.1μg/ ml). 
 
5.3.4 Scanning electron microscopy (SEM) 
Cut pellets were mounted on carbon tape and coated with Pt/ Pd under an argon 
atmosphere at 2.5 kV and 20 mA to a thickness of 15 nm with a Cressington sputter 
coater 208 HR (Cressington Scientific Instruments Ltd., Watford, UK). The samples were 
analyzed with a Zeiss Supra 40VP SEM (Carl Zeiss AG, Germany) equipped with a 
Gemini column operating in field emission mode at an acceleration voltage of 5 kV and 
an emission current of 300 µA. Photographs were taken using Smart SEM V05.02.03 
software. 
 
5.3.5 Powder X-ray diffraction (PXRD) 
The crystallinity of physical mixtures and ground extrudates was investigated 
with a Philips Electronic Instrument Type 42273 (Philips Electronic Instrument, Mount 
Vernon, NY). The generator operating voltage and current were 40 kV and 30 mA. 
Samples were spread in a powder bed and scanned in the 2-Theta range between 5-40° at 





5.4 RESULTS AND DISCUSSION 
5.4.1 Selection of the enteric matrix polymer 
The preparation of enteric pellets by hot-melt extrusion requires the use of a 
thermoplastic matrix polymer with acidic groups. Two cellulosic polymers, HPMC AS 
LF and HPMC AS HF (Aqoat® LF and HF) and three polymethacrylates (Eudragit® 
L100-55, L100 and S100) were investigated as potential carrier materials. The 
compositions of blends containing 10% theophylline in the different enteric polymers, the 
extrusion parameters (temperature and torque) and the average diameter of the extruded 
polymer strands are listed in Table 5.1. Unplasticized Eudragit® S100 and L100 exhibit 
high glass transition temperatures (Tg) of 172°C and 194°C (determined by MDSC), 
respectively, and undergo thermal degradation above 180°C [18]. High TEC levels (30% 
based on the polymer weight, 20.8% absolute) were necessary to sufficiently lower the 
Tg and the processing temperature of polymethacrylic blends below the threshold 
temperature of thermal degradation, while formulations with cellulosic polymers 
contained only 20% TEC based on the polymer weight (15% absolute). Yet, blends that 
were prepared with polymethacrylates had to be extruded at high temperatures (160 and 
170°C) to efficiently reduce the torque and produce melt viscosities that were low enough 
to enable the exit of the polymer strand through the 500 µm die.  Extrudates of Eudragit® 
L100-55 could not be produced as the melt was too viscous and produced torque values 
exceeding the alarm setting (368 Ncm). Pellets based on HPMC AS could be extruded at 
lower temperatures (120-130°C), faster output rates and exhibited less tendency to swell 
after die exit (strand diameters of 647±23μm and 598±8μm for Aqoat® LF and Aqoat® 
HF grade) compared to the polymethacrylates (diameters of 967±65μm and 883±12μm 
for Eudragit® L100 and S100). The advantageous processibility of the cellulosic 
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polymers could be explained by their lower molecular weights (approximate MW around 
18,000) [19] compared to the methacrylic polymers (MW of 135,000 for Eudragit® L100 
and S100, MW of 250,000 for Eudragit® L100-55) [20, 21] and their lower Tg (119°C, 
determined by MDSC), presumably resulting in lower melt viscosities and reduced elastic 
recovery after extrusion. The HPMC AS HF grade displayed slight advantages in 
processibility in comparison to the LF grade, as evidenced by lower and less variable 
torque values.  
The drug release properties of extruded pellets at pH 1.2 (2 hours) and pH 6.8 
(HPMC AS LF, Eudragit® L100) or pH 7.4, respectively (HPMC AS HF, Eudragit® 
S100) are shown in Fig. 5.1. All formulations showed an initial burst effect with a 
relatively high release after 15 min, followed by a sustained release over the remainder of 
the dissolution period in acid. A similar biphasic behavior has been reported for hot-melt 
extruded, insoluble matrix pellets [22]. The initial burst can be correlated with the release 
of drug from the surface of the pellets which were not protected by the enteric polymer 
and exposed to dissolution medium, while diffusion processes dominated at later time 
points. Cellulosic pellets plasticized with TEC exhibited a higher burst effect and faster 
drug diffusion rates in acid than the pellets made with polymethacrylates with more than 
20% drug released after 2 hours. In an attempt to reduce the permeability of the matrix, 
TEC was replaced by the less soluble ATBC, and the amount of plasticizer was reduced 
in favor of the polymer content. The release in acid decreased to 14.84%, but still failed 
to meet the USP requirement of 10% or less after 2 hours. On the other hand, pellets 
extruded with the methacrylic polymers provided excellent gastric protection with 3.85% 
(Eudragit® L100) and 3.76% theophylline (Eudragit® S100) being released after 2 hours. 
Based on the manufacturing process by hot-melt extrusion, the initial porosity of the 
produced matrix pellets is expected to be low and not responsible for the differences in 
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release profiles observed in acidic medium. Cellulosic polymers are more hydrophilic 
than polymethacrylates and demonstrated faster water penetration into the matrix and 
more extensive hydration, presumably leading to increased matrix permeability and drug 
diffusion rates even in acidic medium. Similar results were reported for cured film-coated 
systems [23]. Pellets that were coated with Eudragit® S100 released the drug to a lesser 
extent over two hours in acid than pellets coated with Aqoat® HF. 
In the buffer phase, theophylline was rapidly released from the HPMC AS based 
pellets (> 95% after 2 hours in buffer). The polymethacrylic pellets displayed a more 
sustained release profile with 61.15% (Eudragit® L100) and 66.56% released (Eudragit® 
S100), respectively, after 2 hours in the buffer. Similar extended release profiles in buffer 
were observed for hot-melt extruded matrix tablets based on Eudragit® S100 [12], 
Eudragit® L100-55 [10] and Eudragit® L100 [11]. This release behavior from Eudragit® 
pellets above dissolution pH was attributable to the larger MW and slower hydration and 
erosion characteristics of polymethacrylic copolymers. Siepmann and coworkers 
investigated the water uptake and dry mass loss of thin ethylcellulose films containing 
either HPMC AS or Eudragit® L as enteric polymer. The dry mass of TEC-plasticized 
ethylcellulose: HPMC AS films decreased faster and to a higher extent than that of 
ethylcellulose: Eudragit® L films in buffer pH 7.4, which was attributed to more rapid 
and more substantial dissolution of HPMC AS and leaching of the plasticizer. After 2 
hours in the buffer, HPMC AS was completely released into the dissolution medium 
whereas 37% Eudragit® L remained within the film even after 8 hours [24]. 
Eudragit® S100 was selected as the matrix material for the preparation of pellets 
as it provided good gastric protection. This polymer further displayed acceptable 
processibility when high amounts of plasticizer were employed, and superior thermal 
stability compared to a polymer mixture. Pellets based on a 1:1 mixture of HPMC AS HF 
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and Eudragit® S100 were also investigated since an intermediate drug release profile was 
expected for this formulation. The extrusion temperature for this mixture was selected to 
be 140°C. Lower processing temperatures resulted in selective melting of Aqoat®, while 
the Eudragit® S100 remained as distinct powder particles without forming a coalesced 
matrix. These pellets were very friable and released high amounts of drug in acid, since 
non-molten Eudragit® S100 was less efficient in controlling the drug release. Extrusion 
at temperatures above 130°C, however, resulted in browning of the extrudate due to 
thermal degradation of the cellulose component. Pellets prepared with the mixture 
released 10.88% drug in acid which was lower than for HPMC AS pellets, but still above 
the 10% limit required by the USP. 
 
5.4.2 Influence of drug loading  
The formulation of controlled release matrix systems for high dose drugs poses 
challenges to the pharmaceutical scientist since the release rate is dependant on the 
integrity of the polymeric matrix. The maximum applicable drug loading is limited by the 
percolation threshold, defined as the critical load of soluble material that will form a 
percolating cluster when leaching from the matrix. Above this critical load, a continuous 
porous network will be formed during dissolution, resulting in a loss of the sustained or 
delayed release properties of the dosage form [25]. When multiparticulate matrix systems 
are utilized, the increase in surface area will lead to a higher fraction of drug at the 
surface and thus accessible by the dissolution medium, a circumstance that further 
impedes the incorporation of high drug loadings. Follonier and coworkers demonstrated 
that drug release rates from melt extruded, sustained release pellets correlated with the 
drug-to-polymer ratio, and that both phases, burst release and diffusion controlled release 
were accelerated when the amount of drug was increased [22].  
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To investigate the effects of drug load, enteric pellets were extruded with 
theophylline levels ranging from 10 to 40%, employing Eudragit® S100 as release-
controlling matrix former and TEC as a processing aid at the 40% level based on the 
polymer content (Table 5.2). The increase in plasticizer content from 30 to 40% enabled 
extrusion at a lower temperature (140 instead of 160°C), but also increased the 
permeability of the polymeric matrix in both dissolution media. When comparing the 
drug release profiles of Eudragit® S100 pellets plasticized with 30% TEC (Fig. 5.1) to 
pellets plasticized with 40% TEC based on the polymer weight (Fig. 5.2), an increase in 
drug release from 3.76 to 6.10% was observed after 2 hours in acid, while the release 
after 2 hours in buffer increased from 66.56% (30% TEC) to 83.52% (40% TEC).   
The strand diameter as an indicator for polymer swelling after die exit decreased 
only slightly from 883±12μm (30% TEC) to 870±23μm (40% TEC). However, as 
illustrated in Fig. 5.3, increasing the drug load resulted in reduced swelling as the 
extrudate diameter decreased significantly to 727±35μm (20% theophylline), 655±36μm 
(30% theophylline) and 537±21μm (40% theophylline) (one-way ANOVA, α = 0.05, p < 
0.001). The drug did not melt during extrusion (melting point = 277°C) and remained in 
the crystalline state. Higher amounts of non-melting material increased the resistance 
against the rotation of the screws resulting in higher torques and diminished process 
yields. The extrusion yield was determined as the percentage of the collected extruded 
material relative to the fed material (10 g). The obtained yield values were relatively low 
due to two reasons: The interior volume of the mini extruder holds approximately 5 g of 
material, which is difficult to disgorge and may remain inside the extruder, especially 
when small diameter dies are used. Second, insufficiently plasticized polymers or 
formulations with high solids content encounter a high resistance to exit through the die 
and tend to be pushed into the backflow channel which is part of the extruder design. 
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Possible strategies to optimize the yield include increasing the batch size, using larger 
diameter dies or dies with several orifices and extruding well plasticized blends to 
increase the material output. As can be seen in Fig. 5.2, pH-dependent biphasic 
dissolution profiles were obtained for all the investigated drug loadings. All compositions 
liberated the total amount of drug by matrix erosion after 4 hours in buffer at pH 7.4, with 
the 40% theophylline pellet formulation exhibiting a slightly faster release rate than 
pellets with lower drug content. The selection of the appropriate drug loading in matrix 
systems is generally based on dose requirements, controlled release characteristics and 
process yield as primary decision criteria. While the delayed release characteristics were 
preserved up to 40% theophylline in the formulation, the previous findings demonstrated 
that declining processibility by melt extrusion will limit the applicability to high drug 
loadings.  
 
5.4.3 Plasticization efficiency of various plasticizers on Eudragit® S100 
Plasticizers are traditionally low molecular weight compounds that are added to 
polymers to modify their physico-mechanical properties. Plasticizer-polymer 
compatibility is defined as the ability of the plasticizer to form a homogeneous phase 
with the polymer without exudation (liquid plasticizers) [26] or crystallization (solid-state 
plasticizers). When selecting an appropriate plasticizer, the compatibility with the 
polymer and plasticization efficiency are pivotal selection criteria. Efficient plasticizers 
for the melt extrusion of pellets need to lower the Tg of the plasticized polymer below the 
onset temperature of thermal degradation, and reduce the melt viscosity of the blend to 
enable material transport within the barrel and extrusion through the 500μm die orifice.  
The extent of Tg reduction in the presence of a plasticizer can be used as a 
parameter to assess the plasticization efficiency [27]. Five compounds differing in 
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molecular weight, physical state, hydrophilicity and water solubility were investigated as 
possible plasticizing agents (Table 5.4). These properties were expected to impact 
plasticizer-polymer compatibility, plasticizing efficiency and drug release rates from 
extruded matrices. Citric acid monohydrate (CA MH), PEG 8000 and methylparaben 
(MP) are solid-state plasticizers that need to melt in order to plasticize the polymer. The 
citrates (TEC, ATBC) and PEG have been successfully employed for the plasticization of 
polymethacrylic polymers [28], while MP and CA MH are non-traditional plasticizers 
[29, 30]. The thermal properties of Eudragit® S100 and physical mixtures containing 
30% plasticizer based on the polymer weight were studied by MDSC, and the Tg was 
determined in the second heating cycle (Fig. 5.4). The Tg of the pure polymer was 
recorded at 172°C, a value similar to those reported by other groups, (166°C [12] and 
169°C [31]). Thermal degradation of the polymer starts at 180°C (onset) and accelerates 
above 188°C by formation of cyclic anhydrides between the carboxylic acid groups of the 
polymer [18]. The data in Fig. 5.4 demonstrates the differences in plasticization 
efficiency for the investigated plasticizers. Melting endotherms of MP, CA MH and PEG 
were not present in the second heating cycle, indicating good compatibility of these 
plasticizers with Eudragit® S100. Increasing the TEC concentration gradually from 10 to 
20 and 30% resulted in a Tg decrease to 138, 121 and 101°C, respectively. When 
compared to TEC, CA MH and methylparaben showed similar plasticization efficiencies 
(Tg of 94°C), while ATBC was less suitable to lower the Tg of Eudragit® S100 (134°C). 
The reasons for the low plasticization efficiency of ATBC could be due to its high 
hydrophobicity caused by the butyl groups (low solubility and small hydrophilic fraction) 
and the lack of hydrogen bond donor groups in the molecule structure. All other 
plasticizers showed efficient Tg reduction and potential to be used as processing aids for 
the hot-melt extrusion of Eudragit® S100. When comparing the Tg of the plasticized 
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polymer with the processing temperature that was necessary to produce melt viscosities 
low enough for an extrusion through the 500μm die, it became apparent that an efficient 
plasticization of Eudragit® S100 for this application implied a reduction of the Tg to a 
temperature of 50°C or more below the extrusion temperature. These findings were in 
agreement with previous reports on melt extruded Eudragit® S100 matrices [12]. 
 
5.4.4 Selection of suitable plasticizers based on dissolution properties 
As detailed in the previous sections, efficient plasticization of Eudragit® S100 
was necessary to decrease the Tg and melt viscosity during hot-melt extrusion. However, 
plasticizers may also influence the drug release rate by modifying the matrix 
permeability. Soluble plasticizers can function as pore formers and increase the release of 
water-soluble drugs by enhancing matrix percolation [14, 15]. The formulation without 
plasticizer had to be extruded at 220°C, a temperature higher than the onset temperature 
for thermal degradation and, therefore, unacceptable. Blends containing CA MH or 
ATBC as plasticizers needed to be processed at 170°C and produced low extrudate 
yields. This behavior was expected for ATBC due to its low plasticization efficiency, but 
unexpected for CA MH which produced a Tg of 94°C in the MDSC experiments. 
Formulations with CA MH further showed excessive swelling and produced a porous 
extrudate exhibiting highly variable diameters. This observation could be due to moisture 
evaporation from the CA lattice or possibly thermal degradation of the organic acid and 
the polymer at the high extrusion temperature. Formulations plasticized with TEC, MP or 
PEG could be extruded at 140°C with MP-containing blends producing the lowest torque 
and largest yield. The diameters of extrudates with TEC and PEG were similar, but 
significantly higher for MP-plasticized extrudates (Table 3, One-way ANOVA, α = 0.05, 
p < 0.001). 
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When evaluating the suitability of a plasticizer for the preparation of 
pharmaceutical products, its influence on the drug dissolution profile needs to be taken 
into consideration. The physical and chemical properties of the plasticizer and of the 
plasticized matrix impact the release characteristics of the dosage form. Fig. 5.5 
illustrates the results of dissolution testing according to the USP method A for delayed 
release dosage forms. Pellets plasticized with 20% PEG or CA MH failed to provide 
gastric protection, exhibiting rapid drug release during the acid stage. This finding can 
partially be explained by the high aqueous solubility of these compounds. The porosity of 
the pellets increased during the dissolution experiment since soluble plasticizers can 
function as pore formers when they leach from the matrix. These results were in 
agreement with the findings of Zhu and coworkers who demonstrated faster drug release 
at higher TEC levels due to channel formation in melt extruded matrices [6, 14]. 
Moreover, Zhang et al. showed that the addition of PEG 3350 increased the drug release 
from melt extruded PEO matrix tablets by promoting matrix hydration, decreasing the 
viscosity of the hydrated layer and facilitating drug diffusion [3]. 
While the dissolution of theophylline from CA MH plasticized pellets still 
exhibited pH-dependency, the presence of 20% PEG resulted in the complete loss of the 
biphasic release profile, with more than 80% drug released within 2 hours in acid. This 
behavior was unexpected since CA MH exhibits higher water solubility and a lower MW 
than PEG, favoring faster diffusion from the matrix and enhanced pore formation. 
Several explanations for the more rapid release from PEG-containing systems might be 
responsible for these findings: Although both plasticizers were used at the same mass 
percentage (20%), their volume percentage is different since PEGs have a lower true 
density than CA MH. Calculations based on literature values for true densities of the 
employed materials (Eudragit® S100 = 1.20, theophylline = 1.49, CA MH = 1.54, PEG = 
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1.18) demonstrated that PEG was present at a higher volume percentage than CA MH 
(21.5% versus 17.4%) within the matrix. Consequently, the impact of the soluble PEG on 
the matrix permeability was more pronounced when compared to the CA matrix. Second, 
the acidic functional groups of CA MH likely lowered the microenvironmental pH and 
delayed polymer dissolution. Furthermore, PEG was shown to be a more efficient 
plasticizer for Eudragit® S100 than CA MH, thus presumably increased the polymer’s 
free volume and permeability to a larger extent. Breitkreutz and coworkers demonstrated 
that strong interactions between Eudragit® L film coatings and PEG in acidic dissolution 
medium resulted in an increased penetration of PEG-associated water into the film and 
loss of enteric protection [32]. 
Pellets plasticized with either MP, ATBC or TEC yielded low drug release rates 
similar to the drug release form the unplasticized extrudate (5.91%) with 3.85, 5.84 and 
7.14% theophylline released after 2 hours in acid. This finding suggests that leaching of 
plasticizer during dissolution and drug diffusion through pores were negligible. 
Furthermore, plasticized matrices extruded at lower temperature and non-plasticized 
systems produced at high temperatures exhibited similar drug release properties. It can be 
concluded that a lack of plasticization could be compensated by increasing the processing 
temperature in order to form an intact matrix of low porosity. In buffer, however, 
efficiently plasticized extrudates (MP and TEC) released theophylline at higher rates than 
extrudates with ATBC or without a plasticizer, presumably due to more rapid water 
penetration into the matrix and faster pellet dissolution. 
 
5.4.5 Pellet characterization: microstructure and solid-state properties 
The microstructures of the unprocessed theophylline particles and cut surfaces of 
extruded pellets were examined by SEM (Fig. 5.6). The drug itself was found to be of 
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irregular shape and crystalline, with a wide particle size distribution and agglomerates 
(Fig. 5.6A). Extruded pellets (B) without any plasticizer (C) or comprising MP (D), TEC 
(E) or PEG (F) as plasticizers showed crystalline theophylline particles dispersed in the 
smooth solidified melt. While the particles were still irregular in shape, the particle size 
was reduced and the size distribution more narrow compared to the unprocessed drug, 
presumably due to the effective mixing and high shear forces during processing. Miller 
and coworkers successfully applied hot-melt extrusion for the deaggregation and 
dispersion of engineered particles in a non-solubilizing carrier without altering the solid-
state properties of the individual drug particles [33]. Regardless of the incorporated 
plasticizer, SEM photographs of the pellets showed a smooth matrix of high integrity and 
without pores. While the extrudate without plasticizer predominantly contained the 
theophylline crystals in clusters, the plasticized pellets exhibited a more homogeneous 
drug distribution throughout the entire matrix, favored by the reduced melt viscosity of 
the blend during extrusion. The surfaces of pellets without any plasticizer were further 
partially covered with needle-shaped nanocrystals that had recrystallized from the 
solidified matrix. Drug miscibility with the polymer was increased since this formulation 
was extruded at a higher temperature (220°C), promoting partial drug melting. Fig. 5.6G 
demonstrates that needle-shaped drug crystals had also grown on the entire surface of 
ATBC-plasticized pellets, which had been extruded at 170°C. Drug-polymer interactions 
may decrease the drug’s melting point below the extrusion temperature and increase 
theophylline solubilization in the carrier. Amorphous systems exceeding the solubility 
limit at room temperature are thermodynamically instable and tend to recrystallize at 
storage temperature as previously reported for extrudates containing guaifenesin [34]. In 
addition to this thermodynamic instability, plasticized polymers further possess an 
increased molecular mobility attributed to their higher free volume, so that drug 
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recrystallization processes may occur at accelerated rates, as it has been reported for 
amorphous systems stored at increasing storage temperatures [35]. These findings 
demonstrated that high extrusion temperatures and the formation of partially amorphous 
systems promoted physical instabilities and should therefore be avoided. Pellets 
formulated with CA MH as a plasticizer were also extruded at 170°C and yielded a 
highly porous matrix (Fig. 5.6H). This foam-like microstructure may be caused by the 
evaporation of water liberated by the CA lattice or produced by condensation reactions 
between ionic carboxylic acid groups of the polymer and the plasticizer during thermal 
degradation. It has been reported that the formation of cyclic anhydrides is the main 
pathway of thermal degradation below 200°C for methacrylic acid polymers [18]. Citric 
acid might suppress the onset of polymer degradation below the extrusion temperature or 
directly react with the functional groups of the acrylic polymer. The presence of a 
coherent pore network throughout the pellets plasticized with CA MH enabled rapid 
water penetration and promoted fast drug dissolution during the acid stage. 
The solid-state properties of the extruded pellets were analyzed by PXRD (Fig. 
5.7). Unprocessed, anhydrous theophylline was highly crystalline and exhibited 
characteristic peaks at 2-Theta = 12.9 and 26.7 (highlighted squares in Fig. 5.7), while 
Eudragit® S100 was completely amorphous. The limit of detection for crystalline 
theophylline using this method was below 5% as demonstrated for a physical mixture of 
Eudragit® S100 containing 5% crystalline drug. In all extrudates (EX), the drug was 
present in the crystalline state and as the original polymorph since the diffraction patterns 
displayed the characteristic peaks of the unprocessed drug (Fig. 5.7). The peak intensities 
in extrudates containing PEG, TEC or MP were similar, while extrudates prepared at 
elevated temperatures (ATBC, CA MH, no plasticizer) produced patterns with reduced 
peak intensities attributed to partial drug melting and solubilization in the carrier. The 
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absence of characteristic peaks for crystalline PEG and MP demonstrated that both solid-
state plasticizers completely melted during processing and were miscible with the 
methacrylic polymers at the employed ratio. Pellets prepared with CA MH, however, 
showed additional peaks in their diffraction pattern at 2-Theta = 18.0 and 27.4, which 
were attributed to recrystallized, anhydrous CA. This observation provided evidence that 
the compatibility limit was exceeded at the CA concentration used in this study. 
Recrystallized CA formed a separate phase in the polymer matrix and failed to exert a 
plasticizing effect on the polymer, resulting in poor processibility by melt extrusion. 
 
5.5 CONCLUSION 
Enteric matrix pellets with a diameter below 1 mm and containing up to 40% 
theophylline could be successfully prepared by hot-melt extrusion when plasticized 
Eudragit® S100 was employed as the matrix material. The manufacture of pellets using 
alternative enteric polymers was either compromised by a lack of thermal processibility 
(Eudragit® L100-55 and Eudragit® L100), or the pellets failed to provide gastric 
protection due to high matrix permeability in acid (Aqoat® LF and HF). The influence of 
five different plasticizers on the processibility and drug release kinetics was investigated. 
Methylparaben, PEG 8000 and TEC showed high compatibility with Eudragit® S100, 
plasticized the polymer efficiently and promoted a homogeneous dispersion of the 
crystalline drug within the matrix pellet at reduced particle sizes. Pellets containing 
ATBC, citric acid monohydrate or no plasticizer had to be extruded at high temperatures 
which promoted partial drug solubilization and drug recrystallization on the pellet 
surfaces. Plasticization with water-soluble compounds (PEG 8000 and CA MH) resulted 
in a loss of gastric protection due to plasticizer leaching and pore formation during the 
acidic stage. Pellets containing less soluble plasticizers (TEC, methylparaben, ATBC) or 
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no plasticizer exhibited low drug release rates in acid independently of the plasticization 
efficiency, while the release in buffer was higher for pellets prepared with efficient 
plasticizers (TEC or methylparaben). Methylparaben was superior to the other 
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Table 5.1: Compositions of blends, extrusion parameters and diameters of extruded 
strands containing 10% theophylline and different enteric polymers. (All 










± SD [µm] 
HPMC AS LF 20 120 85-120 647 ± 23 
HPMC AS HF 20 120 80-100 598 ± 8 
HPMC AS HF 10 (ATBC) 130 120-140 625 ± 8 
Eudragit® L100-55 30 160 - - 
Eudragit® L100 30 170 145-160 967 ± 65 
Eudragit® S100 30 160 125-135 883 ± 12 
HPMC AS HF + 




Table 5.2: Formulations and process parameters for Eudragit® S100 based matrix 
pellets containing 10-40% theophylline (Theo) and 40% TEC based on 
polymer content. (All extrusions were conducted at 140°C and using a screw 











Diameter ± SD 
[µm] 
10 64.3 25.7 170-190 28.0 870 ± 23 
20 57.1 22.9 190-210 23.2 727 ± 35 
30 50.0 20.0 200-220 18.3 655 ± 36 




Table 5.3: Compositions and process parameters of Eudragit® S100 matrix pellets 
containing 30% theophylline and different plasticizers. (All extrusions were 











Average ± SD 
[µm] 
50 TEC 140 200-220 18.3 655 ± 36 
50 ATBC 170 100-115 9.0 810 ± 149 
50 PEG 8000 140 225-245 15.5 625 ± 21 
50 CA MH 170 100-115 3.5 917 ± 297 
50 MP 140 170-180 23.3 773 ± 32 




Table 5.4: Physicochemical properties of the compounds investigated as plasticizers 
for the hot-melt extrusion of Eudragit® S100 matrix pellets. 
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Figure 5.1: Influence of the matrix polymer on the release properties of enteric matrix 
pellets. All formulations contained 10% theophylline. ( ) HPMC AS LF, 
15% TEC, ( ) HPMC AS HF, 15% TEC, ( ) HPMC AS HF, 9% ATBC, 
( ) Eudragit® L100, 20.8% TEC, ( ) Eudragit® S100, 20.8% TEC, ( ) 
HPMC AS HF + Eudragit® S100 1:1, 15% TEC.  
Dissolution: USP paddle apparatus, 50 rpm, 37.0±0.5°C, n = 3, 2 hours in 
750 ml SGF pH 1.2 without pepsin, after 2 hours pH change to pH 6.8 
(HPMC AS LF, Eudragit® L100) or pH 7.4 (HPMC AS HF, Eudragit® 



























Figure 5.2: Influence of the theophylline loading on the release properties of Eudragit® 
S100 matrix pellets. ( ) 10%, ( ) 20%, ( ) 30%, and ( ) 40% 
theophylline.  
Dissolution: USP paddle apparatus, 50 rpm, 37.0±0.5°C, n = 3, 2 hours in 
750 ml SGF pH 1.2 without pepsin, after 2 hours pH change to pH 7.4 by 


























Figure 5.3: Influence of the theophylline content on the extrudate diameter and process 




































Figure 5.4: Influence of different compounds on the glass transition temperature of 







































Figure 5.5: Influence of the type of plasticizer on the drug release from Eudragit® S100 
matrix pellets. All formulations contain 30% theophylline and 20% 
plasticizer. ( ) PEG 8000, ( ) CA MH, ( ) MP, ( ) TEC, ( ) ATBC, 
( ) no plasticizer.  
Dissolution: USP paddle apparatus, 50 rpm, 37.0±0.5°C, n = 3, 2 hours in 
750 ml SGF pH 1.2 without pepsin, after 2 hours pH change to pH 7.4 by 


























Figure 5.6: SEM pictures of A) theophylline powder; B and C) Extrudates without 
plasticizer; Extrudates with D) 20% methylparaben, E) 20% TEC, F) 20% 










Figure 5.7: Influence of different plasticizers on the crystallinity of melt extruded 
Eudragit® S100 matrix pellets (EX) containing 30% theophylline (Theo). 
(PM: physical mixture, characteristic theophylline peaks are highlighted) 
5 10 15 20 25 30 35 40
2-Theta
EX 30% Theo, 20% ATBC
EX 30% Theo, 20% MP
EX 30% Theo, 20% TEC
EX 30% Theo, 20% PEG
Theophylline
EX 30% Theo, 20% CA MH
anhydrous CA 
EX 30% Theo, no plasticizer
Eudragit® S100 






Chapter 6: Investigation of the Influence of Plasticizer Type and Level 




The objective was to investigate the influence of three plasticizers (TEC, 
methylparaben and PEG 8000) at two levels (10% or 20%) on the properties of hot-melt 
extruded Eudragit® S100 matrix pellets. Extrusion experiments showed that all 
plasticizers produced similar reductions in polymer melt viscosity. Differential scanning 
calorimetry and powder X-ray diffraction demonstrated that the solid-state plasticizers 
were present in the amorphous state. The drug release in acidic medium was influenced 
by the aqueous solubility of the plasticizer. Less than 10% drug was released after 2 
hours at pH 1.2 when TEC or methylparaben was used, independent of the plasticizer 
level. Drug release at pH 7.4 resulted from polymer dissolution and was not influenced 
by low levels of plasticizer, but increased significantly at the 20% level. Mechanical 
testing by diametral compression demonstrated the high tensile strength of the hot-melt 
extruded pellets that decreased when plasticizers were present. 
                                                 
4 Significant portions of this chapter were taken from: Schilling, S.U., Lirola, H.L., Shah, N.H., Malick, 
A.W., and McGinity, J.W. Influence of plasticizer type and level on the properties of Eudragit® S100 





The interest in the development of multiparticulate systems for the controlled 
delivery of drugs stems from their beneficial pharmacokinetic properties. In contrast to 
monolithic systems, pellets spread into the digestive tract independent of the feeding 
state, avoiding high local drug concentrations and reducing inter-and intra-subject 
variabilities in drug absorption [1]. The drug release properties of pellets can be 
controlled by either a protective film coat (reservoir-type pellets) or by the permeability 
of the matrix material (matrix pellets). 
The process of hot-melt extrusion allows the manufacture of controlled-release 
matrix pellets in a continuous manner avoiding subsequent film coating and the use of 
organic or aqueous solvents. A powder blend comprising the drug, a thermoplastic 
polymer and optional processing aids is mixed and transported inside a heated barrel by 
either one or two rotating screws. The softened material undergoes zones of increasing 
temperature and pressure before exiting through a product-shaping die. The diameter of 
the extruded strand is primarily governed by the diameter of the die orifice, but may also 
be influenced by the viscoelastic properties of the polymeric melt. Several technologies 
have been developed to accomplish a subsequent pelletization and spheronization of the 
extrudate in a continuous or semi-continuous manner [2-4]. Besides technological 
advantages, hot-melt extruded pellets allow the incorporation of higher drug loadings 
under preservation of the controlled release properties which is attributable to the low 
porosity of melt-extruded matrices when compared to pellets prepared by traditional wet-
massing techniques [5]. Melt extruded matrix pellets further offer benefits during 
downstream processing such as direct compression into multiparticulate tablets which are 
related to their high mechanical strength and low friability [6]. 
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The successful preparation of sustained release pellets by hot-melt extrusion has 
been reported in several publications [7-9] and patents [10, 11]. However, the 
manufacture of enteric pellets exhibiting a release of less than 10% after 2 hours in 
simulated gastric fluid remains challenging. Attributed to the larger surface area of small 
pellets, drug release in acid will be increased when compared to tablets as previously 
demonstrated for melt extruded Eudragit® L100-55 matrices containing 20% drug [12]. 
Another parameter to consider is the opposing trend between polymer permeability and 
thermal processibility. In a previously conducted study, we demonstrated that anionic 
cellulosic polymers (Aqoat® LF and HF) could be extruded at lower temperatures and 
higher yields than anionic methacrylic polymers (Eudragit® S100, L100) due to their 
lower glass transition temperature and melt viscosity [13]. However, only pellets 
prepared with Eudragit® S100 and L100 showed low release rates in acidic medium and 
were compliant with the USP requirement to release less than 10% drug after 2 hours at 
pH 1.2. Methylparaben, PEG 8000 and TEC were efficient plasticizers for Eudragit® 
S100 and enabled the extrusion of pellets at temperatures well below the onset of thermal 
degradation. Alternatively, anionic polymers with low glass transition temperature but 
too high permeability in acid (Eudragit® FS) may be blended with a water-insoluble 
polymer (Eudragit® RS, RL or NE) to reduce the drug release in simulated gastric fluid 
as disclosed in patent application WO 2008/101743 [14].  
Based on the results that we obtained for Eudragit® S100 matrix pellets, the 
objective of the current study was to investigate the influence of three efficient 
plasticizers (TEC, methylparaben, PEG 8000) on the physical properties and drug release 
characteristics of melt extruded pellets. Employing a mixture design of experiments, 
pellets comprising one of the three plasticizers at a high level (20%) or low level (10%), 
theophylline at 30% and Eudragit® S100 as release controlling polymer were prepared 
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by hot-melt extrusion. The viscosity-temperature behavior of plasticized polymeric melts 
was studied by extrusion experiments conducted at different temperatures and constant 
shear rate. The pellet formulations were evaluated regarding the process yield, drug 
release after 2 hours in acid and release after 45 minutes in buffer pH 7.4, and the 
optimum plasticizer type and level were determined. The influence of plasticization on 
the solid-state properties of the drug and on the mechanical strength of the pellets was 




Anhydrous theophylline and methylparaben (MP) were purchased from Spectrum 
Chemicals (Gardena, CA), and polyethylene glycol 8000 (PEG, Carbowax Sentry, 
powder NF) was obtained from Dow Chemical Company (Midland, MI). Triethyl citrate 
(TEC) was kindly provided by Vertellus (Greensboro, NC) and Eudragit® S100 was 
donated by Evonik (Piscataway, NJ).  
 
6.3 METHODS 
6.3.1 Preparation of melt extruded pellets 
Powder blends for hot-melt extrusion consisted of a constant amount of 
theophylline (30%), 10 or 20% plasticizer (PEG 8000, TEC, methylparaben) and 
Eudragit® S100 as the thermoplastic matrix former (Table 6.1). The polymer and the 
plasticizer were premixed and then blended with the drug using a kitchen aid mixer (St. 
Joseph, MI). The powder blends (10 g) were manually fed into a twin screw mini 
extruder (Haake Minilab, Rheomax CTW5, Thermo Electron, Germany) operated in 
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flushing mode at a screw speed of 75 rpm. The processing temperatures depended on the 
plasticizer content (Table 6.1). After extrusion through a 500μm circular die, the strands 
were air-cooled to room temperature and manually cut into cylindrical pellets. The 
diameters of the extruded strands were measured with a manual micrometer (Mituoyo 
model C1012EBS, Aurora, IL) prior to cutting. 
 
6.3.2 Plasticization efficiency – relative melt viscosity-temperature behavior of 
plasticized polymer melts 
The processibility of blends containing 30% theophylline and different levels of 
plasticizer (0, 10 or 20%) was investigated using the Haake Minilab extruder described 
above. Five grams of material were manually fed into the extruder, operated in cycling 
mode at 75 rpm and at 3-5 different temperatures between 110 and 220°C. The torque 
values stabilized after approximately five minutes of cycling, and the equilibrium torque 
was monitored over two minutes and reported as the average of 24-32 readings. The 
extrusion speed (shear rate) was kept constant, and proportionality between viscosity and 
torque was assumed. The activation energies for the viscous flow of the polymer melts 











where η is the absolute viscosity, M is the torque, R is the gas constant (8.314 




6.3.3 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry was employed to investigate the crystallinity of 
the drug and the solid-state plasticizers after hot-melt extrusion. Physical mixtures or 
ground extrudates were accurately weighed into aluminum pans (10-15 mg) and crimp 
sealed. The samples were placed inside the furnace of a Thermal Advantage Model 2920 
(TA Instruments, New Castle, DE), kept isothermally at 0°C for 5 min, and then ramped 
to 320°C using a heating rate of 20°C/min. The heat flow against a blank pan was 
reported as a function of the temperature during the first heating cycle. 
 
6.3.4 Powder X-ray diffraction (PXRD) 
The crystallinity of the unprocessed materials and ground extrudates was studied 
with a Philips Electronic Instrument Type 42273 (Philips Electronic Instrument, Mount 
Vernon, NY) at an operating voltage of 40 kV and a current of 30 mA. Samples were 
scanned in the 2-Theta range between 5-40° at a step size of 0.05° with a dwelling time 
of 2 seconds (1.5°/ min). 
 
6.3.5 Dissolution studies and theophylline assay 
The drug release properties of the hot-melt extruded pellets were studied in a 
paddle apparatus (Varian, Cary, NC) according to USP chapter <724> method A for 
delayed release articles. Pellets (100 mg, n = 3) were placed in 750 ml simulated gastric 
fluid pH 1.2 (SGF, without pepsin) at 37.0±0.5°C with a paddle rotation speed of 50 rpm. 
After two hours, the pH was adjusted to 7.4 by addition of 250 ml 0.2M tribasic 
phosphate buffer and diluted sodium hydroxide solution. The theophylline content in 
withdrawn samples was analyzed by HPLC (Waters Inc., Milford, MA) using a C18-
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reversed phase column (Capcell PAK 3 mm * 100 mm, Shiseido Co, Japan) and a UV 
detector (996-PDA, Waters Inc. Milford, MA) extracting at 271.5 nm. A mixture of 20 
mM phosphate buffer pH 5 and acetonitrile (9:1) was used as the mobile phase at a flow 
rate of 0.5 ml/ min, and the theophylline peak areas (retention time 3.5 min) were 
determined with Empower version 5.0 software (Waters Inc.). Linear correlation was 
confirmed between 0.1 and 100.0μg/ ml (R2 = 0.99997) and multiple injections yielded 
good reproducibility with RSD values between 0.08% (100.0μg/ ml) and 1.77% (0.1μg/ 
ml). 
 
6.3.6 Mechanical strength of extruded pellets  
The crushing strength of hot-melt extruded pellets was determined with a 
Chatillon Universal Tension / Compression Tester Model TCD-200 (Ametek, Largo, FL) 
as previously described [15]. A flat, circular steel plate was fitted onto a DFGS 50 digital 
force gauge and lowered in diametral direction towards the lateral surface of an 
individual pellet at a crosshead speed of 2.5 mm/ min. The load-deflection data was 
collected using Chatillon Nexygen TCD force testing software. The mechanical strength 






Specimens with diameters (d) equaling the length (l) were selected for the 
experiments, and the maximum load (P) at which brittle fragmentation of the pellets 




6.3.7 Statistical analysis 
The influence of the plasticizer type and level in hot-melt extruded Eudragit® 
S100 pellets was studied with a mixture design of experiments generated with JMP 7 
software (SAS Institute Inc., Cary. NC). Three plasticizers were investigated at two levels 
(10 and 20%) with the theophylline concentration remaining constant at 30%. The 
product performance was evaluated regarding three response parameters: drug release in 
acid after 2 hours (minimum), release in buffer after 45 minutes (maximum) and 
extrusion yield (maximum). The JMP software was further utilized for one-way ANOVA 
(α = 0.05) and post hoc Tukey Kramer analysis of the mechanical strength data and the 
dissolution rates in buffer. 
 
6.4 RESULTS AND DISCUSSION 
6.4.1 Plasticization efficiency – relative melt viscosity-temperature behavior of 
plasticized polymer melts 
The flow of the blend inside an extruder is primarily controlled by the melt 
viscosity of the polymer. For the preparation of small pellets, the melt viscosity must be 
sufficiently low to enable extrusion through the 500μm die at acceptable output rates 
without exceeding the pressure and torque limits of the equipment. Most polymeric melts 
show non-Newtonian flow behavior with pseudoplastic and viscoelastic elements 
attributed to chain entanglement [18]. The melt viscosity is influenced by many factors 
including polymeric molecular structure, molecular weight, temperature, shear rate and 
degree of plasticization. The temperature dependence of the melt viscosity at a constant 
shear rate can be described by an Arrhenius type equation derived by Eyring (equation 1). 
A plot of the natural logarithm of the viscosity against the reciprocal of the absolute 
temperature produces a straight line with the slope yielding the flow activation energy 
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(Ea) divided by the gas constant when Ea is temperature independent [19]. The flow 
activation energy is dependent on the chemical structure of the polymer, and increasing 
Ea values were shown to correlate with decreasing volume expansion coefficients and 
increasing glass transition temperatures [19, 20]. Several research groups demonstrated 
that torque data can be used instead of viscosities to determine the Ea of polymeric melts, 
as long as the rotation speed remained constant and the time dependency of the 
measurement values was considered [21, 22]. Torque values obtained in the beginning 
were too high due to incomplete melting and lack of temperature equilibrium, while late 
values were too low as a result of polymer degradation.  
The torque after 5 minutes was monitored over a period of 2 minutes when a 
reproducible equilibrium torque was achieved for each composition and temperature 
level. The natural logarithms of the torque values were plotted against the reciprocals of 
the absolute temperature for all formulations (Fig. 6.1). The Ea values were calculated 
from the slope using equation 2 (Table 6.2). High R2-values were obtained for the linear 
correlation (0.984-0.999), confirming the constancy of the Ea-values over the investigated 
temperature range. For unplasticized Eudragit® S100, the flow activation energy was 
highest at 106.4kJ/mol. Attributed to the low polymer chain mobility, high temperatures 
were necessary to overcome the energetic barrier against the viscous flow of the polymer 
melt within the extruder. When TEC, methylparaben or PEG 8000 was incorporated into 
the blend at a 10 or 20% level, the plots shifted to lower temperatures (higher 1/T) values, 
demonstrating that the torques (and hence the melt viscosities) decreased due to 
plasticization of the polymer. These findings were in agreement with previously reported 
results obtained for Eudragit® L100-55 blends plasticized with TEC and PEG 3350 [23]. 
The Ea-values for plasticized Eudragit® S100 decreased to 80-86kJ/mol (10% plasticizer) 
and 45-59kJ/mol (20% plasticizer), respectively. This behavior was expected since 
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plasticizers increase the chain mobility by reducing attractive forces between the polymer 
molecules, resulting in a lower barrier against plastic flow during hot-melt extrusion and 
a reduced sensitivity of the viscosity to the processing temperature. 
These results demonstrated that all tested compounds facilitated the viscous flow 
of the Eudragit® S100 and can be used to efficiently plasticize the polymer. Plasticizers 
at the 20% level decreased the resistance to plastic flow to a higher degree than at the 
10% level. Therefore, in terms of processibility, plasticizers at the high level should 
preferably be used for the preparation of melt extruded pellets. 
 
6.4.2 Solid-state properties of the drug and solid-state plasticizers 
Physical mixtures and extrudates were studied by differential scanning 
calorimetry (DSC) and powder X-ray diffraction (PXRD) to investigate the influence of 
thermal processing on the solid-state properties of the model drug and the solid-state 
plasticizers. The composition of the pellet formulations, the extrusion temperatures and 
the diameters of the extruded strands are listed in Table 6.1. The DSC thermograms of 
physical mixtures containing 20% methylparaben or PEG 8000 showed characteristic 
melting peaks at 123°C (methylparaben) or 61°C (PEG 8000), respectively (Fig. 6.2). In 
the extrudates, these melt transitions were absent, indicating that the solid plasticizers 
dissolved in the polymer during hot-melt extrusion and remained in the amorphous state 
during cooling. These results were confirmed by PXRD analysis where the extrudates 
were devoid of peaks characteristic for the crystalline plasticizers (data not shown).  
The thermogram of Eudragit® S100 displayed two broad endothermic events 
which represented the evaporation of unbound water below 100°C and the thermal 
degradation of the polymer at 200-250°C. This degradation peak interfered with the 
theophylline melting peak, and thus drug crystallinity was studied by PXRD. As 
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previously reported for hot-melt extrudates containing diltiazem hydrochloride and citric 
acid monohydrate, interactions between a crystalline drug and a plasticizer may promote 
drug solubilization in the polymer during extrusion at temperatures below the drug 
melting point [24]. All produced extrudates exhibited peaks in the PXRD patterns that 
were characteristic for anhydrous theophylline. The theophylline peaks for extrudates 
containing only 10% plasticizer were of lower intensity when compared to extrudates 
containing 20% plasticizer. These findings demonstrated that high extrusion temperatures 
rather than the presence of larger plasticizer amounts promoted theophylline 
solubilization during extrusion, and were in agreement with previous results [13]. 
Solubilization of the drug during thermal processing may lead to physical instabilities in 
the form of surface recrystallization during storage when the drug solubility in the 
polymer is exceeded [25]. Therefore, higher plasticizer levels (20% absolute or 40% 
based on the polymer weight) should be used to enable the extrusion of Eudragit® S100 
at lower temperatures and to improve the storage stability of the pellets. 
 
6.4.3 Influence of plasticizer type and level on the release properties and HME 
yield of Eudragit® S100 pellets 
Numerous studies addressing the effects of plasticizers on the physicochemical 
properties of free films and on the drug release properties of film-coated products have 
been published in the literature. Generally, a decrease in drug release rate was observed 
with higher degree of plasticization due to enhanced polymer coalescence during the 
coating process [26], resulting in reduced water permeability [27] and improved 
mechanical integrity of the film [28]. Furthermore, aqueous solubility of the plasticizer 
could be correlated with increased drug release rates. Hydrophilic plasticizers leached 
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into the dissolution medium and promoted water uptake and crack formation in the film 
[29, 30], while lipophilic plasticizers remained in the coating during dissolution [31, 32]. 
Few studies, however, have investigated the mechanisms by which plasticizer 
type and concentration affect the dissolution properties of drugs from melt extruded, 
polymeric matrix systems. Zhu and coworkers showed that the release rate of water-
soluble model drugs from hot-melt extruded tablets increased at higher TEC levels due to 
a faster drug diffusion through water-filled channels that were formed when the 
plasticizer leached from the matrix. In contrast, increased TEC levels produced slower 
drug release rates from coated pellets due to enhanced film coalescence, and from 
compressed matrix tablets due to promoted particle binding [33, 34]. Analogous to film 
coated systems, plasticization of matrix systems with water-soluble compounds 
correlated with faster release rates, while lipophilic plasticizers retarded the drug release 
[35, 36]. 
As can be seen in Table 6.3 and Fig. 6.3 and 6.4, the theophylline release from 
Eudragit® S100 pellets was similar and remained below 10% in acid when moderately 
soluble TEC (1 part dissolves in 15 parts water) or slightly soluble methylparaben (1 part 
dissolves in 400 parts water) was used as the plasticizer. At low pH, Eudragit® S100 was 
insoluble and polymer dissolution was negligible, so that drug release was expected to be 
primarily governed by diffusion processes. Increasing the plasticizer level from 0 to 10 or 
20% did not compromise the gastric resistance of the pellets. Higher extrusion 
temperatures were used for the extrusion of pellets without plasticizer or 10% plasticizer 
and promoted the formation of completely coalesced matrices. Pellets containing PEG 
8000 yielded a faster drug release rate at the 10% level (18.2% released after 2 hours in 
SGF without pepsin), and a complete loss of the enteric properties at the 20% level 
(83.2% released after 2 hours) (Fig. 6.5). Although PEG is very water soluble (50%), its 
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high molecular weight should impede rapid PEG migration into the dissolution medium 
during the acidic phase. The presence of high PEG amounts in the pellet matrix may 
promote water penetration and hence increase drug diffusion through the hydrated 
polymer matrix.  
After 2 hours in acid, the pH was increased to 7.4 to allow ionization and 
dissolution of the polymer. At high pH, theophylline could be released from the matrix by 
different mechanisms including polymer surface erosion, diffusion through swollen 
polymer gels, or diffusion though water filled channels that were generated by bulk 
polymer erosion or dissolution of soluble plasticizers. The drug release rates in Table 6.3 
were calculated from the slopes of the linear portion of the release profiles in Fig. 6.3-6.5 
after pH change (R2 = 0.988-0.998 for the initial 45 minutes). It could be demonstrated 
that low levels of TEC or PEG 8000 did not significantly alter the theophylline release 
rate in buffer when compared to pellets without plasticizer, while the presence of 10% 
methylparaben slightly promoted the drug release.  
Increasing the amount of plasticizer to 20% resulted in a significantly faster drug 
release rates for TEC- and methylparaben-plasticized pellets. The release rate in buffer 
was not calculated for pellets with 20% PEG 8000 since most of the drug had already 
been liberated during the acidic phase. Faster drug release rates from matrices containing 
high plasticizer levels might be attributed to facilitated water penetration, resulting is 
accelerated polymer ionization and pellet dissolution. Bruce and coworkers demonstrated 
that an increase of TEC from 12 to 23% in melt extruded Eudragit® S100 tablets 
promoted drug release due to a faster onset of TEC dissolution from the matrix after pH 
change [37]. Similarly, faster drug release rates at higher plasticizer level due to 
enhanced water ingression were observed for hot-melt extruded matrix tablets based on 
Eudragit® L100-55 and TEC [38].  
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Surprisingly, pellets comprising 20% methylparaben exhibited a significantly 
faster drug release rate than the TEC-plasticized pellets with 78.4% released versus 
59.8% released in 1 hour after pH change. This result was unexpected since TEC exhibits 
higher aqueous solubility and possesses mores sites for hydrogen bonding than 
methylparaben. Fadda and colleagues reported that the dissolution time of plasticized 
Eudragit® S100 films correlated to a larger extent with the ability of the plasticizer to 
interact with the polymer than with the aqueous solubility of the plasticizer. Strong 
plasticizer – polymer interactions disrupted the polymeric structures and increased the 
local mobility of the carboxylic acid groups, making them more accessible for ionization 
and promoting film dissolution [39]. It was further observed that methylparaben-
plasticized Eudragit® S100 showed an increased tendency for elastic recovery upon die 
exit, since the extruded strands exhibited a significantly larger diameter (Table 6.1). This 
elastic expansion of the matrix might decrease the packing density of the polymeric 
chains and facilitate water penetration, resulting in faster drug release rates. 
A mixture design of experiments was employed to identify the optimum 
plasticizer type and amount for the extrusion of Eudragit® S100 pellets. Three response 
parameters were selected including minimum drug release after 2 hours in acid, 
maximum yield of extruded material and maximum drug release after 45 minutes in 
buffer (Table 6.3). As expected, the yield increased with the plasticizer level and 
decreased with the amount of Eudragit® S100 in the formulation, since lower melt 
viscosities enhanced the extrudate output (Fig. 6.6). While the dissolution rate in acid was 
dependent on the type of plasticizer present in the formulation, the drug release in buffer 
was rather independent of the plasticizer type at the low level, but increased significantly 
for the 20% level.  The extrusion of pellets with 20% methylparaben produced the 
highest yield and exhibited the most favorable release properties. Statistical analysis of 
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the experimental results suggested the optimized composition to contain methylparaben 
as the plasticizer at a 19.5% level.  
 
6.4.4 Mechanical properties of extruded matrix pellets 
Most post-pelletization procedures including functional coating, compression into 
tablets, or filling into gelatin capsules require low friability and high mechanical strength 
of the multiparticulates. In the current study, the mechanical strength of hot-melt 
extruded pellets was determined by diametral compression, a method that has been 
reported to be adequate for mechanical strength evaluation of spherical specimens and 
regularly shaped cylinders [17]. As can be seen in Fig. 6.7, melt extruded pellets without 
plasticizer exhibited the highest tensile strength with 40.4 MPa. The tensile strength 
values of the melt extruded Eudragit® S100 pellets were higher than those reported for 
wet-massed extruded pellets containing dispersions of acrylic polymers as granulation 
binder [15, 40]. However, a comparison of the mechanical strength data obtained for melt 
extruded cylindrical pellets to wet-massed spherical pellets is difficult due to differences 
in the used materials, specimen size and geometric shape. Wet-massed pellets mainly fail 
by adhesive or cohesive fracture or crack propagation of flaws in case of porous pellets 
[15]. In contrast to wet-massed matrices, hot-melt extruded dosage forms generally 
exhibit very low porosity, which is attributable to the high temperature and pressure 
during the extrusion process [41]. Hence, pore-mediated crack initiation and breakage by 
crack propagation are rather unlikely mechanisms of failure. Furthermore, melt extruded 
matrices are highly coalesced and held together by intermolecular forces and physical 
entanglement between polymeric chains, while wet-massed pellets remain agglomerates 
of distinct particles. This difference in strength of cohesive forces and the lack of pores 
were responsible for the high mechanical strength of the melt extruded pellets. 
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The presence of a plasticizer in the formulation led to a decrease in the 
mechanical strength of the extruded pellets (Fig. 6.7). This observation was expected 
since plasticizers attenuate the interactions between polymer chains [42], and in 
agreement with previous reports on wet-massed pellets containing increasing amounts of 
plasticizer in an acrylic binder dispersion [40]. Pellets without plasticizer and pellets 
containing 10% plasticizer underwent failure by brittle fragmentation as seen by a sharp 
decline in stress after pellet fracture. The mechanical properties of these pellets were 
dominated by the polymer, which has a high glass transition temperature and is brittle at 
room temperature. The tensile strength values for pellets containing methylparaben and 
TEC were similar and plateaued at 10%, since no significant decrease in tensile strength 
was detected for pellets with 20% plasticizer. In contrast, pellets containing 20% PEG 
8000 showed a further significant decrease in tensile strength, and underwent plastic 
deformation post failure as seen by a yield point instead of a peak in the load-deflection 
profile. PEG itself is a soft, waxy material that has been used to increase the plastic 
deformability of microcrystalline cellulose pellets during tableting [43]. PEG was further 
shown to function as a cushioning excipient for the direct compression of functionally 
coated pellets due to its ability to deform plastically under low yield pressures [44]. It is 
likely that both factors, the plasticizing effect of PEG on the acrylic polymer and the 
tensile properties of PEG itself contributed to the decreased mechanical strength and 




The results of this study demonstrated that the plasticizer type and level 
influenced the processibility by hot-melt extrusion, the solid-state properties of the 
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incorporated drug, the mechanical strength and the drug release properties of Eudragit® 
S100 matrix pellets. The three selected plasticizers (PEG 8000, TEC and methylparaben) 
reduced the extrusion torque, the relative melt viscosity and the activation energy for the 
viscous flow of the polymer in a concentration dependent manner. The solid-state 
plasticizers were distributed within the polymer matrix in the amorphous state after hot-
melt extrusion, while the model drug theophylline remained crystalline. High extrusion 
temperatures used for processing blends with low plasticizer levels promoted drug 
solubilization in the polymer and may lead to physical instabilities during storage. The 
drug release in acidic conditions remained below the required limit of 10% after 2 hours 
when slightly water-soluble methylparaben or moderately soluble TEC was used, 
independent of the plasticizer level. Pellets with water-soluble PEG 8000 showed 
increased drug release rates in acid at the 10% level and a complete loss of enteric 
properties at the 20% level. Low plasticizer levels did not influence the drug release rate 
at pH 7.4, while pellets plasticized with 20% TEC or methylparaben released the drug at 
a significantly faster rate. The mechanical strength of melt extruded pellets was high and 
decreased when plasticizers were added to the formulation.  Pellets containing 20% PEG 
8000 exhibited significantly lower tensile strength values and an increased tendency of 
plastic deformation. 
Efficient plasticizers should be used at the high level (20%) for the hot-melt 
extrusion of Eudragit® S100 pellets to enhance process output and avoid high extrusion 
temperatures. Methylparaben at the 20% level was shown to be the most adequate 
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Table 6.1: Composition of hot-melt extruded Eudragit® S100 pellets, extrusion 












± SD [µm] 
none 0 70 30 220 598 ± 16 
TEC 10 60 30 180 687 ± 19 
TEC 20 50 30 140 655 ± 36 
PEG 8000 10 60 30 180 640 ± 17 
PEG 8000 20 50 30 140 625 ± 21 
Methylparaben 10 60 30 180 737 ± 17 




Table 6.2: Activation energies for the viscous flow of unplasticized Eudragit® S100 
and melts plasticized with either TEC, PEG 8000 or methylparaben (MP) as 
calculated from the slopes of the Arrhenius plots. 
Formulation none 10% TEC 10% PEG 10% MP 20% TEC 20% PEG 20% MP 
Ea [kJ/mol] 106.4 80.3 86.4 83.7 58.5 45.6 51.8 
R2 0.992 0.999 0.995 0.999 0.990 0.984 0.984 
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Table 6.3: Experimental plan of the mixture design and observed responses for hot-
melt extruded Eudragit® S100 pellets containing 30% theophylline and 
three plasticizers (TEC, PEG 8000 or methylparaben = MP) at two levels 
(10 or 20%). Release rates were calculated for the initial 45 minutes after 
pH change. (*) significantly higher values (one-way ANOVA with α = 0.05 













45 min [%] 
Release Rate 




none 0 6.4 5.91± 0.13 31.28 ± 1.88 33.60 ± 2.56 0.988 
TEC 10 12.0 4.18 ± 0.18 28.22 ± 1.46 32.38 ± 2.02 0.998 
TEC 20 18.3 7.14 ± 0.04 51.77 ± 1.71 59.83 ± 2.24* 0.997 
MP 10 13.3 5.66 ± 0.17 36.66 ± 1.56 41.78 ± 2.09* 0.997 
MP 20 23.3 3.85 ± 0.08 61.61 ± 0.82 78.44 ± 0.91* 0.997 
PEG 10 9.0 18.23 ± 0.42 41.32 ± 3.51 31.52 ± 4.85 0.980 






Figure 6.1: Influence of plasticizer type and level on the Arrhenius plots for blends 
containing Eudragit® S100 and 30% theophylline. ( ) no plasticizer; ( ) 
10% PEG 8000; ( ) 10% TEC; ( ) 10% methylparaben; ( ) 20% PEG 




















Figure 6.2: Differential scanning calorimetry profiles of physical mixtures (PM) and 
hot-melt extrudates (EX) containing Eudragit® S100, 30% theophylline 
(Theo) and 20% methylparaben (MP) or PEG 8000. 







PM 30% Theo, 20% MP
EX 30% Theo, 20% MP
PM 30% Theo, 20% PEG
EX 30% Theo, 20% PEG
Tm (MP) = 123°C




Figure 6.3: Influence of TEC content on the drug release from melt extruded pellets 
containing 30% theophylline and Eudragit® S100 as the matrix former.  
( ) no plasticizer, ( ) 10% TEC, ( ) 20% TEC. 
Dissolution: USP paddle apparatus, 50 rpm, 37±0.5°C, n = 3, 2 hours in 750 
ml SGF pH 1.2 without pepsin, after 2 hours pH change to pH 7.4 by 


























Figure 6.4: Influence of methylparaben content on the drug release from extruded 
pellets containing 30% theophylline and Eudragit® S100 as the matrix 
former.  
( ) no plasticizer, ( ) 10% methylparaben, ( ) 20% methylparaben. 
Dissolution: USP paddle apparatus, 50 rpm, 37±0.5°C, n = 3, 2 hours in 750 
ml SGF pH 1.2 without pepsin, after 2 hours pH change to pH 7.4 by 


























Figure 6.5: Influence of PEG 8000 content on the drug release from extruded pellets 
containing 30% theophylline and Eudragit® S100 as the matrix former.  
( ) no plasticizer, ( ) 10% PEG, ( ) 20% PEG. 
Dissolution: USP paddle apparatus, 50 rpm, 37±0.5°C, n = 3, 2 hours in 750 
ml SGF pH 1.2 without pepsin, after 2 hours pH change to pH 7.4 by 


























Figure 6.6: Graphic analysis of the effects of plasticizer type and amount on the release 
properties in acid pH 1.2 and buffer pH 7.4, and on the hot-melt extrusion 
(HME) yield as obtained by the mixture design of experiments. The 
optimized composition consists of 30% theophylline (constant), 50.52% 




Figure 6.7: Tensile strength of melt extruded Eudragit® S100 pellets containing 30% 
theophylline as a function of plasticizer type and level.  
( ) Methylparaben; ( ) TEC; ( ) PEG 8000.  






















Chapter 7: Study of Formulation and Processing Factors that Impact 
the Applicability of Hot-Melt Extrusion for the Embedment of Enteric 
Coated Particles into Multiparticulate Monolithic Matrices 
 
Abstract: 
The objective of this study was to investigate a novel application of hot-melt 
extrusion for the preparation of multiparticulate matrices with preserved delayed drug 
release properties. Particles of different mechanical strength (theophylline granules, 
extruded and spheronized pellets and layered microcrystalline cellulose spheres) were 
enteric coated with an aqueous Eudragit® L30D-55 dispersion and characterized 
regarding potency, moisture content, dissolution properties and tensile strength by 
diametral compression analysis. Six hydrophilic polymers including polyethylene 
glycols, poloxamers and polyethylene oxides were studied as carrier materials for the 
particle extrusion. Dissolution testing of hot-melt extruded matrices showed that the 
particles remained enteric after extrusion in poloxamer 407 independent of their 
mechanical strength, which demonstrated that the film and particle integrity was not 
compromised by mechanical forces. However, the drug release properties were dependent 
on the nature of the carrier polymer. The miscibility between the carrier materials and the 
enteric coating polymer was studied by differential scanning calorimetry. High 
miscibility correlated with increased film permeability and higher drug release in acidic 
media due to a partial solubilization of the film coating by the carrier polymer during the 
extrusion process. Poloxamer 407 exhibited a lower miscibility with the enteric polymer 
than the polyethylene glycols or poloxamer 188. Matrices containing up to 40% enteric 
pellets in poloxamer 407 were compliant with the USP requirements for delayed drug 
release dosage forms, and the release profile remained stable when stored at room 
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temperature for one year. It was demonstrated that drug granules of low mechanical 
strength and coated with brittle Eudragit® L30D-55 could be successfully processed into 
enteric, multiparticulate matrices by hot-melt extrusion, but failed the enteric test when 




Oral dosage forms providing controlled drug delivery can be classified as 
monolithic or multiple-unit systems. Biopharmaceutical advantages of multiple-unit 
dosage forms include reduced gastric transit time, reduction of food effects and a more 
uniform distribution along the intestinal tract, promoting higher and less variable 
bioavailabilities [1]. With regard to the final dosage form, monolithic systems are 
preferred to ensure patient compliance and dosing accuracy. Post-processing technologies 
include compression of the controlled release particles into multiparticulate tablets or 
particle filling into capsules. Tableting of functionally coated particles has experienced 
increasing popularity due to several advantages over encapsulation techniques. 
Multiparticulate tablets can be manufactured at lower costs and higher output rates than 
capsules using commonly available tablet presses. Tablet dosage forms are less sensitive 
to moisture, may be divided to increase dosing flexibility and are less susceptible to 
tampering when compared to capsules [2].  
However, the tableting of functionally coated particles is technologically more 
challenging than the compression of traditional powder blends. The exertion of 
unidirectional compaction forces on particles such as pellets, granules or microspheres 
may induce their deformation and/ or fragmentation. Functionally coated particles may 
experience a loss of their controlled release properties when the film coating is damaged 
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during the compaction process. This problem has been reported for particles coated with 
brittle polymers including ethylcellulose [3-5], Eudragit® RS/RL mixtures [6] or enteric 
polymethacrylates [7-9]. Strategies to preserve the modified release properties during 
compression include the application of films of high flexibility [7, 8, 10] or increased 
thickness [7, 11, 12], reducing the tablet surface area [13] or using appropriate cushioning 
excipients [9, 14, 15]. However, particles with highly flexible films are more difficult to 
prepare, tend to agglomerate during compression and are more susceptible to storage 
instabilities. Pellet tackiness and agglomeration has been reported for pellets coated with 
flexible Eudragit® NE 30D films [16]. Partial film fusion of pellets coated with 
Eudragit® FS 30D during tableting has been associated with slow tablet disintegration 
[12]. Films that are applied as aqueous dispersions and exhibit low glass transition 
temperatures may experience physical aging due to continuing coalescence during 
storage, resulting in decreasing drug release rates as a function of storage time and 
temperature [17]. The requirement for controlled release particles to remain intact during 
compression implicates that these particles do not contribute to tablet hardness in form of 
plastic deformation, densification or brittle fragmentation. As a result, tablet strength 
decreases and tablet friability increases when high particle loads are present in the tablet 
[18]. Large amounts of cushioning and highly compressible tableting excipients limit the 
particle load, but become necessary to absorb compaction forces, to physically separate 
the particles during compression and to produce tablets of acceptable hardness with low 
friability. Differences in particle size and density between pellets and tableting excipients 
further promote blend segregation during tableting and may result in poor content 
uniformity of the final multiparticulate tablets. Increasing the particle loads in the 
formulation or granulation of the filler has been demonstrated to improve content 
uniformity [19, 20].  
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Hot-melt extrusion has been recognized as a valuable technology for the 
preparation of a large variety of pharmaceutical dosage forms including matrix tablets, 
pellets, films and implants [21, 22]. The objective of this study was to investigate a novel 
application of hot-melt extrusion as an alternative method to tableting for the preparation 
of multiparticulate monolithic matrices comprising enteric coated particles with 
preserved delayed release characteristics. Our hypothesis was that shortcomings as they 
are encountered with pellet compaction technologies may be overcome by using hot-melt 
extrusion. Unidirectional compaction forces which potentially damage the integrity of the 
particle core and the film coating are absent during extrusion, making the process 
amenable to particles of low mechanical strength or particles with brittle film coatings. 
Relevant formulation and processing factors influencing the properties of 
multiparticulate, melt extruded tablets were investigated in the current study. Three types 
of particles exhibiting differences in mechanical strength (theophylline granules, pellets 
and layered microcrystalline cellulose spheres) were enteric coated with Eudragit® 
L30D-55 and characterized regarding tensile strength and dissolution properties. The 
thermal behavior of six potential carrier polymers for the particle extrusion was studied, 
and their thermal miscibility with the coating polymer was analyzed by differential 
scanning calorimetry to evaluate potential film solubilization during the extrusion 
process. The influence of the carrier polymer, particle load and the particle strength on 
the preservation of the enteric properties during hot-melt extrusion was investigated. The 
release properties of a poloxamer 407 matrix comprising 30% soft enteric granules were 






Anhydrous theophylline, glycerol monostearate (powder, food grade) and 
polysorbate 80 (Tween® 80, NF) were purchased from Spectrum Chemicals (Gardena, 
CA). Avicel® PH-101 (NF) and Ac-Di-Sol® were donated by FMC BioPolymer 
(Newark, NJ), and hypromellose E3 (Pharmacoat® 603) was obtained from Shin-Etsu 
(Tokyo, Japan). Kollidon® K25, theophylline granules, poloxamer 188 (Lutrol® F 68) 
and poloxamer 407 (Lutrol® F 127) were kindly provided by BASF Corp. (Ledgewood, 
NJ). Polyethylene glycols (PEG 4000 and 8000, Carbowax Sentry™), polyethylene oxide 
100K (PEO 100K, Sentry Polyox™ WSR N-10 NF) and polyethylene oxide 200K (PEO 
200K, Sentry Polyox™ WSR N-80 NF) were donated by Dow Chemical Company 
(Midland, MI). Microcrystalline cellulose spheres (MCC spheres, Ceolus™ CP-305) and 
Ceolus™ KG-802 were kind gifts from Asahi Kasei America, Inc. (New York, NY). 
Triethyl citrate (TEC) was provided by Vertellus (Greensboro, NC), and Eudragit® 
L30D-55 and Eudragit® L100-55 were donated by Evonik (Piscataway, NJ). 
 
7.3 METHODS 
7.3.1 Preparation of core pellets 
Pellets containing 30% theophylline were prepared by wet-mass extrusion and 
spheronization. The drug and Avicel® PH-101 (62.5%) were premixed in a kitchen aid 
mixer (St. Joseph, MI), and an aqueous Kollidon® K25 solution (equivalent to 7.5% 
Kollidon® K25 in the final dry formulation) was added under stirring to form a wet mass 
of appropriate consistency. After manual pre-kneading, the mass was processed with a 
Benchtop granulator (LCI Corp., Charlotte, NC) equipped with a 0.6 mm screen and 
operated at a blade rotation speed of 50 rpm. The extruded strands were transferred into a 
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spheronizer (Caleva Model 120, Dorset, UK) and mesmerized at 700 rpm for 3 minutes. 
After oven drying at 40ºC for 24 hours, the pellets were sieved and the 300-500 μm 
fraction was used for functional coating. 
 
7.3.2 Active layering of MCC spheres 
A binder solution (2%) was prepared by dissolving hypromellose E3 in deionized 
water under magnetic stirring. Theophylline (10%) was added to the binder solution 
under high-shearing with a Polytron homogenizer (Kinematica Inc., Newark, NJ), and the 
obtained suspension was homogenized for another 10 minutes. The theophylline-binder 
dispersion was sprayed onto MCC seed cores (Ceolus™ CP-305, particle size 300-500 
μm) in a Strea-1 fluidized-bed coater (Aeromatic-Fielder, Bubendorf, Switzerland) with 
bottom set-up and a Wurster column. The dispersion was stirred during the process and 
applied with a peristaltic pump through a 1.0 mm nozzle at an atomizing air pressure of 
1.5 bars. The inlet temperature was 75°C and the outlet temperature was 50-51°C. The 
dispersion was sprayed at 10 g per minute and kilogram to obtain MCC spheres with a 
potency of 10% theophylline. The dried particles (40ºC, 24 hours) were sieved, and the 
300-500 μm fraction was used for the enteric coating trial. 
 
7.3.3 Moisture content 
The moisture content of the core particles (granules, pellets or active MCC 
spheres) was determined after equilibration at 25±1°C and 50±5% RH for 24 hours and 
prior to enteric coating using a moisture analyzer AND MF-50 (A&D Engineering, Inc., 
Milpitas, CA). In accordance with the USP loss on drying method, 1 g of particles was 
accurately weighed into a dried aluminum dish and maintained at 110ºC until a constant 
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weight was achieved (weight loss below 0.02%/ min). The average percent weight loss of 
three measurements was reported as the moisture content. 
 
7.3.4 Functional film coating 
Drug-layered MCC spheres, theophylline granules (300-500 μm) and self-made 
pellets were film coated to a polymer weight gain of 50% in the above described fluid 
bed coater using an aqueous dispersion of Eudragit® L30D-55. The composition of the 
coating dispersion is shown in Table 7.1, and the dispersion was prepared as 
recommended by the polymer manufacturer [23]. The process parameters are detailed in 
Table 7.2. The polymeric dispersion was stirred continuously throughout the coating 
process to prevent the sedimentation of solids. The film coated particles were dried and 
sieved, and the 300-500 μm fraction was selected for further analysis and processing. 
 
7.3.5 Mechanical strength testing 
The tensile strength of the three different types of particles before and after 
enteric coating was determined with a Chatillon Universal Tension / Compression Tester 
Model TCD-200 (Ametek, Largo, FL) as previously described [24]. Briefly, a flat, 
circular steel plate was fitted onto a DFGS 50 digital force gauge and lowered in 
diametral direction towards an individual pellet at a crosshead speed of 2.5 mm/ min. The 
load-deflection data was collected using Chatillon Nexygen TCD force testing software. 
The mechanical strength was reported as the average tensile strength of 20 specimens and 
calculated using the Hiramatsu-Oka equation:  









The diameter (d) of each individual particle was obtained from the distance of the 
crosshead plate from the base at the moment of load buildup, and the maximum load (P) 
at which brittle fragmentation of the pellets occurred was used for the calculation of the 
tensile strength. Statistical analysis was performed with JMP® 7 software (SAS Institute 
Inc., Cary, NC) considering an α-level of ≤ 0.05 statistically significant. One-way 
ANOVA and post hoc Tukey-Kramer test were employed to evaluate the influence of the 
particle type on the mechanical strength. The mechanical strength before and after enteric 
coating was compared using the two-sided t-test for dependent data. 
 
7.3.6 Hot-melt extrusion of multiparticulate matrices 
Functionally coated particles (30%, unless stated otherwise) were blended with a 
hydrophilic carrier polymer (70%) and extruded into circular strands using a single screw 
Randcastle extruder (model RCP 0750 Microtruder, Nitralloy 135M screw, Cedar Grove, 
NJ) equipped with a 6 mm rod-shaped die. Six polymers were studied as the hydrophilic 
carriers including PEG 4000 and 8000, poloxamer 188 and 407 and PEO 100K and 
200K. The temperature settings in the three heating zones and in the die zone were 
selected based on the melting point and the viscosity of the individual polymers and are 
listed in Table 7.3. The extruded strands were cooled to room temperature and cut with a 
razor blade to obtain tablets containing 200 mg enteric particles. 
 
7.3.7 Differential scanning calorimetry 
The miscibility between the enteric polymer and the carrier polymers was 
investigated by differential scanning calorimetry (DSC) to evaluate the potential for 
solubilization of the enteric film in the tablet matrix during hot-melt extrusion. Samples 
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(15±3 mg) were accurately weighed into aluminum pans, crimped sealed and placed 
inside the furnace of a Thermal Advantage Model 2920 (TA Instruments, New Castle, 
DE). The carrier polymers were heated either alone or in the presence of an equal amount 
of Eudragit® L100-55 at 10°C/ min to a temperature of 10 degrees above the extrusion 
temperature and kept isothermal at this temperature for 10 minutes to simulate the hot-
melt extrusion process. After quench cooling to 0°C, a second run was performed using 
the same heating rate. The melting points of the carrier polymers are listed in Table 7.3, 
and the melting enthalpies were calculated by peak integration using TA Universal 
analysis 2000 software. The ratio of the melting enthalpies obtained for the second run 
divided by the melting enthalpies obtained for the first run was used to express the 
percentage of relative polymer crystallinity after thermal processing. The term “relative 
crystallinity” was used since the actual degree of crystallinity of the untreated semi-
crystalline polymers was unknown. 
 
7.3.8 Direct compression of multiparticulate tablets 
Enteric coated granules (30%), microcrystalline cellulose (Ceolus™ KG-802, 
65%) and superdisintegrant (Ac-Di-Sol®, 5%) were blended and directly compressed 
into round tablets (333 mg, equivalent to 100 mg particles) using a single station manual 
Carver Press (Fred Carver, Menomonee, WI) equipped with a concave, 10 mm diameter 
die (04-04, #91459, Natoli Engineering, Saint Charles, MO). The compression force was 
5 kN, and the tablet hardness was 17.1 ± 1.6 kP as determined with a Varian VK 200 




7.3.9 Dissolution studies 
The dissolution properties of the enteric coated particles before and after hot-melt 
extrusion or direct compression into multiparticulate matrices were studied in a paddle 
apparatus (Vankel VK 7000, Varian, Cary, NC) according to the USP chapter <724> 
method A for delayed release articles. The bath temperature was maintained at 
37.0±0.5°C, and the paddle rotation speed was set to 100 rpm. Specimens equivalent to 
200 mg particles (n = 3) were initially tested in 750 ml simulated gastric fluid pH 1.2 
(SGF without pepsin) for 2 hours, followed by additional 2 hours in phosphate buffer pH 
6.8 after adding 250 ml of 0.2M tribasic phosphate buffer to increase the pH. Samples 
were withdrawn after selected time intervals using a Vankel VK 8000 auto sampler and 
assayed for theophylline content by HPLC. 
 
7.3.10 Theophylline assay 
The amount of theophylline released during dissolution testing was determined by 
HPLC analysis using a Waters HPLC system (Waters Inc., Milford, MA) equipped with a 
C18-reversed phase column (Capcell PAK 3 mm*100 mm, Shiseido Co, Japan). The 
mobile phase consisted of 20 mM phosphate buffer and acetonitrile (9:1) and was 
delivered at a flow rate of 0.5 ml/min. Theophylline was eluted after 3.5 min, detected 
with a UV detector extracting at 271.5 nm (996-PDA, Waters Inc.) and quantified by 
peak area integration using Empower version 5.0 software (Waters Inc.). Linear 
correlation was confirmed between 0.1 and 100.0 μg/ ml (R2 = 0.99997), and multiple 
injections yielded good reproducibility with RSD values between 0.08% (100.0 μg/ ml) 




7.4 RESULTS AND DISCUSSION 
7.4.1 Characterization of different types of particles 
Three different multiparticulate drug carrier systems (theophylline granules, 
pellets and layered MCC spheres) were prepared and characterized regarding potency, 
moisture content and mechanical strength before and after functional coating with 
Eudragit® L30D-55. The potency and moisture content of the different particles before 
enteric film coating are given in Table 7.4. Drug granules contained 96.3% theophylline, 
were irregularly shaped and very friable. As can be seen in Fig. 7.1, the tensile strength of 
the granules was low and increased significantly by applying an enteric film coat 
(7.31±2.18 MPa before coating versus 9.53±2.75 MPa after coating, paired t-test, p = 
0.0036). The potency of the extruded and spheronized pellets was intermediate between 
the granules and the layered MCC spheres (28.2% for pellets, 10.8% for MCC spheres). 
With regard to the tensile strength, pellets were significantly stronger than granules and 
significantly weaker that MCC spheres before enteric coating. Film coating did not alter 
the mechanical properties of the pellets (21.52±3.03 MPa before coating versus 
20.03±3.38 MPa after coating, paired t-test, p = 0.1329). Uncoated MCC spheres 
exhibited the highest tensile strength which decreased significantly after film coating 
(33.58±5.36 MPa before coating versus 24.05±4.49 MPa after coating, p < 0.0001). 
Pellets and MCC spheres were highly spherical and exhibited low friabilities. 
The differences in mechanical strength between the different types of particles 
were attributed to differences in their composition and manufacturing process. The 
degree of compaction during particle formation influenced the particle porosity and hence 
the tensile strength. High particle strength was further promoted by larger contents of 
MCC in the formulation due to the high plasticity of this material, which was confirmed 
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by the superior tensile strength of the MCC spheres. The influence of enteric film coating 
with Eudragit® L30D-55 on the mechanical properties was dependent on the tensile 
strength of the core material. The mechanical robustness of the soft theophylline granules 
could be enhanced by the application of the film coat. Eudragit® L30D-55 films were 
demonstrated to be relatively strong and exhibit high tensile strengths and elastic moduli 
[25]. Similar increases in crushing force after film coating have been previously reported 
for spheres coated with Eudragit® RS 30D/RL 30D [6] or Eudragit® L30D-55 [9]. 
Extruded and spheronized pellets exhibited an intermediate tensile strength before 
functional coating, and the application of a polymeric film did not alter their resistance to 
diametral compression forces. An independence of particle strength from functional 
coating has been demonstrated by other groups [26, 27]. These findings indicated that a 
fracture of the pellet core was the dominating failure mechanism during tensile testing, 
and that the core and the film exhibited similar mechanical properties. On the other hand, 
the tensile strength values of enteric MCC spheres decreased when compared to the 
uncoated material. In this case, the mechanical properties were mainly dictated by the 
high strength of the core material. The application of a film did not alter the load that was 
required for particle crushing, but increased the particle size, so that the calculated tensile 
strength values were smaller than for the uncoated MCC spheres. These results 
demonstrated that the influence of functional coating on the mechanical properties of the 
particles was dependent on the mechanical strength of the core material and increasing, 




7.4.2 Influence of carrier polymers on the dissolution properties of enteric pellets 
after hot-melt extrusion 
Hot-melt extrusion requires the presence of a thermoplastic carrier in the form of 
a malleable or meltable polymer, wax or lipid [21]. The behavior of the carrier in 
dissolution media in terms of dissolution rate and swelling characteristics controls the 
release rate of the active ingredient, and in the case of particle extrusion, the liberation of 
the multiparticulates from the matrix. Conventional multiparticulate tablets prepared by 
compaction methods may be formulated with a superdisintegrant to ensure rapid tablet 
disintegration and particle release in the stomach. The particle release from melt extruded 
tablets is mainly controlled by the dissolution rate of the carrier due to the lack of matrix 
disintegration. For this reason, carrier polymers should exhibit high aqueous solubilities 
and refrain from forming highly viscous gels in dissolution media. It is very important 
that the carrier exhibits low miscibility with the enteric polymer and a low glass transition 
temperature or melting point to allow hot-melt extrusion at moderate temperatures. High 
polymer miscibility and elevated processing temperatures would potentially promote a 
solubilization and damage of the enteric film during particle extrusion. 
Semi-crystalline polymers with low melting points were advantageous since they 
solidified quickly and showed negligible elastic recovery (die swell) upon extruder exit. 
Furthermore, physical instabilities during storage in the form of plasticizer migration 
from the enteric film coat into the matrix or carrier migration into the film were less 
likely due to the small free volume and low permeability of semi-crystalline materials in 
the solid state. Six water-soluble polymers with low melting points and semi-crystalline 
properties were studied as potential carrier materials (Table 7.3): poloxamer 188 and 407, 
PEG 4000 and 8000, PEO 100K and 400K. The poloxamers and PEG’s melted between 
57 and 65ºC and could be extruded at temperatures below their melting points (47-55ºC) 
 
 196
since shearing of the material under elevated pressure promoted polymer softening. In a 
similar manner, it has been demonstrated that lipids can be extruded at temperatures 
below their melting ranges with 80-90% of the thermal binder remaining in the solid state 
during the extrusion process. These conditions were shown to reduce the matrix porosity 
and improve the storage stability of the lipid carrier, since complete melting and 
recrystallization of metastable modifications were avoided [28]. Polyethylene oxides 
needed to be processed above their melting point (70ºC) and showed pronounced elastic 
recovery (die swell), which was probably due to a higher percentage of amorphous 
regions in these polymers.  
Differential scanning calorimetry was employed to investigate the influence of 
thermal processing on the crystallinity of the carrier polymers and their miscibility with 
Eudragit® L. All specimens were cycled twice, and the melting enthalpy as detected for 
the melting point of the crystalline part of the polymer in the second run was related to 
the melting enthalpy found in the first run, which was considered as 100% crystallinity. 
The results in Fig. 7.2 show that the relative crystallinity of the poloxamers and PEG’s 
decreased only slightly after heating to 92-96% of their original crystallinity. The effect 
of thermal treatment on the crystallinity of the PEO’s was more significant as it was 
reduced to 77-78% in the second cycle. This diverging thermal behavior could be 
explained by differences in molecular weight. The relatively low molecular weights and 
melt viscosities of the poloxamers and PEG’s allowed a quick rearrangement of the 
disordered chains into ordered crystalline structures during the cooling period after the 
first cycle. This process was hindered within the highly viscous PEO melts due to the 
high molecular weights of these polymers (100,000 and 200,000), resulting in an 
increased portion of amorphous regions after the first heating. 
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The melting enthalpies of physical mixtures with Eudragit® L100-55 (1:1) in the 
first run were equivalent to those of the pure polymer. The melting enthalpies in the 
second cycle were lower due to decreased carrier crystallinity in the presence of the 
coating polymer (Fig. 7.2). These findings indicated a partial miscibility between all 
selected carriers and the enteric polymer at elevated temperatures. The formation of 
miscible phases with the highly viscous methacrylic polymer hindered the 
recrystallization process of the carrier during the cooling period. This phenomenon was 
most distinctive for the low molecular weight PEG (relative crystallinity of 9% in second 
run), and least for the PEO’s (61-62%). The miscibility with poloxamer 188 or PEG 8000 
was also high (21-24%), while poloxamer 407 yielded only moderate miscibility with the 
coating polymer (46% relative crystallinity in second run). These results suggested that 
the PEO’s and poloxamer 407 were more suitable carriers for the melt extrusion of 
enteric particles coated with Eudragit® L30D-55 than the PEG’s or poloxamer 188. 
However, all polymers exhibited a certain degree of miscibility with the coating polymer 
which might encourage film solubilization during extrusion and compromise the gastric 
resistance of the particles. 
The dissolution profiles of matrix systems containing 30% coated pellets are 
shown in Fig. 7.3. The release properties in acid were controlled by the permeability of 
the enteric film and, to a lesser extent, by the dissolution rate of the carrier. As expected 
from the findings of the DSC studies, the PEG 4000 based matrix yielded high drug 
release rates in acid with 14.6% theophylline released after 2 hours. Matrices prepared 
with poloxamer 188, PEG 8000 or the PEO’s released the drug to a similar, intermediate 
extent in acid (9.9-11.2% after 2 hours). Lower molecular weight PEG’s have been 
demonstrated to be unsuitable carriers for Eudragit® L30D-55 coated pellets in 
congealed matrices since they dissolved the coating and increased the film permeability 
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[29]. The high miscibility between Eudragit® polymers and PEG’s was expected since 
PEG’s are commonly used as plasticizers for polymethacrylic polymers [30]. The lowest 
drug release in acid was obtained for the poloxamer 407 matrix with 7.4% theophylline 
released after 2 hours.  
The drug release in buffer pH 6.8 was mainly governed by the dissolution kinetics 
of the carriers since the enteric film dissolved rapidly. Polyethylene oxide matrices 
formed highly viscous gels acting as barriers towards penetrating water and diffusing 
drug, which resulted in the slowest drug release after 45 minutes in buffer (72.2% for 
PEO 100K and 66.3% for PEO 200K). The release profiles of the poloxamer 188 and 
PEG 4000 matrices were superimposable with those of the original pellets during the 
buffer phase (> 98.8% released after 45 min), attesting that the polymer matrix was 
dissolved and the theophylline release rate was only controlled by the dissolution rate of 
the enteric film. The release from the PEG 8000 matrices yielded an approximate 15-20 
min lag phase in buffer, after which the drug was rapidly released to reach 93.4% after 45 
minutes in buffer. Hot-melt extruded poloxamer 407 tablets provided an intermediate 
dissolution profile which was between the fast dissolving carriers and the highly viscous 
PEO’s with 87.1% theophylline released after 45 minutes in buffer pH 6.8. The retarded 
matrix dissolution of poloxamer 407 compared to poloxamer 188 was attributed to the 
slightly higher molecular weight (9840–14600 versus 7680–9510) and a higher 
percentage of less hydrophilic polypropylene oxide units (PEO: PPO ratio of 1.8:1 versus 
3.0:1 for poloxamer 188). Targeting the USP requirements of a minimum drug release 
below 10% in acid and a release higher than 80% in buffer, poloxamer 407 was selected 




7.4.3 Influence of pellet loading on the properties of hot-melt extruded matrices 
The properties of compressed tablets containing multiparticulates have been 
demonstrated to be influenced by the pellet-to-filler ratio. High amounts of pellets in the 
formulation increase the number of inter-particle contacts, leading to pellet deformation 
and film damage not only on the tablet surface, but also in the interior of the tablets. The 
drug release rate from pellets coated with Eudragit® L30D-55 was shown to increase as a 
function of the pellets content [7, 9]. Partial film fusion and pellet agglomeration during 
compaction may compromise rapid tablet disintegration as demonstrated for tablets 
containing Eudragit® FS 30D film coated pellets [12]. High pellet loads may further 
decrease the mechanical strength and increase the friability of the multiparticulate tablets 
[18]. 
Poloxamer 407 matrices containing an increasing amount of pellets (30, 40 and 
50%) were prepared by melt extrusion, and their release characteristics were studied. 
Increasing the pellet load up to 50% did not compromise the processibility, and all 
formulations could be prepared using the same extrusion conditions. The hardened 
strands were not friable despite the relatively high amount of non-meltable material in the 
formulation. The influence of the pellet content on the delayed release properties is 
shown in Fig. 7.4. Poloxamer 407 matrices containing 30% or 40% enteric pellets were 
compliant with the USP requirement to release less than 10% of their drug content after 2 
hours in acid (7.4% and 9.2%). However, the tablets prepared with 50% pellets failed this 
criterion with 14.8% theophylline released. Drug dissolution at the buffer stage was 
independent of the pellet loading and fulfilled the USP requirement to release more than 
80% within 45 minutes (84-87%). These results demonstrated that the release properties 
in acid were the limiting factor for the amount of pellets that could be loaded into the 
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system, and that multiparticulate extrudates containing up to 40% pellets were in 
compliance with the USP criteria for delayed release articles. 
 
7.4.4 Influence of type of particles on the preservation of the release properties 
after hot-melt extrusion 
Previous studies by Beckert and coworkers have demonstrated that pellets with 
high mechanical strength were better able to withstand compression forces during 
tableting [7]. Excessive deformation or fragmentation of the particle core will result in 
stretching and eventual rupture of the functional film. As shown in Fig. 7.1, the three 
different types of particles (granules, pellets and MCC spheres) displayed significant 
differences in mechanical properties, with granules yielding the lowest and MCC spheres 
yielding the highest tensile strength. In contrast to compression technologies, an exposure 
of the coated particles to high unidirectional forces was absent during the hot-melt 
extrusion process. The shear forces acting on the particles during extrusion are dependent 
on the carrier viscosity, screw and extruder design and on the shear rate or screw rotation 
speed. Preliminary studies on pellets of different particle sizes demonstrated that the 
conveyance of pellets with diameters larger than 500 μm through the extruder was 
hindered, resulting in increased drug release rates in acid above 10%. Fig. 7.5 shows the 
influence of the core material on the percentage of theophylline released after 2 hours 
from melt extruded poloxamer 407 matrix tablets containing 30% enteric particles. All 
formulations were compliant with the USP criteria for the release in acid and in buffer pH 
6.8. All multiparticulate matrices experienced a similar increase in % drug released after 
extrusion which was between 5.7 and 6.6% and independent of the mechanical strength 
of the embedded particles. These findings provided evidence that hot-melt extrusion is a 
suitable process to convert particles of low mechanical strength such as granulated drug 
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into monolithic dosage forms. Furthermore, the slight increase in drug release was more 
likely a result of partial solubilization of the film in the carrier polymer during extrusion 
due to partial polymer miscibility as demonstrated in the DSC study, than a result of 
mechanical rupture of the film. 
 
7.4.5 Comparison of multiparticulate matrices prepared by hot-melt extrusion 
versus direct compression and storage stability 
Our hypothesis was that hot-melt extrusion technology would be advantageous 
over direct compression for the preparation of multiparticulate tablets, especially when 
the particles are of low mechanical strength and coated with tough but brittle polymeric 
films. High drug loadings as necessary for the formulation of high-dose drugs reduce the 
mechanical strength of the multiparticulates [31]. Particles coated with polymers forming 
tough films and exhibiting high glass transition temperatures show reduced sticking 
tendency and enhanced storage stability when compared to particles coated with highly 
flexible films. As demonstrated by Zheng and coworkers, pellet agglomeration during the 
coating process and during storage could be prevented if Eudragit® L30D-55 was added 
to a Eudragit® NE 30D coating formulation. The presence of Eudragit® L30D-55 in the 
film coating also decreased the curing time and stabilized the drug release rate during 
storage [16].  
For comparison purposes, tablets containing 30% enteric granules were prepared 
by direct compression using low compaction forces (5 kN) and a highly compressible 
MCC grade (Ceolus™ KG-802) as the filler material. The release properties of these 
tablets were compared to melt extruded poloxamer 407 matrices containing 30% enteric 
granules (Fig. 7.6). Direct compression of the soft granules coated with Eudragit® L30D-
55 resulted in a significant increase in the amount of drug released in acid with 33.8% 
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released after 2 hours compared to 8.4% for the melt extruded formulation. This loss in 
gastric protection was presumably attributed to partial film rupture during compaction 
induced by particle fragmentation at the tablet surface. Similar observations have been 
reported by other groups for pellets coated with Eudragit® L30D-55 [7] or Kollicoat® 
MAE [8] when flexible polymers were absent in the coating formulation. The drug 
release from the melt extruded poloxamer 407 matrix remained below the 10% limit in 
acid, demonstrating that the enteric film remained to a large extent intact during hot-melt 
extrusion, and that high film flexibility and particle strength were not required to preserve 
the enteric release profile of the particles.  
Furthermore, the stability of the dissolution profile was investigated after one year 
of storage at room temperature and ambient humidity. As shown in Fig. 7.6, the drug 
release after 2 hours in acid decreased only slightly from 8.4 to 7.5%, which was 
probably due to ongoing film coalescence during storage. The stability of the extruded 
dosage form could potentially be compromised by several factors including aging of the 
enteric film, aging of the carrier polymer and migration of the carrier into the enteric 
coating during storage. The latter mechanism has been proposed as explanation for the 
increase in drug release during storage at room temperature when pellets coated with 
TEC-plasticized Eudragit® RS were embedded in a PEG 4000 matrix. This effect was 
not observed for ethylcellulose coated pellets due to the higher glass transition 
temperature and lower affinity of this polymer to PEG 4000, impeding a migration of the 
carrier into the film [29]. Similar aspects and the higher molecular weight of poloxamer 
407 compared to PEG 4000 were probably responsible for the good storage stability of 





Enteric particles were prepared by fluidized bed coating of three different core 
materials, theophylline granules, pellets and layered MCC spheres, using an aqueous 
Eudragit® L30D-55 dispersion. The multiparticulates exhibited differences in tensile 
strength, and the effect of functional coating on the tensile strength depended on the 
initial strength of the uncoated core material. 
The enteric particles were processed into multiparticulate matrix systems by hot-
melt extrusion using low melting polymers with high aqueous solubility as carrier 
materials. The preservation of the delayed release profile was demonstrated to be 
independent of the mechanical strength of the extruded particles, but dependent on the 
nature of the carrier polymer. These results indicated that the enteric film was more 
susceptible to solubilization by the carrier polymer during the hot-melt extrusion process 
than to mechanical rupture due to shear forces. Poloxamer 407 was selected as the carrier 
since it showed only moderate miscibility with the enteric polymer and produced tablets 
with optimized dissolution properties. Matrices containing up to 40% enteric pellets in 
poloxamer 407 fulfilled the USP requirements for delayed release dosage forms to release 
less than 10% drug after 2 hours at pH 1.2 and more than 80% after 45 minutes at pH 6.8. 
In contrast to directly compressed tablets, the enteric properties of drug granules 
exhibiting low mechanical strength and coated with brittle Eudragit® L30D-55 could be 
successfully preserved when hot-melt extrusion in poloxamer 407 was used for the 
preparation of the multiparticulate matrices. The release properties of the multiparticulate 
poloxamer 407 matrices were further demonstrated to be stable for one year when stored 
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Table 7.1: Formulation used for the enteric coating of theophylline particles. 
Formulation Percentage Amount [g] 
Eudragit® L30D-55 12% polymer in dispersion 400 (120g polymer) 
TEC 10% based on polymer content 12 
GMS 7.5% based on polymer content 9 
Tween 80 40% based on GMS 3.6 
Water  - 575.4 
Solids content 14.46% 144.6 




Table 7.2: Conditions used for the enteric coating of theophylline particles in a Strea-1 
fluidized bed coater. 
Parameter Condition 
Inlet temperature 36-38°C 
Exhaust temperature 32-33°C 
Nozzle diameter 1.0 mm 
Spray rate 10 g/ (min*kg) 




Table 7.3: Carrier polymers and temperature settings used for the hot-melt extrusion of 
enteric pellets into multiparticulate matrices. 
Extrusion Temperature [°C] Polymer Supplier & Grade Melting  









BASF, Lutrol F68 
NF Prill 
57.1 ± 0.3 40 45 47 47 
Poloxamer  
407 
BASF, Lutrol F127 
NF Prill 




Sentry PEG 4000 




Sentry PEG 8000 




Polyox WSR N-10 




Polyox WSR N-80 




Table 7.4: Core materials used for the preparation of enteric film coated particles.  
The theophylline content was determined for the uncoated particles using 
HPLC  (n = 3).  
The moisture content of the particles was determined as the loss on drying 
after equilibration at 22±1°C and 50±5% RH for at least 24 hours (n = 3). 




Drug Granules BASF 96.3 2.15 ± 0.13 
Pellets Self-made  28.2 3.52 ± 0.08 






Figure 7.1: Mechanical strength of three different types of particles before and after film 
coating with Eudragit® L30D-55.  


























Figure 7.2: Influence of thermal processing and Eudragit® L in a 50:50 physical 
mixture on the degree of crystallinity of the carrier polymers.  
(DSC, heating rate 10°/min, samples: 15±3mg, crimp-sealed in aluminum 
pans, cycled twice, n = 3. The relative crystallinity was calculated as the 






































Figure 7.3: Influence of carrier polymer on the drug release properties of hot-melt 
extruded matrix tablets containing 30% enteric pellets. ( ) Original enteric 
pellets, (▲) pellets in poloxamer 188, ( ) pellets in poloxamer 407, ( ) 
pellets in PEG 4000, ( ) pellets in PEG 8000, ( ) pellets in PEO 100K, 
( ) pellets in PEO 200K. 
Dissolution: USP paddle apparatus, 100 rpm, 37±0.5°C, n = 3, 2 hours in 
750 ml simulated gastric fluid pH 1.2 (without pepsin), after 2 hours pH 




























Figure 7.4: Influence of pellet loading on the drug release properties of hot-melt 
extruded poloxamer 407 matrices. ( ) Original enteric pellets; Extrudates 
containing ( ) 30% pellets, ( ) 40% pellets, ( ) 50% pellets. 
Dissolution: USP paddle apparatus, 100 rpm, 37±0.5°C, n = 3, 2 hours in 
750 ml simulated gastric fluid pH 1.2 (without pepsin), after 2 hours pH 




























Figure 7.5:  Influence of the particle type on the drug release in acid after 2 hours before 
and after hot-melt extrusion of 30% particles in poloxamer 407. 
Dissolution: USP paddle apparatus, 100 rpm, 37±0.5°C, n = 3, 750 ml 

































Figure 7.6: Influence of particle embedment method and storage on the release 
properties of enteric coated theophylline granules. ( ) Original enteric 
granules, ( ) fresh prepared hot-melt extruded matrix tablets containing 
30% granules in poloxamer 407, ( ) hot-melt extruded matrix tablets 
containing 30% granules in poloxamer 407 after one year of storage at room 
temperature and ambient humidity, (▲) directly compressed tablets 
containing 30% granules in Ceolus™ KG 802. 
Dissolution: USP paddle apparatus, 100 rpm, 37±0.5°C, n = 3, 2 hours in 
750 ml simulated gastric fluid pH 1.2 (without pepsin), after 2 hours pH 




























Chapter 8: Summary and Conclusion 
Sustained release matrix tablets containing Eudragit® RS PO and citric acid as a 
solid-state plasticizer were prepared by hot-melt extrusion. It was demonstrated by tensile 
testing of plasticized films and in extrusion experiments that citric acid monohydrate 
functioned as an efficient plasticizer for the polymer when used at concentrations below 
the characteristic compatibility limit of the binary system. The anhydrous form of citric 
acid exhibited lower plasticization efficiency since its elevated melting point hindered a 
solubilization in the polymer during extrusion. The release rates of diltiazem 
hydrochloride from Eudragit® RS PO matrix tablets were increased and became 
independent of the initial drug particle when increasing levels of citric acid monohydrate 
were used as the processing aid. These release-enhancing effects of citric acid were 
demonstrated to be attributed to several mechanisms:  The dissolution of citric acid from 
the matrix increased the porosity and hence the drug diffusion rate during dissolution 
testing. Solid-state interactions between citric acid and diltiazem hydrochloride depressed 
the drug’s melting point below the extrusion temperature and enabled the fine dispersion 
of the melted drug in its amorphous state during extrusion. The plasticizing properties of 
citric acid further increased the free volume and permeability of the polymeric network to 
water penetration and drug diffusion.  
Enteric matrix pellets with a diameter below 1 mm and containing up to 40% 
theophylline could be successfully prepared by hot-melt extrusion when plasticized 
Eudragit® S100 was employed as the matrix material. The manufacture of pellets using 
alternative enteric polymers was either compromised by a lack of thermal processibility 
(Eudragit® L100-55 and Eudragit® L100), or the pellets failed to provide gastric 
protection due to an elevated matrix permeability in acid (Aqoat® LF and HF). 
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Methylparaben, PEG 8000 and TEC showed high compatibility with Eudragit® S100, 
plasticized the polymer efficiently and facilitated a homogeneous dispersion of the drug 
in its original polymorphic form but at reduced particle sizes in the pellet matrix during 
hot-melt extrusion. Pellets containing ATBC, citric acid monohydrate or no plasticizer 
had to be extruded at high temperatures, resulting in partial drug solubilization and the 
recrystallization of needle-shaped theophylline crystals on the pellet surfaces. The 
aqueous solubility and the amount of plasticizer influenced the drug release rate. 
Plasticization with water-soluble compounds impaired gastric protection due to pore 
formation during the acidic stage, while pellets containing less soluble plasticizers (TEC, 
methylparaben, ATBC) or no plasticizer exhibited low drug release rates at pH 1.2. The 
mechanical strength of melt extruded pellets was high and decreased when plasticizers 
were added to the formulation. Eudragit® S100 matrix pellets that were efficiently 
plasticized with poorly or moderately soluble plasticizers exhibited low porosities during 
dissolution testing in acidic medium and could contain up to 40% drug without 
compromising the delayed-release properties. 
Hot-melt extrusion was further used to embed enteric coated particles into 
hydrophilic matrices with the objective to preserve the delayed-release properties of the 
original particles. Matrices containing up to 40% enteric particles in poloxamer 407 
fulfilled the USP requirements for delayed release dosage forms to release less than 10% 
drug after 2 hours at pH 1.2 and more than 80% after 45 minutes at pH 6.8. The extrusion 
process was demonstrated to be applicable for the embedment of soft drug granules that 
were coated with a brittle Eudragit® L30D-55 film, while directly compressed tablets 
containing the same enteric particles released more than 30% drug at pH 1.2 due to film 
rupture during compaction. The preservation of the delayed release profile was 
demonstrated to be independent of the mechanical strength of the extruded particles, but 
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dependent on the nature of the carrier polymer. A high miscibility between the enteric 
polymer and the carrier polymer promoted the solubilization of the enteric film in the 
matrix during extrusion and resulted in increased drug release rates in acidic media. 
These results indicated that the enteric film was more susceptible to solubilization in the 
carrier polymer than to mechanical rupture by shear forces during the hot-melt extrusion 
process. Poloxamer 407 was selected as the carrier polymer due to its dissolution 
properties and only moderate miscibility with the enteric polymer, and the prepared 
multiparticulate matrices exhibited stable dissolution profiles when stored for one year at 
room temperature.  
In conclusion, hot-melt extrusion was demonstrated to be a versatile process that 
was successfully employed for the preparation of extended release tablets, delayed 
release matrix pellets and multiparticulate matrices. The selection of the type and amount 
of plasticizer in the formulation impacted not only the thermal processibility during 
extrusion, but also the drug-release performance of the final dosage form by influencing 
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